David S Hong, MD

Peer-Reviewed Articles

1. Lim, JU, Lin, Y, Kang, L, Le, H, Tang, T, Champiat, S, Dumbrava, EE, Le, X, Naing, A, Piha-Paul, SA, Rodon Ahnert, J, Tsimberidou, AM, Yap, TA, Fu, S, Meric-Bernstam, F, Hong, DS. Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson. npj Precision Oncology 10(1), 2026. e-Pub 2026. PMID: 41530472.
2. Piha-Paul, SA, Tseng, C, Thompson, E, Stafford, RJ, Le, H, Kang, L, Fu, S, Tsimberidou, AM, Blumenschein, GR, Rodon Ahnert, J, Slopis, JM, Hong, DS, Naing, A, Meric-Bernstam, F, Ng, CS, Westin, SN, Sood, AK. Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies. Oncologist 31(3), 2026. e-Pub 2026. PMID: 41389341.
3. Yang, RK, Rashid, A, Roy Chowdhuri, S, Hong, DS, Bryan, J. Clinicopathological features and outcomes for colorectal carcinomas with KRAS codon 146 mutations. ESMO Gastrointestinal Oncology 10, 2025. e-Pub 2025.
4. Subbiah, V, Yu, PP, Sarangarajan, R, Kiebish, MA, Rodrigues, LO, Miller, GM, Akmaev, VR, Luan, S, McCook, JP, Tanna, N, Reilly, T, Chen, E, Bussberg, V, Ravipaty, S, Vishnudas, VK, Gesta, S, Lucius, D, Bruce, C, Hazarika, S, Lyng, A, Klotz, A, Tolstikov, V, Stevens, J, Chua, VS, Granger, E, Tekumalla, PK, Benaim, E, Modur, V, Rudoltz, M, Song, PY, Tagawa, ST, Hendifer, A, Chawla, SP, Shah, MA, Hong, DS, Zinner, RG, Narain, NR, Kundranda, M. Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients. Cancer Research Communications 5(12):2207-2223, 2025. e-Pub 2025. PMID: 41251181.
5. Gracie, JR, Barnes, JM, Sim, AJ, Gardner, L, Beatley, E, Bates, JE, Chen, X, Sharifzadeh, Y, Shen, X, Winkfield, KM, Chin, AL, Hong, DS, Paravati, AJ, Luh, JY, Sio, TT, Jimenez, RB, Chino, F. The growing burden of prior authorization. JCO Oncology Practice 21:98, 2025. e-Pub 2025.
6. George, GC, Piha-Paul, SA, Rodon Ahnert, J, Ileana Dumbrava, EE, Tsimberidou, AM, Appleton, G, Yap, TA, Meric-Bernstam, F, Hong, DS. Dietary links with symptoms in early-phase immune checkpoint combinations trials. JCO Oncology Practice 21:341, 2025. e-Pub 2025.
7. Lin, SH, Subbiah, V, Cohen, E, Li, Z, Lu, YJ, Son, YL, Lyu, Y, Gao, H, Jayachandran, G, Neri, S, Sharma, A, Fang, PQ, Karp, DD, Hong, DS, Rodon Ahnert, J, Yu, H, Peng, J, Lloyd, GK, Tonra, JR, Reuben, JM, Huang, L, Fu, S. Plinabulin following radiation enhances dendritic cell maturation and checkpoint inhibitor retreatment of relapsed/refractory cancers. Med 6(10), 2025. e-Pub 2025. PMID: 40580957.
8. Nelson, BE, Janku, F, Fu, S, Ileana Dumbrava, EE, Hong, DS, Karp, DD, Naing, A, Rodon Ahnert, J, Tsimberidou, AM, Murthy, R, Sheth, RA, Amaria, RN, Conley, AP, Damodaran, S, Raghav, KS, Carapanceanu, N, Singh, MP, Carapanceanu, V, Pezeshki, A, Leontovich, A, Kreider, B, Tung, D, Varterasian, M, Khazaie, K, Piha-Paul, SA. Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. Clinical Cancer Research 31(18):3864-3875, 2025. e-Pub 2025. PMID: 40643985.
9. Derbala, M, Hajjar, J, Stephen, B, Gurses, S, Kwiatkowski, E, Budde, P, Zucht, HD, Bräutigam, M, Lindemann, AS, Abhari, BA, Gouda, M, Castillo, L, Zarifa, A, How, JA, Rodriguez, E, Moyers, JT, Hong, DS, Fu, S, Meric-Bernstam, F, Naing, A. Autoantibody profiling to predict response to the anti-PD-1 therapy, pembrolizumab, in rare tumors. ESMO Open 10(8), 2025. e-Pub 2025. PMID: 40768895.
10. Skoulidis, F, Li, BT, De Langen, AJ, Hong, DS, Lena, H, Wolf, J, Dy, GK, Curioni-Fontecedro, A, Tomasini, P, Velcheti, V, van der Wekken, AJ, Dooms, C, Paz-Ares Rodriguez, L, Mountzios, G, Sacher, A, Nadal, E, Couraud, S, Kim, SW, O’Byrne, K, Rocco, D, Toyozawa, R, Chmielewska, I, Lindsay, CR, Hindoyan, A, Mukundan, L, Wilmanski, T, Anderson, A, Ardito-Abraham, CM, Pati, A, Reddy, A, Mehta, B, Schuler, M. Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer. Nature medicine 31(8):2755-2767, 2025. e-Pub 2025. PMID: 40437272.
11. Siu, LL, Hong, DS, Docke, WD, Tetzner, R, Trautwein, M, Phelps, C, Willuda, J, Yu, XQ, Nogai, H, Johnson, M, Goh, BC. A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors. Targeted oncology 20(4):637-649, 2025. e-Pub 2025. PMID: 40465170.
12. Yap, TA, Rixe, O, Baldini, C, Brown-Glaberman, UA, Efuni, S, Hong, DS, Massard, C, Muzaffar, J, Varga, A, Yilmaz, E, Ikawa, Y, Shiue, LH, Liu, Y, Hruska, MW, Zhao, H, Tokunaga, A, Sahebjam, S. First-in-human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors. Cancer 131(13), 2025. e-Pub 2025. PMID: 40536766.
13. Hong, DS, Xu, R, Shen, L, Dierselhuis, MP, Orbach, D, Mcdermott, R, Italiano, A, Tahara, M, Bernard-Gauthier, V, Neu, N, Mussi, CE, De La Cuesta, E, Laetsch, TW, Drilon, A. Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer. ESMO Open 10(6), 2025. e-Pub 2025. PMID: 40408921.
14. Qi, C, Shen, L, Andre, T, Chung, HC, Cannon, TL, Garralda, E, Italiano, A, Rieke, D, Liu, TS, Burcoveanu, DI, Neu, N, Mussi, C, Xu, R, Hong, DS, Drilon, A, Berlin, J. Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer. European Journal of Cancer 220, 2025. e-Pub 2025. PMID: 40068370.
15. Nardo, M, Xavier, CB, Stephen, B, How, JA, Moyers, JT, Subbiah, V, Hong, DS, Naing, A. Pembrolizumab in Patients with Advanced Miscellaneous Rare Cancers. Journal of Immunotherapy and Precision Oncology 8(2):143-151, 2025. e-Pub 2025. PMID: 40212844.
16. Fox, DA, Tran, C, Blot, V, Hong, DS. Treatment of c-MET Antibody-Drug Conjugate Asymptomatic Pneumonitis with a Novel Steroid Regimen in Non–Small Cell Lung Cancer. Journal of Immunotherapy and Precision Oncology 8(2):108-112, 2025. e-Pub 2025. PMID: 40066205.
17. Johnson, M, Hong, DS, Brana, I, Schöffski, P, Galvao, V, Rangwala, F, Ma, B, Hernandez, R, Kamat, A, Kato, K, Schreiber, TH, Pandite, LN, Siu, LL. First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma. Investigational New Drugs 43(2):284-292, 2025. e-Pub 2025. PMID: 40042547.
18. Vailati Negrao, M, Paula, AG, Molkentine, D, Hover, LD, Nilsson, M, Vokes, N, Engstrom, LD, Calinisan, A, Briere, DM, Waters, L, Hallin, J, Diao, L, Altan, M, Blumenschein, GR, Skoulidis, F, Wang, J, Kopetz, S, Hong, DS, Gibbons, DL, Olson, P, Christensen, JG, Heymach, JV. Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. Clinical Cancer Research 31(6):1069-1081, 2025. e-Pub 2025. PMID: 39804166.
19. Marczyk, VR, Fazeli, S, Dadu, R, Busaidy, NL, Iyer, PC, Hu, MI, Sherman, SI, Hamidi, S, Hosseini, SM, Williams, MD, Ahmed, S, Routbort, MJ, Luthra, R, Roy Chowdhuri, S, San Lucas, FA, Patel, KP, Hong, DS, Zafereo, M, Wang, RJ, Maniakas, A, Waguespack, SG, Cabanillas, ME. NTRK Fusion-Positive Thyroid Carcinoma. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 39983078.
20. Fox, DA, Bhamidipati, D, Kopetz, S, Hong, DS. Durable Remission After Targeted Therapy in BRAF V600E–Mutant Metastatic Colorectal Cancer. Journal of Immunotherapy and Precision Oncology 8(1):11-14, 2025. e-Pub 2025. PMID: 39811421.
21. Alhalabi, O, Gouda, MA, Milton, D, Momin, HA, Yilmaz, B, Stephen, B, Ejezie, CL, Moyers, JT, Gurses, S, How, JA, Fu, S, Rodon Ahnert, J, Hong, DS, Piha-Paul, SA, Subbiah, V, Elena Dumbrava, E, Karp, DD, Janku, F, Meric-Bernstam, F, Tannir, NM, Naing, A. A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma. Cancer medicine 14(4), 2025. e-Pub 2025. PMID: 39945382.
22. Nelson, BE, O'Brien, S, Sheth, RA, Hong, DS, Naing, A, Zhang, X, Xu, A, Hamuro, L, Suryawanshi, R, McKinley, D, Novosiadly, R, Piha-Paul, SA. Phase i study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors. Journal for immunotherapy of cancer 13(1), 2025. e-Pub 2025. PMID: 39824531.
23. Xavier, CB, Andersen, C, Lim, J, Slade, JH, Bean, S, Kang, L, Le, H, Tsimberidou, AM, Naing, A, Hong, DS, Ileana Dumbrava, EE, Rodon Ahnert, J, Pohlmann, PR, Piha-Paul, SA, Champiat, S, Yap, TA, Tang, T, Meric-Bernstam, F, Fu, S. Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials. Cancer Research Communications 5(9):1631-1641, 2025. e-Pub 2025. PMID: 40862547.
24. Tao DL, Nardo M, Leung CH, Lin HY, Kang L, Le H, Dumbrava EE, Hong DS. Obesity and Outcomes in Adoptive Cellular Therapy in Solid Tumors. JAMA Netw Open 7(11):e2447617, 2024. e-Pub 2024. PMID: 39585697.
25. Dilly J, Hoffman MT, Abbassi L, Li Z, Paradiso F, Parent BD, Hennessey CJ, Jordan AC, Morgado M, Dasgupta S, Uribe GA, Yang A, Kapner KS, Hambitzer FP, Qiang L, Feng H, Geisberg J, Wang J, Evans KE, Lyu H, Schalck A, Feng N, Lopez AM, Bristow CA, Kim MP, Rajapakshe KI, Bahrambeigi V, Roth JA, Garg K, Guerrero PA, Stanger BZ, Cristea S, Lowe SW, Baslan T, Van Allen EM, Mancias JD, Chan E, Anderson A, Katlinskaya YV, Shalek AK, Hong DS, Pant S, Hallin J, Anderes K, Olson P, Heffernan TP, Chugh S, Christensen JG, Maitra A, Wolpin BM, Raghavan S, Nowak JA, Winter PS, Dougan SK, Aguirre AJ. Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Cancer Discov 14(11):2135-2161, 2024. e-Pub 2024. PMID: 38975874.
26. Gouda, MA, Stephen, B, Tian, Y, Alshawa, A, Onwugaje, DO, Albittar, A, Yang, Y, Zarifa, A, Yilmaz, B, Gurses, S, Sprenger, A, Derbala, M, Brink, AL, How, JA, Moyers, JT, Piha-Paul, SA, Hong, DS, Meric-Bernstam, F, Patel, SP, Oliva, IC. A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma. Journal of Immunotherapy and Precision Oncology 7(4):247-254, 2024. e-Pub 2024. PMID: 39524469.
27. Araujo HA, Pechuan-Jorge X, Zhou T, Do MT, Hu X, Rojas Alvarez FR, Salvatierra ME, Ibarguen HP, Lee R, Raghulan R, Shah H, Moreno Ayala MA, Chen K, Tovbis Shifrin N, Wu S, Solis Soto LM, Negrao MV, Gibbons DL, Hong DS, Roth JA, Heymach JV, Zhang J, Jiang J, Singh M, Smith JAM, Quintana E, Skoulidis F. Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung Cancer. Cancer Discov 14(11):2183-2208, 2024. e-Pub 2024. PMID: 38975897.
28. Gouda MA, Stephen B, Tian Y, Alshawa A, Onwugaje DOC, Albittar A, Yang Y, Zarifa A, Yilmaz B, Gurses S, Sprenger A, Derbala MH, Brink A, How JA, Moyers J, Piha-Paul SA, Hong DS, Meric-Bernstam F, Patel SP, Oliva IG. A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma. J Immunother Precis Oncol 7(4):247-254, 2024. e-Pub 2024. PMID: 39524469.
29. Knisely, A, Ahmed, J, Stephen, B, Piha-Paul, SA, Karp, DD, Zarifa, A, Fu, S, Hong, DS, Rodon Ahnert, J, Yap, TA, Tsimberidou, AM, Alshawa, A, Ileana Dumbrava, EE, Yang, Y, Song, J, Meric-Bernstam, F, Jazaeri, AA, Naing, A. Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. Cancer 130(3):400-409, 2024. e-Pub 2024. PMID: 37864520.
30. Chang JY, Xu X, Shroff GS, Comeaux NI, Li W, Rodon Ahnert J, Karp DD, Dumbrava EE, Verma V, Chen A, Welsh J, Hong DS. Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies. J Immunother Cancer 12(10), 2024. e-Pub 2024. PMID: 39384194.
31. Butner JD, Dogra P, Chung C, Koay EJ, Welsh JW, Hong DS, Cristini V, Wang Z. Hybridizing mechanistic modeling and deep learning for personalized survival prediction after immune checkpoint inhibitor immunotherapy. NPJ Syst Biol Appl 10(1):88, 2024. e-Pub 2024. PMID: 39143136.
32. Piha-Paul, SA, Tseng, C, Leung, CH, Yuan, Y, Karp, DD, Subbiah, V, Hong, DS, Fu, S, Naing, A, Rodon Ahnert, J, Javle, M, Ajani, JA, Raghav, KS, Somaiah, N, Mills, GB, Tsimberidou, AM, Zheng, X, Chen, K, Meric-Bernstam, F. Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations. NPJ Precis Oncol 8(1), 2024. e-Pub 2024. PMID: 39085400.
33. Tang, C, Hartley, G, Couillault, CA, Yuan, Y, Lin, Y, Nicholas, C, Srinivasamani, A, Dai, J, Ileana Dumbrava, EE, Fu, S, Karp, DD, Naing, A, Piha-Paul, SA, Rodon Ahnert, J, Pant, S, Subbiah, V, Yap, T, Tsimberidou, AM, Guerrero, PA, Dhebat, S, Proia, T, Curran, M, Hong, DS. Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer. BMJ Oncology 3(1), 2024. e-Pub 2024. PMID: 39886125.
34. Son, J, Zhang, Y, Lin, Y, Mirallas, O, Ballesteros, PA, Nardo, M, Clark, N, Hillman, RT, Campbell, E, Holla, V, Johnson, A, Biter, A, Yuan, Y, Cobb, LP, Gershenson, DM, Jazaeri, AA, Lu, KH, Soliman, PT, Westin, SN, Euscher, ED, Lawson, BC, Yang, RK, Meric-Bernstam, F, Hong, DS. Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers. Clinical Cancer Research 30(14):2986-2995, 2024. e-Pub 2024. PMID: 38687597.
35. Hong, DS. Diagnosing NTRK fusions in lung and thyroid cancer. Clinical advances in hematology & oncology : H&O 22(6):2-5, 2024. e-Pub 2024. PMID: 38953726.
36. Wang, T, Navenot, JM, Rafail, S, Kurtis, C, Carroll, M, Van Kerckhoven, M, Van Rossom, S, Schats, K, Avraam, K, Broad, R, Howe, K, Liddle, A, Clayton, A, Wang, R, Quinn, LL, Sanderson, JP, McAlpine, C, Carozza, C, Pimpinella, E, Hsu, SH, Brophy, F, Elefant, E, Bayer, P, Williams, D, Butler, M, Clarke, JM, Gainor, J, Govindan, R, Moreno, V, Johnson, M, Tu, J, Hong, DS, Blumenschein, GR. Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patients. Molecular Therapy Methods and Clinical Development 32(2), 2024. e-Pub 2024. PMID: 38872830.
37. Gouda M, Shunyakova J, Naing A, Dumbrava E, Hong D, Yuan Y, Yang P, Myers A, Liang Y, Ping J, Karp D, Tsimberidou A, Rodon Ahnert J, Yap T, Piha-Paul S, Meric-Bernstam F, Fu S. A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors. ESMO Open , 2024. e-Pub 2024. PMID: 38914452.
38. Torrado, C, Brink, AL, Gouda, M, Kang, L, Osburn, JA, Patterson, CJ, Charles, S, Poullard, A, Urschel, G, Ileana Dumbrava, EE, Karp, DD, Naing, A, Piha-Paul, SA, Pohlmann, PR, Rodon Ahnert, J, Tsimberidou, AM, Yap, TA, Hong, DS, Meric-Bernstam, F, Fu, S. Telehealth consultations and recruitment trends in clinical trials. Journal of Clinical Oncology 42(16):1635, 2024. e-Pub 2024.
39. Piha-Paul SA, Xu B, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Raghav K, Ajani JA, Conley AP, Mott F, Fan Y, Fan J, Peng P, Wang H, Ni S, Sun C, Qiang X, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. Oncologist, 2024. e-Pub 2024. PMID: 38297981.
40. Hong, DS, Cappuzzo, F, Chul Cho, B, Dowlati, A, Hussein, M, Kim, DW, Percent, I, Christensen, JG, Morin, J, Potvin, D, Faltaos, D, Tassell, V, Der-Torossian, H, Chao, RC. Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations. Lung Cancer 190, 2024. e-Pub 2024. PMID: 38417277.
41. Coleman N, Naing A, Zhang S, Piha-Paul SA, Tsimberidou AM, Janku F, Rodon J, Pant S, Dumbrava EE, Fu S, Hong DS, Meric-Bernstam F, Subbiah V. Phase I study of mTORC1/2 inhibitor sapanisertib (TAK-228) in combination with metformin in patients (pts) with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies. Cancer Res Commun 4(2):378-387, 2024. e-Pub 2024. PMID: 38126764.
42. Tao, DL, Nardo, M, Leung, CH, Lin, HY, Kang, L, Le, H, Ileana Dumbrava, EE, Hong, DS. The role of obesity on outcomes of adoptive cellular therapy in solid tumors. Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
43. Sun, L, Fayette, J, Salas, S, Hong, DS, Adkins, D, Dunn, LA, Ciardiello, F, Cirauqui, B, William Jr, WN, Saba, NF, Chung, CH, Birnbaum, AE, Zandberg, DP, Wehr, A, Viana Nicacio, L, Soumaoro, I, Carret, AS, Seiwert, T. Tisotumab vedotin in head and neck squamous cell carcinoma. Journal of Clinical Oncology 42(16):6012, 2024. e-Pub 2024.
44. Liu, A, Gammon, ST, Pisaneschi, F, Boda, A, Ager, CR, Piwnica-Worms, D, Hong, DS, Curran, M. Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration. JCI Insight 9(1), 2024. e-Pub 2024. PMID: 37988164.
45. Kuboki, Y, Fakih, MG, Strickler, JH, Yaeger, R, Masuishi, T, Kim, EJ, Bestvina, CM, Kopetz, S, Falchook, GS, Langer, CJ, Krauss, JC, Puri, S, Cardona, P, Chan, E, Varrieur, T, Mukundan, L, Anderson, A, Tran, Q, Hong, DS. Sotorasib with panitumumab in chemotherapy-refractory KRAS G12C-mutated colorectal cancer. Nature medicine 30(1):265-270, 2024. e-Pub 2024. PMID: 38177853.
46. Shen, L, Andre, T, Chung, HC, Deeken, J, Garralda, E, Italiano, A, Leyvraz, S, Liu, TS, Burcoveanu, DI, Grugel, R, Mussi, CE, Xu, R, Hong, DS, Drilon, A, Berlin, J. Updated efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion gastrointestinal (GI) cancer. Journal of Clinical Oncology 42(3_suppl):109, 2024. e-Pub 2024.
47. Gouda, M, Lin, HY, Kang, L, Le, H, Ileana Dumbrava, EE, Fu, S, Karp, DD, Tsimberidou, AM, Naing, A, Piha-Paul, SA, Pohlmann, PR, Ahnert, JR, Yap, TA, Meric-Bernstam, F, Hong, DS. Response to RAF/MEK/ERK inhibitors in patients with RAS altered and wild-type tumors. Journal of Clinical Oncology 42(16):3099, 2024. e-Pub 2024.
48. Lin, CC, Garralda, E, Schöffski, P, Hong, DS, Siu, LL, Martin, M, Maur, M, Hui, R, Soo, RA, Chiu, J, Zhang, T, Ma, BB, Kyi, C, Tan, DS, Cassier, PA, Sarantopoulos, J, Weickhardt, AJ, Carvajal, R, Spratlin, J, Esaki, T, Rolland, F, Akerley, W, Deschler-Baier, B, Rispoli, L, Samant, TS, Chowdhury, NR, Gusenleitner, D, Kwak, EL, Askoxylakis, V, De Braud, F. A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies. OncoImmunology 13(1), 2024. e-Pub 2024. PMID: 38170160.
49. Fountzilas, C, Cohen, S, Duvivier, HL, Hong, DS, Pedersen, KS, Pisick, E, Sommerhalder, D, Cacovean, A, Follit, C, Kowalczyk, N, Munneke, B, Tong, T, Morris, S, Butler, T, Spira, AI. COVALENT-102. Journal of Clinical Oncology 42(3_suppl):TPS716-TPS716, 2024. e-Pub 2024.
50. Miyashita H, Hong DS. Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer. J Cancer Immunol (Wilmington) 6(2):62-69, 2024. e-Pub 2024. PMID: 39175850.
51. Hong D, Drilon A, Tan D, Lin J, Kummar S, McDermott R, Berlin J, italiano A, Lassen U, Leyvraz S, Tahara M, Norenberg R, D-I B, Brega N, Shen L. Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer. Cancer, 2023. e-Pub 2023. PMID: 37769113.
52. Kummar, S, Shen, L, Hong, DS, Mcdermott, R, Keedy, V, Casanova, M, Demetri, GD, Dowlati, A, Melcón, SG, Lassen, U, Leyvraz, S, Liu, TS, Moreno, V, Patel, JD, Patil, T, Mallick, AB, Sousa, N, Tahara, M, Ziegler, DS, Norenberg, R, Arvis, P, Brega, N, Drilon, A, Tan, DS. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas. Cancer 129(23):3772-3782, 2023. e-Pub 2023. PMID: 37769113.
53. Surana R, Gonzalez GN, Rogers J, Hong DS, Yap TA, Rodon J, Naing A, Wolff RA, Smaglo BG, Bernstam FM, Subbiah V, Pant S. Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical Trials. J Gastrointest Cancer 54(4):1308-1315, 2023. e-Pub 2023. PMID: 37119430.
54. Uzunparmak B, Haymaker C, Raso G, Zhu C, Masciari S, Wang L, Kirby B, Lin H, Gorur A, A-M C, Kennon A, Ding Q, Palmieri A, Urschel GE, Yuan Y, Feng G, Rizvi Y, Hussain A, Subbiah V, Yap TA, Rodon-Ahnert J, Piha-Paul SA, Hong DS, Meric-Bernstam F, Dumbrava EE. HER2-low expression in patients with advanced or metastatic solid tumors. Ann Oncol, 2023. e-Pub 2023. PMID: 37619847.
55. Strati P, Jallouk A, Deng Q, Li X, Feng L, Sun R, Adkins S, Johncy S, Cain T, Steiner RE, Ahmed S, Chihara D, Fayad LE, Padmanabhan Iyer S, Horowitz SB, Nastoupil LJ, Nair R, Hassan A, Daoud T, Hawkins M, Rodriguez MA, Shpall EJ, Ramdial JL, Kebriaei P, Hong DS, Westin JR, Neelapu SS, Green MR. A Phase I Study of Prophylactic Anakinra to Mitigate ICANS in Patients with Large B-cell Lymphoma. Blood Adv 7(21):6785-6789, 2023. e-Pub 2023. PMID: 37389847.
56. Chen CH, Chin RL, Hartley GP, Lea ST, Engel BJ, Hsieh CE, Prasad R, Roszik J, Shingu T, Lizee GA, Heimberger AB, Millward SW, Hu J, Hong DS, Curran MA. Novel Murine Glioblastoma Models That Reflect the Immunotherapy Resistance Profile of Human Disease. Neuro Oncol 25(8):1415-1427, 2023. e-Pub 2023. PMID: 36705543.
57. He K, Hong DS, Ke D, Kebriaei P, Wang T, Danesi H, Bertolet G, Leuschner C, Puebla-Osorio N, Voss TA, Lin Q, Norry E, Fracasso PM, Welsh JW. Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report. Melanoma Res 33(4):332-337, 2023. e-Pub 2023. PMID: 37325860.
58. Hassan, R, Butler, M, O’Cearbhaill, RE, Oh, DY, Johnson, M, Zikaras, K, Smalley, M, Ross, M, Tanyi, J, Ghafoor, A, Shah, N, Saboury, B, Cao, L, Quintás-Cardama, A, Hong, DS. Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors. Nat Med 29(8):2099-2109, 2023. e-Pub 2023. PMID: 37501016.
59. Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul SA, More JA, Yilmaz B, Karp DD, Dumbrava EE, Tsimberidou AM, Hong DS, Rodon Ahnert J, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase Ib study of selinexor and eribulin combination in advanced solid tumors and triple-negative breast cancer. Cancer, 2023. e-Pub 2023. PMID: 37016732.
60. He K, Berz D, Gadgeel SM, Iams WT, Bruno DS, Blakely CM, Spira AI, Patel MR, Waterhouse DM, Richards DA, Pham A, Jotte R, Hong DS, Garon EB, Traynor A, Olson P, Latven L, Yan X, Shazer R, Leal TA. MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. J Thorac Oncol 18(7):907-921, 2023. e-Pub 2023. PMID: 36842467.
61. Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov 13(7):1556-1571, 2023. e-Pub 2023. PMID: 37068173.
62. Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul S, Moore JA, Yilmaz B, Ogbonna D, Karp DD, Ileana Dumbrava E, Tsimberidou AM, Hong DS, Rodon Ahnert J, Milton DR, Zheng X, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Cancer 129(14):2201-2213, 2023. e-Pub 2023. PMID: 37016732.
63. He K, Hong DS, Tang C, Sezen D, Cox L, Maleki A, Bertolet G, Nguyen QN, Comeaux NI, Schuda L, Chen D, Welsh JW. Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease. Radiother Oncol 183:109618, 2023. e-Pub 2023. PMID: 36921766.
64. Dy GK, Govindan R, Velcheti V, Falchook GS, Italiano A, Wolf J, Sacher AG, Takahashi T, Ramalingam SS, Dooms C, Kim DW, Addeo A, Desai J, Schuler M, Tomasini P, Hong DS, Lito P, Tran Q, Jones S, Anderson A, Hindoyan A, Snyder W, Skoulidis F, Li BT. Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100. J Clin Oncol 41(18):3311-3317, 2023. e-Pub 2023. PMID: 37098232.
65. Hong DS, Postow M, Chmielowski B, Sullivan R, Patnaik A, Cohen EEW, Shapiro G, Steuer C, Gutierrez M, Yeckes-Rodin H, Ilaria R, O'Connell B, Peng J, Peng G, Zizlsperger N, Tolcher A, Wolchok JD. Eganelisib, a First-in-Class PI3Kg Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res 29(12):2210-2219, 2023. e-Pub 2023. PMID: 37000164.
66. Moreno A, Solanki AA, Xu T, Lin R, Palta J, Daugherty E, Hong D, Hong J, Kamran SC, Katsoulakis E, Brock K, Feng M, Fuller C, Mayo C, Cancer Consortium BP. Identification of Key Elements in Prostate Cancer for Ontology Building via a Multidisciplinary Consensus Agreement. Cancers (Basel) 15(12):3121, 2023. e-Pub 2023. PMID: 37370731.
67. Carmagnani Pestana R, Moyers JT, Roszik J, Sen S, Hong DS, Naing A, Herzog CE, Fu S, Piha-Paul SA, Rodon J, Yap TA, Karp DD, Tsimberidou AM, Pant S, Zarzour MA, Ratan R, Ravi V, Benjamin RS, Lazar AJ, Wang WL, Daw N, Gill JB, Harrison DJ, Lewis VO, Roland CL, Patel SR, Livingston JA, Somaiah N, Ludwig JA, Conley AP, Hamerschlak N, Gorlick R, Meric-Bernstam F, Subbiah V. Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res 29(9):1708-1718, 2023. e-Pub 2023. PMID: 37058010.
68. Alhalabi O, Groisberg R, Zinner R, Hahn AW, Naing A, Zhang S, Tsimberidou AM, Rodon J, Fu S, Yap TA, Hong DS, Sun M, Jiang Y, Pant S, Shah AY, Zurita A, Tannir NM, Vikram R, Roszik J, Meric-Bernstam F, Subbiah V. Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. NPJ Precis Oncol 7(1):37, 2023. e-Pub 2023. PMID: 37072571.
69. Gounder MM, Bauer TM, Schwartz GK, Weise AM, LoRusso P, Kumar P, Tao B, Hong Y, Patel P, Lu Y, Lesegretain A, Tirunagaru VG, Xu F, Doebele RC, Hong DS. A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas. J Clin Oncol 41(9):1714-1724, 2023. e-Pub 2023. PMID: 36669146.
70. Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, Spira A, Angevin E, Su WC, Hong DS, Strickler JH, Motwani M, Dunbar M, Parikh A, Noon E, Blot V, Wu J, Kelly K. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol 41(5):1105-1115, 2023. e-Pub 2023. PMID: 36288547.
71. Nelson BE, Roszik J, Janku F, Hong DS, Kato S, Naing A, Piha-Paul S, Fu S, Tsimberidou A, Cabanillas M, Busaidy NL, Javle M, Byers LA, Heymach JV, Meric-Bernstam F, Subbiah V. BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. NPJ Precis Oncol 7(1):19, 2023. e-Pub 2023. PMID: 36801912.
72. Son J, Lin HY, Fu S, Biter AB, Dumbrava EE, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Yap TA, Frumovitz MM, Jazaeri AA, Ramirez PT, Westin SN, Yuan Y, Meric-Bernstam F, Hong DS. Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. J Immunother Precis Oncol 6(1):10-18, 2023. e-Pub 2023. PMID: 36751659.
73. Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med 29(1):115-126, 2023. e-Pub 2023. PMID: 36658425.
74. Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, Schuler M, Burns TF, Coveler AL, Falchook GS, Vincent M, Sunakawa Y, Dahan L, Bajor D, Rha SY, Lemech C, Juric D, Rehn M, Ngarmchamnanrith G, Jafarinasabian P, Tran Q, Hong DS. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. N Engl J Med 388(1):33-43, 2023. e-Pub 2023. PMID: 36546651.
75. Westin SN, Fu S, Tsimberidou A, Piha-Paul S, Akhmedzhanov F, Yilmaz B, McQuinn L, Brink AL, Gong J, Leung CH, Lin H, Hong DS, Pant S, Carter B, Jazaeri A, Gershenson D, Sood AK, Coleman RL, Shah J, Meric-Bernstam F, Naing A. Selinexor in combination with weekly paclitaxel in patients with advanced or metastatic solid tumors: results of an open label, single-center, multiarm Phase 1b study. Gynecol Oncol, 2023. e-Pub 2023. PMID: 36423446.
76. Kollmannsberger C, Hurwitz H, Bazhenova L, Cho BC, Hong D, Park K, Reckamp KL, Sharma S, Der-Torossian H, Christensen JG, Faltaos D, Potvin D, Tassell V, Chao R, Shapiro GI. Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors. Target Oncol 18(1):105-118, 2023. e-Pub 2023. PMID: 36459255.
77. Moyers JT, Pestana RC, Roszik J, Hong DS, Naing A, Fu S, Piha-Paul S, Yap TA, Karp D, Rodon J, Livingston A, Zarzour MA, Ravi V, Patel S, Benjamin RS, Ludwig J, Herzog C, Ratan R, Somaiah N, Conley A, Gorlick R, Meric-Bernstam F, Subbiah V. Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res 29(2):401-409, 2023. e-Pub 2023. PMID: 36288393.
78. Coleman N, Marcelo KL, Hopkins JF, Khan NI, Du R, Hong L, Park E, Balsara B, Leoni M, Pickering C, Myers J, Heymach J, Albacker LA, Hong D, Gillison M, Le X. HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma. JCO Precis Oncol 7:e2200211, 2023. e-Pub 2023. PMID: 36603172.
79. Hong DS, Van Tine BA, Biswas S, McAlpine C, Johnson ML, Olszanski AJ, Clarke JM, Araujo D, Blumenschein GR, Kebriaei P, Lin Q, Tipping AJ, Sanderson JP, Wang R, Trivedi T, Annareddy T, Bai J, Rafail S, Sun A, Fernandes L, Navenot JM, Bushman FD, Everett JK, Karadeniz D, Broad R, Isabelle M, Naidoo R, Bath N, Betts G, Wolchinsky Z, Batrakou DG, Van Winkle E, Elefant E, Ghobadi A, Cashen A, Grand'Maison A, McCarthy P, Fracasso PM, Norry E, Williams D, Druta M, Liebner DA, Odunsi K, Butler MO. Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial. Nat Med 29(1):104-114, 2023. e-Pub 2023. PMID: 36624315.
80. Westin SN, Fu S, Tsimberidou A, Piha-Paul S, Akhmedzhanov F, Yilmaz B, McQuinn L, Brink AL, Gong J, Leung CH, Lin H, Hong DS, Pant S, Carter B, Jazaeri A, Gershenson D, Sood AK, Coleman RL, Shah J, Meric-Bernstam F, Naing A. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecol Oncol 168:76-82, 2023. e-Pub 2023. PMID: 36423446.
81. Tan WK, Segal BD, Curtis MD, Baxi SS, Capra WB, Garrett-Mayer E, Hobbs BP, Hong DS, Hubbard RA, Zhu J, Sarkar S, Samant M. Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerations. Contemp Clin Trials Commun 30:101000, 2022. e-Pub 2022. PMID: 36186544.
82. Vo HH, Fu S, Hong DS, Karp DD, Piha-Paul S, Subbiah V, Janku F, Naing A, Yap TA, Rodon J, Ajani JA, Cartwright C, Johnson A, Song IW, Beck J, Kahle M, Nogueras-Gonzalez GM, Miller V, Chao C, Vining DJ, Berry DA, Meric-Bernstam F, Tsimberidou AM. Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. NPJ Precis Oncol 6(1):78, 2022. e-Pub 2022. PMID: 36302890.
83. Hong DS, Gopal AK, Shoushtari AN, Patel SP, He AR, Doi T, Ramalingam SS, Patnaik A, Sandhu S, Chen Y, Davis CB, Fisher TS, Huang B, Fly KD, Ribas A. Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer. Front Immunol 13:897991, 2022. e-Pub 2022. PMID: 35983060.
84. Mendoza TR, Hong DS, Peterson CB, Stephen B, Dumbrava E, Pant S, Tsimberidou AM, Yap TA, Sheshadri A, Altan M, George G, Castillo L, Rodriguez E, Gong J, Subbiah V, Janku F, Fu S, Piha-Paul SA, Ahnert JR, Karp DD, Cleeland C, Meric-Bernstam F, Naing A. Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. Sci Rep 12(1):14367, 2022. e-Pub 2022. PMID: 35999229.
85. Gouda MA, Huang HJ, Piha-Paul SA, Call SG, Karp DD, Fu S, Naing A, Subbiah V, Pant S, Dustin DJ, Tsimberidou AM, Hong DS, Rodon J, Meric-Bernstam F, Janku F. Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. JCO Precis Oncol 6:e2100512, 2022. e-Pub 2022. PMID: 35834760.
86. Thein KZ, Biter AB, Banks KC, Duda AW, Saam J, Roszik J, Janku F, Skoulidis F, Heymach JV, Kopetz S, Meric-Bernstam F, Hong DS. Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer. JCO Precis Oncol 6:e2100547, 2022. e-Pub 2022. PMID: 35862868.
87. Doz F, van Tilburg CM, Geoerger B, Højgaard M, Øra I, Boni V, Capra M, Chisholm J, Chung HC, DuBois SG, Gallego-Melcon S, Gerber NU, Goto H, Grilley-Olson JE, Hansford JR, Hong DS, Italiano A, Kang HJ, Nysom K, Thorwarth A, Stefanowicz J, Tahara M, Ziegler DS, Gavrilovic IT, Norenberg R, Dima L, De La Cuesta E, Laetsch TW, Drilon A, Perreault S. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro Oncol 24(6):997-1007, 2022. e-Pub 2022. PMID: 34850167.
88. Son J, George GC, Nardo M, Krause KJ, Jazaeri AA, Biter AB, Hong DS. Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis. Gynecol Oncol 165(3):664-670, 2022. e-Pub 2022. PMID: 35400527.
89. Nelson BE, Ejezie CL, Stephen BA, Nardo M, Campbell E, Gong J, Hong DS, Fu S, Yap TA, Murphy MB, Piha-Paul S, Daver NG, Rojas-Hernandez CM, Naing A. Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience. J Hematol 11(3):113-120, 2022. e-Pub 2022. PMID: 35837373.
90. Le X, Baik C, Bauman J, Gilbert J, Brose MS, Grilley-Olson JE, Patil T, McDermott R, Raez LE, Johnson JM, Shen L, Tahara M, Ho AL, Norenberg R, Dima L, Brega N, Drilon A, Hong DS. Larotrectinib Treatment for Patients with TRK Fusion-Positive Salivary Gland Cancers. Oncologist 29(6):e779-e788, 2022. e-Pub 2022. PMID: 35536733.
91. Raghav, KS, Stephen, B, Karp, DD, Piha-Paul, SA, Hong, DS, Jain, D, Chudy Onwugaje, DO, Abonofal, A, Willett, A, Overman, MJ, Smaglo, BG, Huey, RW, Meric-Bernstam, F, Varadhachary, GR, Naing, A. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP). J Immunother Cancer 10(5):e004822, 2022. e-Pub 2022. PMID: 35618285.
92. Ibarra Rovira J, Thirumurthi S, Taggart M, Yilmaz B, Lin H, Zhong LL, Ejezie CL, Akhmedzhanov FO, Zarifa A, Leung CH, Hong DS, Vikram R. Role of Abdominal and Pelvic CT Scans in Diagnosis of Patients with Immunotherapy-Induced Colitis. J Immunother Precis Oncol 5(2):32-36, 2022. e-Pub 2022. PMID: 35664090.
93. Yao S, Meric-Bernstam F, Hong D, Janku F, Naing A, Piha-Paul SA, Tsimberidou AM, Karp D, Subbiah V, Yap TA, Ahnert JR, Pant S, Dumbrava EEI, Wathoo C, Campbell E, Yu L, Yamamura Y, Fu S. Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Sci Rep 12(1):8701, 2022. e-Pub 2022. PMID: 35610322.
94. Waguespack SG, Drilon A, Lin JJ, Brose MS, McDermott R, Almubarak M, Bauman J, Casanova M, Krishnamurthy A, Kummar S, Leyvraz S, Oh D, Park K, Sohal D, Sherman E, Norenberg R, Silvertown JD, Brega N, Hong DS, Cabanillas ME. Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC). Eur J Endocrinol , 2022. e-Pub 2022. PMID: 35333737.
95. Harding JJ, Garrido-Laguna I, Chen X, Basu C, Dowlati A, Forgie A, Hooper AT, Kamperschroer C, Max SI, Moreau A, Shannon M, Wong GY, Hong DS. A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors. Front Immunol 13:845417, 2022. e-Pub 2022. PMID: 35493516.
96. Waguespack SG, Drilon A, Lin JJ, Brose MS, McDermott R, Almubarak M, Bauman J, Casanova M, Krishnamurthy A, Kummar S, Leyvraz S, Oh DY, Park K, Sohal D, Sherman E, Norenberg R, Silvertown JD, Brega N, Hong DS, Cabanillas ME. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol 186(6):631-643, 2022. e-Pub 2022. PMID: 35333737.
97. Thein KZ, Karp DD, Tsimberidou A, Gong J, Sulovic S, Shah J, Milton DR, Hong DS, Janku F, McQuinn L, Stephen BA, Colen R, Carter BW, Yap TA, Piha-Paul SA, Fu S, Meric-Bernstam F, Naing A. Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm Phase Ib study. Invest New Drugs 40(2):290-299, 2022. e-Pub 2022. PMID: 34562230.
98. Hong DS, Butler MO, Pachynski RK, Sullivan R, Kebriaei P, Boross-Harmer S, Ghobadi A, Frigault MJ, Dumbrava EE, Sauer A, Brophy F, Navenot JM, Fayngerts S, Wolchinsky Z, Broad R, Batrakou DG, Wang R, Solis LM, Duose DY, Sanderson JP, Gerry AB, Marks D, Bai J, Norry E, Fracasso PM. Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. Front Oncol 12:818679, 2022. e-Pub 2022. PMID: 35372008.
99. Sargent RE, Vazquez E, Kang I, Lu J, Manchandia T, Sheth P, Terando A, Nelson ME, Carr A, Hong DS, Sener SF. Factors associated with relapse-free survival after neoadjuvant chemotherapy for breast cancer at a safety net medical center. Am J Surg 223(3):539-542, 2022. e-Pub 2022. PMID: 34801227.
100. Hong DS, Rixe O, Chiu VK, Forde PM, Dragovich T, Lou Y, Nayak-Kapoor A, Leidner R, Atkins JN, Collaku A, Fox FE, Marshall MA, Olszanski AJ. Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors. Clin Cancer Res 28(3):479-488, 2022. e-Pub 2022. PMID: 34753777.
101. Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Beltran K, Campbell E, Le H, Campbell MT, Shah A, Tannir NM, Siefker-Radtke A, Gao J, Roszik J, Subbiah V. Validation of prognostic scores in patients with metastatic urothelial cancer enrolling in Phase I targeted therapy or next generation immunotherapy trials. Clin Genitourin Cancer 20(1):e16-e24, 2022. e-Pub 2022. PMID: 34362693.
102. Zhu L, Hobbs B, Roszik J, Holla V, Hong DS. Investigating the natural history and prognostic nature of NTRK gene fusions in solid tumors. Invest New Drugs 40(1):157-162, 2022. e-Pub 2022. PMID: 34341905.
103. Rolfo C, Drilon A, Hong D, McCoach C, Dowlati A, Lin JJ, Russo A, Schram AM, Liu SV, Nieva JJ, Nguyen T, Eshaghian S, Morse M, Gettinger S, Mobayed M, Goldberg S, Araujo-Mino E, Vidula N, Bardia A, Subramanian J, Sashital D, Stinchcombe T, Kiedrowski L, Price K, Gandara DR. NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. Br J Cancer 126(3):514-520, 2022. e-Pub 2022. PMID: 34480094.
104. Kato S, Adashek JJ, Subbiah V, Fu S, Sun M, Nguyen L, Brown EJ, Yap TA, Karp DD, Piha-Paul SA, Hong DS. A Phase I study of ixazomib and erlotinib in patients with advanced solid tumors. Invest New Drugs 40(1):99-105, 2022. e-Pub 2022. PMID: 34468905.
105. Schöffski P, Tan DSW, Martín M, Ochoa-de-Olza M, Sarantopoulos J, Carvajal RD, Kyi C, Esaki T, Prawira A, Akerley W, De Braud F, Hui R, Zhang T, Soo RA, Maur M, Weickhardt A, Krauss J, Deschler-Baier B, Lau A, Samant TS, Longmire T, Chowdhury NR, Sabatos-Peyton CA, Patel N, Ramesh R, Hu T, Carion A, Gusenleitner D, Yerramilli-Rao P, Askoxylakis V, Kwak EL, Hong DS. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. J Immunother Cancer 10(2):e003776, 2022. e-Pub 2022. PMID: 35217575.
106. DiPeri, TP, Demirhan, ME, Karp, DD, Fu, S, Hong, DS, Subbiah, V, Lim, J, Ballester, L, Tayar, JH, Suarez-Almazor, M, Javle, M, Meric-Bernstam, F. Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma. J Immunother Precis Oncol 5(1):26-30, 2022. e-Pub 2022. PMID: 35663835.
107. Fakih MG, Kopetz S, Kuboki Y, Kim TW, Munster PN, Krauss JC, Falchook GS, Han SW, Heinemann V, Muro K, Strickler JH, Hong DS, Denlinger CS, Girotto G, Lee MA, Henary H, Tran Q, Park JK, Ngarmchamnanrith G, Prenen H, Price TJ. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol 23(1):115-124, 2022. e-Pub 2022. PMID: 34919824.
108. Califf RM, Wong C, Doraiswamy PM, Hong DS, Miller DP, Mega JL, Group BS. Biological and clinical correlates of the patient health questionnaire-9: exploratory cross-sectional analyses of the baseline health study. BMJ Open 12(1):e054741, 2022. e-Pub 2022. PMID: 34983769.
109. Rudzinski ER, Hechtman J, Roy-Chowdhuri S, Rudolph M, Lockwood CM, Silvertown J, Wierzbinska J, Shen K, Norenberg R, Nogai H, Hong DS, Drilon A, Laetsch TW. Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib. Cancer Genet 260-261:46-52, 2022. e-Pub 2022. PMID: 34929613.
110. Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, Angevin E, Hong DS, Rybkin II, Barve M, Bauer TM, Delmonte A, Dunbar M, Motwani M, Parikh A, Noon E, Wu J, Blot V, Kelly K. A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC. JTO Clin Res Rep 3(1):100262, 2022. e-Pub 2022. PMID: 35005654.
111. Kummar, S, Berlin, J, Mascarenhas, L, van Tilburg, CM, Geoerger, B, Lassen, U, Schilder, RJ, Turpin, B, Nanda, S, Keating, KN, Childs, BH, Chirila, C, Laetsch, TW, Hyman, DM, Drilon, A, Hong, DS. Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib. Current Problems in Cancer 45(6), 2021. e-Pub 2021. PMID: 33865615.
112. Fu, S, Piccioni, D, Liu, H, Lukas, RV, Kesari, S, Aregawi, D, Hong, DS, Yamaguchi, K, Whicher, K, Zhang, Y, Chen, YL, Poola, N, Eddy, J, Blum, D. A Phase I study of the WT2725 dosing emulsion in patients with advanced malignancies. Sci Rep 11(1), 2021. e-Pub 2021. PMID: 34785698.
113. Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Fu S, Subbiah V, Hong DS, Yap TA, Shah J, Milton DR, McQuinn L, Gong J, Tran Y, Carter BW, Colen R, Meric-Bernstam F, Naing A. Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors. Exp Hematol Oncol 10(1):59, 2021. e-Pub 2021. PMID: 34965890.
114. Camidge DR, Morgensztern D, Heist RS, Barve M, Vokes EE, Goldman JW, Hong DS, Bauer TM, Strickler JH, Angevin E, Motwani M, Parikh A, Sun Z, Bach BA, Wu J, Komarnitsky PB, Kelly K. Phase 1 study of 2- or 3-week dosing of telisotuzumab vedotin, an antibody-drug conjugate targeting c-Met, monotherapy in patients with advanced non-small cell lung carcinoma. Clin Cancer Res 27(21):5781-5792, 2021. e-Pub 2021. PMID: 34426443.
115. Butner, JD, Martin, GV, Wang, Z, Corradetti, B, Ferrari, M, Esnaola, N, Chung, C, Hong, DS, Welsh, J, Hasegawa, N, Mittendorf, EA, Curley, SA, Chen, SH, Pan, PY, Libutti, SK, Ganesan, S, Sidman, RL, Pasqualini, R, Arap, W, Koay, EJ, Cristini, V. Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling. eLife 10, 2021. e-Pub 2021. PMID: 34749885.
116. Ileana Dumbrava, EE, Call, SG, Huang, H, Stuckett, AL, Madwani, K, Adat, A, Hong, DS, Piha-Paul, SA, Subbiah, V, Karp, DD, Fu, S, Naing, A, Tsimberidou, AM, Moulder, S, Koenig, KB, Barcenas, CH, Kee, BK, Fogelman, D, Kopetz, S, Meric-Bernstam, F, Janku, F. PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. ESMO Open 6(5), 2021. e-Pub 2021. PMID: 34479035.
117. Saleh MN, Patel MR, Bauer TM, Goel S, Falchook GS, Shapiro GI, Chung KY, Infante JR, Conry RM, Rabinowits G, Hong DS, Wang JS, Steidl U, Naik G, Guerlavais V, Vukovic V, Annis DA, Aivado M, Meric-Bernstam F. Phase 1 trial of ALRN-6924, a dual inhibitor of MDMX and MDM2, in patients with solid tumors and lymphomas bearing wild-type TP53. Clin Cancer Res 27(19):5236-5247, 2021. e-Pub 2021. PMID: 34301750.
118. Patel RR, He K, Barsoumian HB, Chang JY, Tang C, Verma V, Comeaux N, Chun SG, Gandhi S, Truong MT, Erasmus JJ, Hong DS, Lee PP, Ning MS, Nguyen QN, Heymach JV, Altan M, Blumenschein G, Fossella FV, Sezen D, Chen D, Carter BW, Davies MA, Glitza IC, Diab A, Ferrarotto R, Cabanillas ME, Yuan Y, Shah SJ, Parra ER, Sun B, Cortez MA, Welsh JW. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: results of a Phase II trial. Radiother Oncol 162:60-67, 2021. e-Pub 2021. PMID: 34237343.
119. Moore, K, Hong, DS, Patel, MR, Pant, S, Ulahannan, SV, Jones, SF, Meric-Bernstam, F, Wang, JS, Aljumaily, R, Hamilton, E, Wittchen, ES, Wang, X, Lin, AB, Bendell, JC. A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. Target Oncol 16(5):569-589, 2021. e-Pub 2021. PMID: 34559360.
120. Mansfield AS, Hong DS, Hann CL, Farago AF, Beltran H, Waqar SN, Hendifar AE, Anthony LB, Taylor MH, Bryce AH, Tagawa ST, Lewis K, Niu J, Chung CH, Cleary JM, Rossi M, Ludwig C, Valenzuela R, Luo Y, Aggarwal R. A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. NPJ Precis Oncol 5(1):74, 2021. e-Pub 2021. PMID: 34354225.
121. Huey RW, George GC, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul S, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Rodon J, Meric-Bernstam F, Shih YT, Hong DS. Patient-reported out-of-pocket costs and financial toxicity during early-phase oncology clinical trials. Oncologist 26(7):588-596, 2021. e-Pub 2021. PMID: 33783054.
122. Kim ST, Tayar J, Fu S, Ke D, Norry E, Sun A, Miller J, Hong DS. Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab. J Immunother Cancer 9(7):e002716, 2021. e-Pub 2021. PMID: 34233963.
123. Kurzrock R, Lin CC, Wu TC, Hobbs BP, Pestana RC, Hong DS. Moving beyond 3+3: the future of clinical trial design. Am Soc Clin Oncol Educ Book 41:e133-e144, 2021. e-Pub 2021. PMID: 34061563.
124. Hegde A, Jayaprakash P, Couillault CA, Piha-Paul S, Karp D, Rodon J, Pant S, Fu S, Dumbrava EE, Yap TA, Subbiah V, Bhosale P, Coarfa C, Higgins JP, Williams ET, Wilson TF, Lim J, Meric-Bernstam F, Sumner E, Zain H, Nguyen D, Nguyen LM, Rajapakshe K, Curran MA, Hong DS. A Phase I dose-escalation study to evaluate the safety and tolerability of evofosfamide in combination with ipilimumab in advanced solid malignancies. Clin Cancer Res 27(11):3050-3060, 2021. e-Pub 2021. PMID: 33771853.
125. Ho AL, Brana I, Haddad R, Bauman J, Bible K, Oosting S, Wong DJ, Ahn MJ, Boni V, Even C, Fayette J, Flor MJ, Harrington K, Hong DS, Kim SB, Licitra L, Nixon I, Saba NF, Hackenberg S, Specenier P, Worden F, Balsara B, Leoni M, Martell B, Scholz C, Gualberto A. Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations. J Clin Oncol 39(17):1856-1864, 2021. e-Pub 2021. PMID: 33750196.
126. Xiong, W, Friese-Hamim, M, Johne, A, Stroh, C, Klevesath, M, Falchook, GS, Hong, DS, Girard, P, El Bawab, S. Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose. CPT Pharmacometrics Syst Pharmacol 10(5):428-440, 2021. e-Pub 2021. PMID: 33818908.
127. Piha-Paul SA, Dumbrava EE, Nair BC, Xiong W, Xu L, Mostorino R, Subbiah V, Tannir N, Fu S, Naing A, Janku F, Karp DD, Patel S, Daw NC, Hong D, Meric-Bernstam F, Zinner R. A Phase I trial of the MET/ALK/ROS1 inhibitor crizotinib combined with the VEGF inhibitor pazopanib in patients with advanced solid malignancies. Onco Targets Ther 14:3037-3049, 2021. e-Pub 2021. PMID: 33994796.
128. Krebs, M, Blay, JY, Le Tourneau, C, Hong, DS, Veronese, L, Antoniou, M, Bennett, I. Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications. ESMO Open 6(2), 2021. e-Pub 2021. PMID: 33676294.
129. Yao S, Janku F, Subbiah V, Stewart J, Patel SP, Kaseb A, Westin SN, Naing A, Tsimberidou AM, Hong D, Piha-Paul SA, Shi N, Johnston A, Bomalaski J, Fu S. Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. Br J Cancer 124(9):1533-1539, 2021. e-Pub 2021. PMID: 33674736.
130. Cascone, T, Sacks, R, Subbiah, IM, Drobnitzky, N, Piha-Paul, SA, Hong, DS, Hess, KR, Amini, B, Bhatt, T, Fu, S, Naing, A, Janku, F, Karp, DD, Falchook, GS, Conley, AP, Sherman, SI, Meric-Bernstam, F, Ryan, A, Heymach, JV, Subbiah, V. Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors. ESMO Open 6(2), 2021. e-Pub 2021. PMID: 33721621.
131. Hong, DS, Moore, K, Bendell, JC, Karp, DD, Wang, JS, Ulahannan, SV, Jones, SF, Wu, W, Donoho, GP, Ding, Y, Capen, A, Wang, X, Lin, AB, Patel, MR. Preclinical evaluation and phase Ib study of prexasertib, a CHK1 inhibitor, and samotolisib (LY3023414), a dual PI3K/mTOR inhibitor. Clin Cancer Res 27(7):1864-1874, 2021. e-Pub 2021. PMID: 33495309.
132. Butner JD, Wang Z, Elganainy D, Al Feghali KA, Plodinec M, Calin GA, Dogra P, Nizzero S, Ruiz-Ramírez J, Martin GV, Tawbi HA, Chung C, Koay EJ, Welsh JW, Hong DS, Cristini V. A mathematical model for the quantification of a patient's sensitivity to checkpoint inhibitors and long-term tumour burden. Nat Biomed Eng 5(4):297-308, 2021. e-Pub 2021. PMID: 33398132.
133. Ballhausen A, Wheler JJ, Karp DD, Piha-Paul SA, Fu S, Pant S, Tsimberidou AM, Hong DS, Subbiah V, Holley VR, Huang H, Brewster AM, Koenig KB, Ibrahim NK, Meric-Bernstam F, Janku F. Phase I study of everolimus, letrozole, and trastuzumab in patients with hormone receptor-positive metastatic breast cancer or other solid tumors. Clin Cancer Res 27(5):1247-1255, 2021. e-Pub 2021. PMID: 33115815.
134. Tsimberidou AM, Hong DS, Fu S, Karp DD, Piha-Paul S, Kies MS, Ravi V, Subbiah V, Patel SM, Tu SM, Janku F, Heymach J, Johnson A, Cartwright C, Zhao L, Zhang J, Berry DA, Vining DJ, Futreal A, Miller VA, Meric-Bernstam F. Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. NPJ Precis Oncol 5(1):21, 2021. e-Pub 2021. PMID: 33742104.
135. Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes. Mol Cancer Res 19(3):395-402, 2021. e-Pub 2021. PMID: 33323389.
136. Hajjar J, Mendoza T, Zhang L, Fu S, Piha-Paul SA, Hong DS, Janku F, Karp DD, Ballhausen A, Gong J, Zarifa A, Peterson CB, Meric-Bernstam F, Jenq R, Naing A. Associations between the gut microbiome and fatigue in cancer patients. Sci Rep 11(1):5847, 2021. e-Pub 2021. PMID: 33712647.
137. Kopetz S, Guthrie KA, Morris VK, Lenz HJ, Magliocco AM, Maru D, Yan Y, Lanman R, Manyam G, Hong DS, Sorokin A, Atreya CE, Diaz LA, Allegra C, Raghav KP, Wang SE, Lieu CH, McDonough SL, Philip PA, Hochster HS. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). J Clin Oncol 39(4):285-294, 2021. e-Pub 2021. PMID: 33356422.
138. Janku F, Sakamuri D, Kato S, Huang HJ, Call SG, Naing A, Holley VR, Patel SP, Amaria RN, Falchook GS, Piha-Paul SA, Zinner RG, Tsimberidou AM, Hong DS, Meric-Bernstam F. Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers. Cancer 127(3):391-402, 2021. e-Pub 2021. PMID: 33119140.
139. Janku F, Zhang HH, Pezeshki AM, Goel S, Murthy R, Wang-Gillam A, Shepard DR, Helgason T, Masters T, Hong DS, Piha-Paul SA, Karp DD, Klang M, Huang SY, Sakamuri D, Raina A, Torrisi J, Solomon SB, Weissfeld A, Trevino E, DeCrescenzo GA, Collins A, Miller M, Salstrom JL, Korn R, Zhang L, Saha S, Leontovich AA, Tung D, Kreider B, Varterasian M, Khazaie K, Gounder MM. Intratumoral injection of Clostridium novyi-NT spores in patients with treatment-refractory advanced solid tumors. Clin Cancer Res 27(1):96-106, 2021. e-Pub 2021. PMID: 33046513.
140. Yap TA, Tan DS, Terbuch A, Caldwell R, Guo C, Goh BC, Heong V, Haris NRM, Bashir S, Drew Y, Hong DS, Meric-Bernstam F, Wilkinson G, Hreiki J, Wengner AM, Bladt F, Schlicker A, Ludwig M, Zhou Y, Liu L, Bordia S, Plummer R, Lagkadinou E, de Bono JS. First-in-human trial of the oral ataxia telangiectasia and Rad3-related inhibitor BAY 1895344 in patients with advanced solid tumors. Cancer Discov 11(1):80-91, 2021. e-Pub 2021. PMID: 32988960.
141. Le, X, Hong, L, Hensel, CH, Chen, R, Kemp, HN, Coleman, N, Ciunci, CA, Liu, SV, Vailati Negrao, M, Yen, J, Xia, X, Scheuenpflug, J, Stroh, C, Juraeva, D, Tsao, A, Hong, DS, Raymond, VM, Paik, PK, Zhang, J, Heymach, JV. Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping. JCO Precis Oncol 5:1802-1812, 2021. e-Pub 2021. PMID: 34957368.
142. Henry, JT, Coker, O, Chowdhury, S, Shen, JY, Morris, VK, Dasari, NV, Raghav, KS, Nusrat, M, Kee, BK, Parseghian, C, Pant, S, Jeyakumar, N, Zhu, L, Nishioka, Y, Fogelman, D, Wolff, RA, Hong, DS, Overman, MJ, Vauthey, JN, Kopetz, S, Johnson, B. Comprehensive clinical and molecular characterization of KRASG12C-mutant colorectal cancer. JCO Precis Oncol 5:613-621, 2021. e-Pub 2021. PMID: 34250391.
143. Subbiah V, Erwin W, Mawlawi O, McCoy A, Wages D, Wheeler C, Gonzalez-Lepera C, Liu H, Macapinlac H, Meric-Bernstam F, Hong DS, Pant S, Le D, Santos E, Gonzalez J, Roszik J, Suzuki T, Subach RA, Madden T, Johansen M, Nomura F, Satoh H, Matsuura T, Kajita M, Nakamura E, Funase Y, Matsushima S, Ravizzini G. Phase I study of p-cadherin-targeted radioimmunotherapy with 90Y-FF-21101 monoclonal antibody in solid tumors. Clin Cancer Res 26(22):5830-5842, 2020. e-Pub 2020. PMID: 32816889.
144. Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA. Safety and efficacy of vorinostat plus sirolimus or everolimus in patients with relapsed refractory Hodgkin lymphoma. Clin Cancer Res 26(21):5579-5587, 2020. e-Pub 2020. PMID: 33055173.
145. Italiano A, Nanda S, Briggs A, Garcia-Foncillas J, Lassen U, Vassal G, Kummar S, van Tilburg CM, Hong DS, Laetsch TW, Keating K, Reeves JA, Fellous M, Childs BH, Drilon A, Hyman DM. Larotrectinib versus prior therapies in tropomyosin receptor kinase fusion cancer: an intra-patient comparative analysis. Cancers 12(11):3246, 2020. e-Pub 2020. PMID: 33158040.
146. Hahn, AW, Alhalabi, O, Msaouel, P, Meric-Bernstam, F, Naing, A, Jonasch, E, Piha-Paul, SA, Hong, DS, Pant, S, Yap, TA, Campbell, E, Le, H, Tannir, NM, Roszik, J, Subbiah, V. Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open 5(6), 2020. e-Pub 2020. PMID: 33229506.
147. Atkins JT, George GC, Hess K, Marcelo-Lewis KL, Yuan Y, Borthakur G, Khozin S, LoRusso P, Hong DS. Pre-clinical animal models are poor predictors of human toxicities in Phase 1 oncology clinical trials. Br J Cancer 123(10):1496-1501, 2020. e-Pub 2020. PMID: 32868897.
148. Jaiswal AR, Liu AJ, Pudakalakatti S, Dutta P, Jayaprakash P, Bartkowiak T, Ager CR, Wang ZQ, Reuben A, Cooper ZA, Ivan C, Ju Z, Nwajei F, Wang J, Davies MA, Davis RE, Wargo JA, Bhattacharya PK, Hong DS, Curran MA. Melanoma evolves complete immunotherapy resistance through the acquisition of a hypermetabolic phenotype. Cancer Immunol Res 8(11):1365-1380, 2020. e-Pub 2020. PMID: 32917656.
149. Barsoumian HB, Ramapriyan R, Younes AI, Caetano MS, Menon H, Comeaux NI, Cushman TR, Schoenhals JE, Cadena AP, Reilly TP, Chen D, Masrorpour F, Li A, Hong DS, Diab A, Nguyen QN, Glitza I, Ferrarotto R, Chun SG, Cortez MA, Welsh J. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer 8(2):e000537, 2020. e-Pub 2020. PMID: 33106386.
150. Mendoza T, Sheshadri A, Altan M, Hess K, George G, Stephen B, Castillo L, Rodriguez E, Gong J, Peterson C, Rodon Ahnert J, Fu S, Piha-Paul SA, Pant S, Dumbrava E, Yap TA, Janku F, Tsimberidou AM, Subbiah V, Karp DD, Zarifa A, McQuinn LM, Cleeland C, Hong DS, Naing A. Evaluating the psychometric properties of the immunotherapy module of the MD Anderson Symptom Inventory. J Immunother Cancer 8(2):e00093, 2020. e-Pub 2020. PMID: 33097611.
151. Siu L, Brody J, Gupta S, Marabelle A, Jimeno A, Munster P, Grilley-Olson J, Rook AH, Hollebecque A, Wong RKS, Welsh JW, Wu Y, Morehouse C, Hamid O, Walcott F, Cooper ZA, Kumar R, Ferté C, Hong DS. Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors. J Immunother Cancer 8(2):e001095, 2020. e-Pub 2020. PMID: 33037117.
152. Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Ali SM, Lee J, Elamin YY, Simon GR, Blumenschein GR, Papadimitrakopoulou VA, Hong D, Meric-Bernstam F, Heymach J, Subbiah V. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open 5(5):e000799, 2020. e-Pub 2020. PMID: 33097651.
153. Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Ramalingam SS, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Friberg G, Lito P, Govindan R, Li BT. KRASG12C inhibition with sotorasib in advanced solid tumors. N Engl J Med 383(13):1207-1217, 2020. e-Pub 2020. PMID: 32955176.
154. Zamarin D, Hamid O, Nayak-Kapoor A, Sahebjam S, Sznol M, Collaku A, Fox FE, Marshall MA, Hong DS. Mogamulizumab in combination with durvalumab or tremelimumab in patients with advanced solid tumors: a Phase I study. Clin Cancer Res 26(17):4531-4541, 2020. e-Pub 2020. PMID: 32586937.
155. George GC, Mendoza TR, Iwuanyanwu EC, Manandhar M, Afshar SF, Piha-Paul SA, Tsimberidou A, Naing A, Cleeland CS, Hong DS. Factors affecting symptom presentation in an early-phase clinical trials clinic patient population. Invest New Drugs 38(4):1166-1174, 2020. e-Pub 2020. PMID: 31761957.
156. Sheth RA, Murthy R, Hong DS, Patel S, Overman MJ, Diab A, Hwu P, Tam A. Assessment of image-guided intratumoral delivery of immunotherapeutics in patients with cancer. JAMA Netw Open 3(7):e207911, 2020. e-Pub 2020. PMID: 32725245.
157. Hong DS, Parikh A, Shapiro GI, Varga A, Naing A, Meric-Bernstam F, Ö A, Reyderman L, Binder TA, Ren M, Liu M, Dayal S, Siu AY, Sachdev P, Xu L, Bhagawati-Prasad V, Tchakov I, Ooi CE, Bao X, Marabelle A. First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers. J Immunother Cancer 8(1):e000222, 2020. e-Pub 2020. PMID: 32554609.
158. Kato S, Okamura R, Sicklick JK, Daniels GA, Hong DS, Goodman A, Weihe E, Lee S, Khalid N, Collier R, Mareboina M, Riviere P, Whitchurch TJ, Fanta PT, Lippman SM, Kurzrock R. Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies. Int J Cancer 146(12):3450-3460, 2020. e-Pub 2020. PMID: 31782524.
159. Schuler M, Berardi R, Lim WT, de Jonge M, Bauer TM, Azaro A, Gottfried M, Han JY, Lee DH, Wollner M, Hong DS, Vogel A, Delmonte A, Akimov M, Ghebremariam S, Cui X, Nwana N, Giovannini M, Kim TM. Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial. Ann Oncol 31(6):789-797, 2020. e-Pub 2020. PMID: 32240796.
160. Hong DS, Kang YK, Borad M, Sachdev J, Ejadi S, Lim HY, Brenner AJ, Park K, Lee JL, Kim TY, Shin S, Becerra CR, Falchook G, Stoudemire J, Martin D, Kelnar K, Peltier H, Bonato V, Bader AG, Smith S, Kim S, O'Neill V, Beg MS. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer 122(11):1630-1637, 2020. e-Pub 2020. PMID: 32238921.
161. Groisberg R, Roszik J, Conley AP, Lazar AJ, Portal DE, Hong DS, Naing A, Herzog CE, Somaiah N, Zarzour MA, Patel S, Brown RE, Subbiah V. Genomics, morphoproteomics, and treatment patterns of patients with alveolar soft part sarcoma and response to multiple experimental therapies. Mol Cancer Ther 19(5):1165-1172, 2020. e-Pub 2020. PMID: 32127467.
162. Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, van Tilburg CM, Nagasubramanian R, Berlin JD, Federman N, Mascarenhas L, Geoerger B, Dowlati A, Pappo AS, Bielack S, Doz F, McDermott R, Patel JD, Schilder RJ, Tahara M, Pfister SM, Witt O, Ladanyi M, Rudzinski ER, Nanda S, Childs BH, Laetsch TW, Hyman DM, Drilon A. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 21(4):531-540, 2020. e-Pub 2020. PMID: 32105622.
163. Subbiah V, Dumbrava EI, Jiang Y, Thein KZ, Naing A, Hong DS, Fu S, Piha-Paul SA, Tsimberidou AM, Janku F, Meric-Bernstam F, Kurzrock R, Falchook G. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a Phase 1 dose escalation triplet combination trial. Exp Hematol Oncol 9(1):7, 2020. e-Pub 2020. PMID: 32337094.
164. Butner JD, Elganainy D, Wang CX, Wang Z, Chen SH, Esnaola NF, Pasqualini R, Arap W, Hong DS, Welsh J, Koay EJ, Cristini V. Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy. Sci Adv 6(18):eaay6298, 2020. e-Pub 2020. PMID: 32426472.
165. Pairawan S, Hess KR, Janku F, Sánchez NS, Shaw KRM, Eng C, Damodaran S, Javle M, Kaseb AO, Hong DS, Subbiah V, Fu S, Fogelman DR, Raymond VM, Lanman RB, Meric-Bernstam F. Cell-free circulating tumor DNA variant allele frequency associates with survival in metastatic cancer. Clin Cancer Res 26(8):1924-1931, 2020. e-Pub 2020. PMID: 31852833.
166. Piha-Paul SA, Hann CL, French CA, Cousin S, Braña I, Cassier PA, Moreno V, de Bono JS, Harward SD, Ferron-Brady G, Barbash O, Wyce A, Wu Y, Horner T, Annan M, Parr NJ, Prinjha RK, Carpenter CL, Hilton J, Hong DS, Haas NB, Markowski MC, Dhar A, O'Dwyer PJ, Shapiro GI. Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors. JNCI Cancer Spectr 4(2):pkz093, 2020. e-Pub 2020. PMID: 32328561.
167. Hong DS, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, Arkenau HT, Machiels JP, Spicer JF, Jones R, Forster M, Cornez N, Gennigens C, Johnson ML, Thistlethwaite FC, Rangwala RA, Ghatta S, Windfeld K, Harris JR, Lassen UN, Coleman RL. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. Clin Cancer Res 26(6):1220-1228, 2020. e-Pub 2020. PMID: 31796521.
168. Falchook GS, Kurzrock R, Amin HM, Xiong W, Fu S, Piha-Paul SA, Janku F, Eskandari G, Catenacci DV, Klevesath M, Bruns R, Stammberger U, Johne A, Bladt F, Friese-Hamim M, Girard P, El Bawab S, Hong DS. First-in-man phase I trial of the selective MET inhibitor tepotinib in patients with advanced solid tumors. Clin Cancer Res 26(6):1237-1246, 2020. e-Pub 2020. PMID: 31822497.
169. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8(1):e000347, 2020. e-Pub 2020. PMID: 32188704.
170. Bang YJ, Su WC, Schuler M, Nam DH, Lim WT, Bauer TM, Azaro A, Poon RTP, Hong D, Lin CC, Akimov M, Ghebremariam S, Zhao S, Giovannini M, Ma B. Phase 1 study of capmatinib in MET-positive solid tumor patients: dose escalation and expansion of selected cohorts. Cancer Sci 111(2):536-547, 2020. e-Pub 2020. PMID: 31778267.
171. Wang Y, Janku F, Piha-Paul S, Hess K, Broaddus R, Liu L, Shi N, Overman M, Kopetz S, Subbiah V, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Fu S. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Sci Rep 10(1):3080, 2020. e-Pub 2020. PMID: 32080210.
172. Sullivan RJ, Hollebecque A, Flaherty KT, Shapiro GI, Rodon Ahnert J, Millward MJ, Zhang W, Gao L, Sykes A, Willard MD, Yu D, Schade AE, Crowe K, Flynn DL, Kaufman MD, Henry JR, Peng SB, Benhadji KA, Conti I, Gordon MS, Tiu RV, Hong DS. A Phase I study of LY3009120, a pan-RAF Inhibitor, in patients with advanced or metastatic cancer. Mol Cancer Ther 19(2):460-467, 2020. e-Pub 2020. PMID: 31645440.
173. Kairemo K, Santos EB, Macapinlac HA, Patel S, Conley AP, Hong DS, Subbiah V. Molecular imaging with 3'-deoxy-3'[(18)F]-fluorothymidine (18F-FLT) PET/CT for early response to targeted therapies in sarcomas: a pilot study. Diagnostics 10(3):125, 2020. e-Pub 2020. PMID: 32106426.
174. Tsimberidou AM, Hong DS, Wheler JJ, Falchook GS, Janku F, Naing A, Fu S, Piha-Paul S, Cartwright C, Broaddus RR, Nogueras Gonzalez GM, Hwu P, Kurzrock R. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J Hematol Oncol 12(1):145, 2019. e-Pub 2019. PMID: 31888672.
175. Welsh JW, Tang C, de Groot P, Naing A, Hess KR, Heymach JV, Papadimitrakopoulou VA, Cushman TR, Subbiah V, Chang JY, Simon GR, Ramapriyan R, Barsoumian HB, Menon H, Cortez MA, Massarelli E, Nguyen Q, Sharma P, Allison JP, Diab A, Verma V, Raju U, Shaaban SG, Dadu R, Cabanillas ME, Wang K, Anderson C, Gomez DR, Hahn S, Komaki R, Hong DS. Phase II trial of ipilimumab with stereotactic radiation therapy for metastatic disease: outcomes, toxicities, and low-dose radiation-related abscopal responses. Cancer Immunol Res 7(12):1903-1909, 2019. e-Pub 2019. PMID: 31658994.
176. Reilley MJ, Morrow B, Ager CR, Liu A, Hong DS, Curran MA. TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma. J Immunother Cancer 7(1):323, 2019. e-Pub 2019. PMID: 31771649.
177. Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, Gaida K, Holt T, Knutson CG, Koppada N, Lanman BA, Werner J, Rapaport AS, San Miguel T, Ortiz R, Osgood T, Sun JR, Zhu X, McCarter JD, Volak LP, Houk BE, Fakih MG, O'Neil BH, Price TJ, Falchook GS, Desai J, Kuo J, Govindan R, Hong DS, Ouyang W, Henary H, Arvedson T, Cee VJ, Lipford JR. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575(7781):217-223, 2019. e-Pub 2019. PMID: 31666701.
178. Garrido-Laguna I, Krop I, 3rd BH, Hamilton E, Braiteh F, Weise AM, Abu-Khalaf M, Werner TL, Pirie-Shepherd S, Zopf CJ, Lakshminarayanan M, Holland JS, Baffa R, Hong DS. First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors. Int J Cancer 145(7):1798-1808, 2019. e-Pub 2019. PMID: 30680712.
179. Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND, Boraddus RR, Pant S, Subbiah V, Hong DS, Zarifa A, Fu S, Karp DD, Meric-Bernstam F, Naing A. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer 7(1):253, 2019. e-Pub 2019. PMID: 31533818.
180. Vishnoi M, Liu NH, Yin W, Boral D, Scamardo A, Hong D, Marchetti D. The identification of a TNBC liver metastasis gene signature by sequential CTC-xenograft modelling. Mol Oncol 13(9):1913-1926, 2019. e-Pub 2019. PMID: 31216110.
181. Menon H, Chen D, Ramapriyan R, Verma V, Barsoumian HB, Cushman TR, Younes AI, Cortez MA, Erasmus JJ, de Groot P, Carter BW, Hong DS, Glitza IC, Ferrarotto R, Altan M, Diab A, Chun SG, Heymach JV, Tang C, Nguyen QN, Welsh JW. Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy. J Immunother Cancer 7(1):237, 2019. e-Pub 2019. PMID: 31484556.
182. Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res 21(1):78, 2019. e-Pub 2019. PMID: 31277699.
183. Subbiah V, Anderson PM, Kairemo K, Hess K, Huh WW, Ravi V, Daw NC, Somaiah N, Ludwig JA, Benjamin RS, Chawla SP, Hong DS, Meric-Bernstam F, Ravizzini G, Kleinerman ES, Macapinlac HA, Rohren E. Alpha particle radium 223 dichloride in high-risk osteosarcoma: a Phase I dose escalation trial. Clin Cancer Res 25(13):3802-3810, 2019. e-Pub 2019. PMID: 30733229.
184. Hong D, Rasco D, Veeder M, Luke JJ, Chandler J, Balmanoukian A, George TJ, Munster P, Berlin JD, Gutierrez M, Mita A, Wakelee H, Samakoglu S, Guan S, Dimery I, Graef T, Borazanci E. A Phase 1b/2 Study of the bruton tyrosine kinase inhibitor ibrutinib and the PD-L1 inhibitor durvalumab in patients with pretreated solid tumors. Oncology 97(2):102-111, 2019. e-Pub 2019. PMID: 31230047.
185. Dumbrava EI, Brusco L, Daniels M, Wathoo C, Shaw K, Lu K, Zheng X, Strong L, Litton J, Arun B, Eterovic AK, Routbort M, Patel K, Qi Y, Piha-Paul S, Subbiah V, Hong D, Rodon J, Kopetz S, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations. JCO Precis Oncol 2019(3):1-11, 2019. e-Pub 2019. PMID: 31517177.
186. Hong DS, LoRusso PM, Hamid O, Janku F, Kittaneh M, Catenacci DVT, Chan E, Bekaii-Saab T, Gadgeel S, Loberg RD, Amore BM, Hwang YC, Tang R, Ngarmchamnanrith G, Kwak EL. Phase I study of AMG 337, a highly selective small-molecule MET inhibitor, in patients with advanced solid tumors. Clin Cancer Res 25(8):2403-2413, 2019. e-Pub 2019. PMID: 30425090.
187. Palaskas N, Morgan J, Daigle T, Banchs J, Durand JB, Hong D, Naing A, Le H, Hassan SA, Karimzad K, Mouhayar E, Kim P, Lopez-Mattei J, Thompson K, Yusuf SW, Iliescu C. Targeted cancer therapies with pericardial effusions requiring pericardiocentesis focusing on immune checkpoint inhibitors. Am J Cardiol 123(8):1351-1357, 2019. e-Pub 2019. PMID: 30765065.
188. de Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels JP, Arkenau HT, Plummer R, Jones RH, Nielsen D, Windfeld K, Ghatta S, Slomovitz BM, Spicer JF, Yachnin J, Ang JE, Mau-Sørensen PM, Forster MD, Collins D, Dean E, Rangwala RA, Lassen U. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, Phase 1-2 trial. Lancet Oncol 20(3):383-393, 2019. e-Pub 2019. PMID: 30745090.
189. George GC, Iwuanyanwu EC, Buford AS, Piha-Paul SA, Subbiah V, Fu S, Karp DD, Pant S, Hinojosa CO, Hess KR, Cleeland CS, Bernstam EV, Meric-Bernstam F, Hong DS. Cancer-related internet use and its association with patient decision making and trust in physicians among patients in an early drug development clinic: a questionnaire-based cross-sectional observational study. J Med Internet Res 21(3):e10348, 2019. e-Pub 2019. PMID: 30869638.
190. Hobbs BP, Barata PC, Kanjanapan Y, Paller CJ, Perlmutter J, Pond GR, Prowell TM, Rubin EH, Seymour LK, Wages NA, Yap TA, Feltquate D, Garrett-Mayer E, Grossman W, Hong DS, Ivy SP, Siu LL, Reeves SA, Rosner GL. Seamless designs: current practice and considerations for early-phase drug development in oncology. J Natl Cancer Inst 111(2):118-128, 2019. e-Pub 2019. PMID: 30561713.
191. Hong DS, Bauer TM, Lee JJ, Dowlati A, Brose MS, Farago AF, Taylor M, Shaw AT, Montez S, Meric-Bernstam F, Smith S, Tuch BB, Ebata K, Cruickshank S, Cox MC, Burris HA, Doebele RC. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, Phase I dose-escalation study. Ann Oncol 30(2):325-331, 2019. e-Pub 2019. PMID: 30624546.
192. Hegde A, Hong DS, Behrang A, Ali SM, Juckett L, Meric-Bernstam F, Subbiah V. Activity of brigatinib in crizotinib and ceritinib-resistant ROS1-rearranged non-small-cell lung cancer. JCO Precis Oncol 3:1-6, 2019. e-Pub 2019. PMID: 32775947.
193. Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol 30(2):243-249, 2019. e-Pub 2019. PMID: 30462160.
194. George GC, Buford A, Hess K, Piha-Paul SA, Zinner R, Subbiah V, Hinojosa C, Cleeland CS, Meric-Bernstam F, Bernstam EV, Hong DS. Cancer-related internet use and online social networking among patients in an early-phase clinical trials clinic at a comprehensive cancer center. JCO Clin Cancer Inform 2(2):1-14, 2018. e-Pub 2018. PMID: 30652565.
195. Aghajanian C, Bell-McGuinn KM, 3rd BH, Siu LL, Stayner LA, Wheler JJ, Hong DS, Kurkjian C, Pant S, Santiago-Walker A, Gauvin JL, Antal JM, Opalinska JB, Morris SR, Infante JR. A Phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors. Invest New Drugs 36(6):1016-1025, 2018. e-Pub 2018. PMID: 29611022.
196. Hobbs BP, Kane MJ, Hong DS, Landin R. Statistical challenges posed by uncontrolled master protocols: sensitivity analysis of the vemurafenib study. Ann Oncol 29(12):2296-2301, 2018. e-Pub 2018. PMID: 30335125.
197. Hinchcliff E, Hong D, Le H, Chisholm G, Iyer R, Naing A, Hwu P, Jazaeri A. Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. Gynecol Oncol 151(3):407-413, 2018. e-Pub 2018. PMID: 30366646.
198. Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Curran M, Liu Q, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MVP, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR, Hong DS. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a Phase 1b trial. J Immunother Cancer 6(1):119, 2018. e-Pub 2018. PMID: 30446007.
199. Tan, DS, Lassen, U, Albert, CM, Kummar, S, van Tilburg, CM, Dubois, SG, Geoerger, B, Mascarenhas, L, Federman, N, Basu-Mallick, A, Doz, F, Berlin, J, Oh, DY, Bielack, S, McDermott, R, Cruickshank, S, Ku, NC, Cox, MC, Drilon, A, Hong, DS. Larotrectinib efficacy and safety in TRK fusion cancer. Ann Oncol 29:ix23, 2018. e-Pub 2018. PMID: 32177963.
200. Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL. Comparative effectiveness of an mTOR-based systemic therapy regimen in advanced, metaplastic and nonmetaplastic triple-negative breast cancer. Oncologist 23(11):1300-1309, 2018. e-Pub 2018. PMID: 30139837.
201. Fountzilas E, Krishnan E, Janku F, Fu S, Karp DD, Naing A, Subbiah V, Hong DS, Piha-Paul SA, Vining DJ, Tsimberidou AM. A Phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. Cancer Chemother Pharmacol 82(5):877-885, 2018. e-Pub 2018. PMID: 30182147.
202. Hong, DS, Butler, MO, Johnson, M, Olszanski, AJ, Norry, E, Van Winkle, E, Chagin, KD, Amado, RG. Initial safety assessment of MAGE-A4 SPEAR T-cells. Ann Oncol 29:viii412, 2018. e-Pub 2018. PMID: 32137033.
203. Lassen, U, Albert, CM, Kummar, S, van Tilburg, CM, Dubois, SG, Geoerger, B, Mascarenhas, L, Federman, N, Schilder, RJ, Doz, F, Berlin, J, Oh, DY, Bielack, S, McDermott, R, Tan, DS, Cruickshank, S, Ku, NC, Cox, MC, Drilon, A, Hong, DS. Larotrectinib efficacy and safety in TRK fusion cancer. Ann Oncol 29:viii133, 2018. e-Pub 2018. PMID: 32136201.
204. Lam, VK, Hong, DS, Heymach, JV, Blumenschein, GR, Butler, MO, Johnson, M, Creelan, BC, Gainor, J, Govindan, R, Mudad, R, Neal, J, Brophy, F, Fang, F, Hyland, N, Holdich, T, Ma, Y, Trivedi, T, Norry, E, Amado, RG. Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials. Ann Oncol 29:viii731, 2018. e-Pub 2018. PMID: 32138012.
205. Concin, N, Vergote, IB, Lassen, U, Drew, Y, Machiels, JP, Arkenau, HT, Forster, M, Jones, RH, Johnson, M, Slomovitz, BM, Spicer, J, Cornez, N, Gennigens, C, Coleman, R, Windfeld, K, Ghatta, S, Rangwala, R, Hong, DS. A Phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer. Ann Oncol 29:viii344, 2018. e-Pub 2018. PMID: 32136816.
206. Cohen, EE, Harrington, K, Hong, DS, Mesía, R, Brana, I, Perez-Segura, P, Wise-Draper, TM, Scott, ML, Mitchell, PD, Mugundu, GM, McCoon, P, Cook, C, Mehta, M, Keilholz, U. A Phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC). Ann Oncol 29:viii372, 2018. e-Pub 2018. PMID: 32136905.
207. Subbiah V, Sen S, Hess KR, Janku F, Hong DS, Khatua S, Karp DD, Munoz J, Falchook GS, Groisberg R, Tsimberidou AM, Sherman SI, Hwu P, Meric-Bernstam F. Phase I study of the BRAF inhibitor vemurafenib in combination with the mammalian target of rapamycin inhibitor everolimus in patients with BRAF-mutated malignancies. JCO Precis Oncol 2:1-12, 2018. e-Pub 2018. PMID: 32913986.
208. Wang Y, Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Hess K, Broaddus R, Shan B, Naing A, Hong D, Tsimberidou AM, Karp D, Lu C, Papadimitrakopoulou V, Heymach J, Meric-Bernstam F, Fu S. Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer. Oncotarget 9(70):33258-33270, 2018. e-Pub 2018. PMID: 30279957.
209. Patnaik A, Gordon M, Tsai F, Papadopoulos KP, Rasco D, Beeram M, Fu S, Janku F, Hynes SM, Gundala SR, Willard MD, Zhang W, Lin AB, Hong D. A Phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. Cancer Chemother Pharmacol 82(3):407-418, 2018. e-Pub 2018. PMID: 29926131.
210. Dembla V, Somaiah N, Barata P, Hess K, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Shaw K, Meric-Bernstam F, Hong DS. Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson Phase 1 clinic. Oncotarget 9(69):33232-33243, 2018. e-Pub 2018. PMID: 30237864.
211. Subbiah V, Murthy R, Hong DS, Prins RM, Hosing C, Hendricks K, Kolli D, Noffsinger L, Brown R, McGuire M, Fu S, Piha-Paul S, Naing A, Conley AP, Benjamin RS, Kaur I, Bosch ML. Cytokines produced by dendritic cells administered intratumorally correlate with clinical outcome in patients with diverse cancers. Clin Cancer Res 24(16):3845-3856, 2018. e-Pub 2018. PMID: 30018119.
212. Fujii T, Colen RR, Bilen MA, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Tsimberidou A, Janku F, Gong J, Stephen B, Subbiah V, Piha-Paul SA, Fu S, Sharma P, Mendoza T, Patel A, Thirumurthi S, Sheshadri A, Meric-Bernstam F, Naing A. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs 36(4):638-646, 2018. e-Pub 2018. PMID: 29159766.
213. Colen RR, Fujii T, Bilen MA, Kotrotsou A, Abrol S, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Giniebra-Camejo D, Stephen B, Subbiah V, Sheshadri A, Mendoza T, Fu S, Sharma P, Meric-Bernstam F, Naing A. Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Invest New Drugs 36(4):601-607, 2018. e-Pub 2018. PMID: 29075985.
214. Hong DS, Moore K, Patel M, Grant SC, 3rd BH, Jr WW, Jones S, Meric-Bernstam F, Infante J, Golden L, Zhang W, Martinez R, Wijayawardana S, Beckmann R, Lin AB, Eng C, Bendell J. Evaluation of prexasertib, a checkpoint kinase 1 inhibitor, in a Phase Ib study of patients with squamous cell carcinoma. Clin Cancer Res 24(14):3263-3272, 2018. e-Pub 2018. PMID: 29643063.
215. Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S. Evaluating for pseudoprogression in colorectal and pancreatic tumors treated with immunotherapy. J Immunother 41(6):284-291, 2018. e-Pub 2018. PMID: 29668571.
216. Groisberg R, Hong DS, Roszik J, Janku F, Tsimberidou AM, Javle M, Meric-Bernstam F, Subbiah V. Clinical next-generation sequencing for precision oncology in rare cancers. Mol Cancer Ther 17(7):1595-1601, 2018. e-Pub 2018. PMID: 29654067.
217. Subbiah IM, Tang C, Rao A, Falchook GS, Subbiah V, Tsimberidou AM, Karp D, Kurzrock R, Hong DS. Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. Oncotarget 9(48):28842-28848, 2018. e-Pub 2018. PMID: 29989021.
218. Oba J, Kim SH, Wang WL, Macedo MP, Carapeto F, McKean MA, Van Arnam J, Eterovic AK, Sen S, Kale CR, Yu X, Haymaker CL, Routbort M, Haydu LE, Bernatchez C, Lazar AJ, Grimm EA, Hong DS, Woodman SE. Targeting the HGF/MET axis counters primary resistance to KIT inhibition in KIT-mutant melanoma. JCO Precis Oncol 2018:1-8, 2018. e-Pub 2018. PMID: 30094412.
219. Kato S, Jardim DL, Johnson FM, Subbiah V, Piha-Paul S, Tsimberidou AM, Falchook GS, Karp D, Zinner R, Wheler J, Janku F, Fu S, Lim J, Bean S, Nguyen L, Urban S, Browne E, Meric-Bernstam F, Hong DS. Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Invest New Drugs 36(3):416-423, 2018. e-Pub 2018. PMID: 29047029.
220. Nathenson, MJ, Demetri, GD, Lassen, U, Hong, DS, Boni, V, Deeken, J, Dowlati, A, Cox, MC, Ku, NC, Cruickshank, S, Qamoos, H, Drilon, A. Activity of larotrectinib in patients with TRK fusion GI malignancies. Ann Oncol 29:v107, 2018. e-Pub 2018. PMID: 32176998.
221. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer 120:137-141, 2018. e-Pub 2018. PMID: 29748008.
222. Liu L, Toung JM, Jassowicz AF, Vijayaraghavan R, Kang H, Zhang R, Kruglyak KM, Huang HJ, Hinoue T, Shen H, Salathia NS, Hong DS, Naing A, Subbiah V, Piha-Paul SA, Bibikova M, Granger G, Barnes B, Shen R, Gutekunst K, Fu S, Tsimberidou AM, Lu C, Eng C, Moulder SL, Kopetz ES, Amaria RN, Meric-Bernstam F, Laird PW, Fan JB, Janku F. Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification. Ann Oncol 29(6):1445-1453, 2018. e-Pub 2018. PMID: 29635542.
223. Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer 118(11):1419-1424, 2018. e-Pub 2018. PMID: 29695765.
224. Ghosh P, Chandler AG, Hobbs BP, Sun J, Rong J, Hong D, Subbiah V, Janku F, Naing A, Hwu WJ, Ng CS. Quantification of the effect of shuttling on computed tomography perfusion parameters by investigation of aortic inputs on different table positions from shuttle-mode scans of lung and liver tumors. J Comput Assist Tomogr 42(3):357-364, 2018. e-Pub 2018. PMID: 29189398.
225. Somaiah N, Beird HC, Barbo A, Song J, Mills Shaw KR, Wang WL, Eterovic K, Chen K, Lazar A, Conley AP, Ravi V, Hwu P, Futreal A, Simon G, Meric-Bernstam F, Hong D. Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget 9(28):19891-19899, 2018. e-Pub 2018. PMID: 29731991.
226. Maitland ML, Piha-Paul S, Falchook G, Kurzrock R, Nguyen L, Janisch L, Karovic S, McKee M, Hoening E, Wong S, Munasinghe W, Palma J, Donawho C, Lian GK, Ansell P, Ratain MJ, Hong D. Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. Br J Cancer 118(8):1042-1050, 2018. e-Pub 2018. PMID: 29551775.
227. Sen S, Hess K, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Subbiah IM, Liu H, Khanji R, Huang L, Moorthy S, Karp DD, Tsimberidou A, Meric-Bernstam F, Subbiah V. Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor Phase 1 clinical trials. Br J Cancer 118(6):763-769, 2018. e-Pub 2018. PMID: 29462132.
228. Bartkowiak T, Jaiswal AR, Ager CR, Chin R, Chen CH, Budhani P, Ai M, Reilley MJ, Sebastian MM, Hong DS, Curran MA. Activation of 4-1BB on liver myeloid cells triggers hepatitis via an interleukin-27-dependent pathway. Clin Cancer Res 24(5):1138-1151, 2018. e-Pub 2018. PMID: 29301830.
229. Sakamuri D, Glitza IC, Betancourt Cuellar SL, Subbiah V, Fu S, Tsimberidou AM, Wheler JJ, Hong DS, Naing A, Falchook GS, Fanale MA, Cabanillas ME, Janku F. Phase I dose-escalation study of anti-CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers. Mol Cancer Ther 17(3):671-676, 2018. e-Pub 2018. PMID: 29237802.
230. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, (co-senior author) HD, Hyman DM. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. New Engl J Med 378(8):731-739, 2018. e-Pub 2018. PMID: 29466156.
231. Fang L, Chen H, Tang Z, Kalhor N, Liu CH, Yao H, Hu S, Lin P, Zhao J, Luthra R, Singh RR, Routbort MJ, Hong D, Medeiros LJ, Lu X. MET amplification assessed using optimized FISH reporting criteria predicts early distant metastasis in patients with non-small cell lung cancer. Oncotarget 9(16):12959-12970, 2018. e-Pub 2018. PMID: 29560123.
232. Tang C, Hobbs B, Amer A, Li X, Behrens C, Canales JR, Cuentas EP, Villalobos P, Fried D, Chang JY, Hong DS, Welsh JW, Sepesi B, Court L, Wistuba II, Koay EJ. Development of an immune-pathology informed radiomics model for non-small cell lung cancer. Sci Rep 8(1):1922, 2018. e-Pub 2018. PMID: 29386574.
233. Ileana Dumbrava, EE, Balaji, K, Raghav, KS, Hess, KR, Javle, M, Blum Murphy, M, Ajani, JA, Kopetz, S, Broaddus, R, Routbort, MJ, Demirhan, ME, Zheng, X, Pant, S, Tsimberidou, AM, Subbiah, V, Hong, DS, Rodon Ahnert, J, Shaw, KM, Piha-Paul, SA, Meric-Bernstam, F. Targeting ERBB2 (HER2) amplification identified by next-generation sequencing in patients with advanced or metastatic solid tumors beyond conventional indications. JCO Precis Oncol 2, 2018. e-Pub 2018. PMID: 32923865.
234. Möhrmann L, Huang HJ, Hong DS, Tsimberidou AM, Fu S, Piha-Paul SA, Subbiah V, Karp DD, Naing A, Krug A, Enderle D, Priewasser T, Noerholm M, Eitan E, Coticchia C, Stoll G, Jordan LM, Eng C, Kopetz ES, Skog J, Meric-Bernstam F, Janku F. Liquid biopsies using plasma exosomal nucleic acids and plasma cell-free DNA compared with clinical outcomes of patients with advanced cancers. Clin Cancer Res 24(1):181-188, 2018. e-Pub 2018. PMID: 29051321.
235. Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, Naing A, Fu S, Benjamin R, Patel S, Somaiah N, Conley A, Meric-Bernstam F, Subbiah V. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer 5(1):100, 2017. e-Pub 2017. PMID: 29254498.
236. Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Roszik J, Meric-Bernstam F, Subbiah V. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep 7(1):15963, 2017. e-Pub 2017. PMID: 29162825.
237. Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget 8(50):87163-87173, 2017. e-Pub 2017. PMID: 29152071.
238. Sen S, Meric-Bernstam F, Hong DS, Hess KR, Subbiah V. Co-occurring genomic alterations and association with progression-free survival in BRAF V600-mutated nonmelanoma tumors. J Natl Cancer Inst 109(10):djx094, 2017. e-Pub 2017. PMID: 29117359.
239. Janku F, Zhang S, Waters J, Liu L, Huang HJ, Subbiah V, Hong DS, Karp DD, Fu S, Cai X, Ramzanali NM, Madwani K, Cabrilo G, Andrews DL, Zhao Y, Javle M, Kopetz ES, Luthra R, Kim HJ, Gnerre S, Satya RV, Chuang HY, Kruglyak KM, Toung J, Zhao C, Shen R, Heymach JV, Meric-Bernstam F, Mills GB, Fan JB, Salathia NS. Development and validation of an ultra-deep next-generation sequencing assay for testing of plasma cell-free DNA from patients with advanced cancer. Clin Cancer Res 23(18):5648-5656, 2017. e-Pub 2017. PMID: 28536309.
240. Boral D, Vishnoi M, Liu HN, Yin W, Sprouse ML, Scamardo A, Hong DS, Tan TZ, Thiery JP, Chang JC, Marchetti D. Molecular characterization of breast cancer CTCs associated with brain metastasis. Nat Commun 8(1):196, 2017. e-Pub 2017. PMID: 28775303.
241. Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku F, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): an MD Anderson precision medicine study. JCO Precis Oncol 2017(1):1-18, 2017. e-Pub 2017. PMID: 29082359.
242. Bugano DDG, Hess K, Jardim DLF, Zer A, Meric-Bernstam F, Siu LL, Razak ARA, Hong DS. Use of expansion cohorts in phase I trials and probability of success in phase II for 381 anticancer drugs. Clin Cancer Res 23(15):4020-4026, 2017. e-Pub 2017. PMID: 28377482.
243. Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DS. Insurance clearance for early-phase oncology clinical trials following the Affordable Care Act. Clin Cancer Res 23(15):4155-62, 2017. e-Pub 2017. PMID: 28729355.
244. Fu S, Hirte H, Welch S, Ilenchuk TT, Lutes T, Rice C, Fields N, Nemet A, Dugourd D, Piha-Paul S, Subbiah V, Liu L, Gong J, Hong D, Stewart JM. First-in-human Phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. Invest New Drugs 35(3):324-333, 2017. e-Pub 2017. PMID: 28150073.
245. Groisberg R, Hong DS, Holla V, Janku F, Piha-Paul S, Ravi V, Benjamin R, Kumar Patel S, Somaiah N, Conley A, Ali SM, Schrock AB, Ross JS, Stephens PJ, Miller VA, Sen S, Herzog C, Meric-Bernstam F, Subbiah V. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget 8(24):39254-39267, 2017. e-Pub 2017. PMID: 28424409.
246. Schroeder RD, Choi W, Hong DS, McConkey DJ. Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells. Oncotarget 8(31):51675-51687, 2017. e-Pub 2017. PMID: 28881678.
247. Sundar R, Hong DS, Kopetz S, Yap TA. Targeting BRAF-mutant colorectal cancer: progress in combination strategies. Cancer Discov 7(6):558-560, 2017. e-Pub 2017. PMID: 28576843.
248. Subbiah IM, Tsimberidou A, Subbiah V, Janku F, Roy-Chowdhuri S, Hong DS. Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. Oncoscience 4(5-6):47-56, 2017. e-Pub 2017. PMID: 28781987.
249. Fu C, Gombos DS, Lee J, George GC, Hess K, Whyte A, Hong DS. Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. Oncotarget 8(35):58709-58727, 2017. e-Pub 2017. PMID: 28938590.
250. Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Gong J, Wathoo C, Shaw K, Hess K, Broaddus R, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Meric-Bernstam F, Fu S. Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget 8(20):33796-33806, 2017. e-Pub 2017. PMID: 28430579.
251. Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, 3rd MJ, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL. Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: evidence from a Phase 1 trial of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab. JAMA Oncol 3(4):509-515, 2017. e-Pub 2017. PMID: 27893038.
252. Beg MS, Brenner AJ, Sachdev J, Borad M, Kang YK, Stoudemire J, Smith S, Bader AG, Kim S, Hong DS. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs 35(2):180-188, 2017. e-Pub 2017. PMID: 27917453.
253. Wagner AJ, Banerji U, Mahipal A, Somaiah N, Hirsch H, Fancourt C, Johnson-Levonas AO, Lam R, Meister AK, Russo G, Knox CD, Rose S, Hong DS. Phase I trial of the human double minute 2 inhibitor MK-8242 in patients with advanced solid tumors. J Clin Oncol 35(12):1304-1311, 2017. e-Pub 2017. PMID: 28240971.
254. Tolcher AW, Berlin JD, Cosaert J, Kauh J, Chan E, Piha-Paul SA, Amaya A, Tang S, Driscoll K, Kimbung R, Kambhampati SRP, Gueorguieva I, Hong DS. A Phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors. Cancer Chemother Pharmacol 79(4):673-680, 2017. e-Pub 2017. PMID: 28280971.
255. Reilley MJ, Bailey A, Subbiah V, Janku F, Naing A, Falchook G, Karp D, Piha-Paul S, Tsimberidou A, Fu S, Lim J, Bean S, Bass A, Montez S, Vence L, Sharma P, Allison J, Meric-Bernstam F, Hong DS. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer 5(1):35, 2017. e-Pub 2017. PMID: 28428884.
256. Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS. First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight 2(8):90380, 2017. e-Pub 2017. PMID: 28422758.
257. Tang C, Sherman SI, Price M, Weng J, Davis SE, Hong DS, Yao JC, Buzdar A, Wilding G, Lee JJ. Clinical trial characteristics and barriers to participant accrual: the MD Anderson Cancer Center experience over 30 years, a historical foundation for trial improvement. Clin Cancer Res 23(6):1414-1421, 2017. e-Pub 2017. PMID: 28275168.
258. Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS. Ipilimumab with stereotactic ablative radiation therapy: Phase I results and immunologic correlates from peripheral T-cells. Clin Cancer Res 23(6):1388-1396, 2017. e-Pub 2017. PMID: 27649551.
259. Tang C, Hess KR, Sanders D, Davis SE, Buzdar AU, Kurzrock R, Lee JJ, Meric-Bernstam F, Hong DS. Modifying the clinical research infrastructure at a dedicated clinical trials unit: assessment of trial development, activation, and participant accrual. Clin Cancer Res 23(6):1407-1413, 2017. e-Pub 2017. PMID: 27852698.
260. Janku F, Huang HJ, Fujii T, Shelton DN, Madwani K, Fu S, Tsimberidou AM, Piha-Paul SA, Wheler JJ, Zinner RG, Naing A, Hong DS, Karp DD, Cabrilo G, Kopetz ES, Subbiah V, Luthra R, Kee BK, Eng C, Morris VK, Karlin-Neumann GA, Meric-Bernstam F. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. Ann Oncol 28(3):642-650, 2017. e-Pub 2017. PMID: 27993791.
261. Bupathi M, Hajjar J, Bean S, Fu S, Hong D, Karp D, Stephen B, Hess K, Meric-Bernstam F, Naing A. Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: the MD Anderson Cancer Center experience. Invest New Drugs 35(1):59-67, 2017. e-Pub 2017. PMID: 27687047.
262. Subbiah IM, Wheler JJ, Hess KR, Hong DS, Naing A, Fu S, Kurzrock R, Tsimberidou AM. Outcomes of patients ≥65 years old with advanced cancer treated on Phase I trials at MD Anderson Cancer Center. Int J Cancer 140(1):208-15, 2017. e-Pub 2017. PMID: 27599876.
263. Kinahan H, Maiti A, Hess K, Dempsey J, Beatty L, Baldwin S, Hong DS, Naing A, Fu S, Tsimberidou AM, Piha-Paul S, Janku F, Karp D, Reddy S, Yennu S, Epner D, Bruera E, Meric-Bernstam F, Falchook G, Subbiah V. Post-discharge survival outcomes of patients with advanced cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) inpatient unit. Oncology 92(1):14-20, 2017. e-Pub 2017. PMID: 27802448.
264. Johnson A, Khotskaya YB, Brusco L, Zeng J, Holla V, Bailey AM, Litzenburger BC, Sanchez N, Shufean MA, Piha-Paul S, Subbiah V, Hong D, Routbort M, Broaddus R, Mills Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F. Clinical use of Precision Oncology Decision Support. JCO Precis Oncol 2017(1):1-12, 2017. e-Pub 2017. PMID: 30320296.
265. Wang Z, Shi N, Naing A, Janku F, Subbiah V, Araujo DM, Patel SR, Ludwig JA, Ramondetta LM, Levenback CF, Ramirez PT, Piha-Paul SA, Hong D, Karp DD, Tsimberidou AM, Meric-Bernstam F, Fu S. Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Med 5(12):3437-3444, 2016. e-Pub 2016. PMID: 27882721.
266. Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou A, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S. Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAF V600E mutation. Cancer Discov 6(12):1352-1365, 2016. e-Pub 2016. PMID: 27729313.
267. Shi E, Chmielecki J, Tang CM, Wang K, Heinrich MC, Kang G, Corless CL, Hong D, Fero KE, Murphy JD, Fanta PT, Ali SM, De Siena M, Burgoyne AM, Movva S, Madlensky L, Heestand GM, Trent JC, Kurzrock R, Morosini D, Ross JS, Harismendy O, Sicklick JK. FGFR1 and NTRK3 actionable alterations in "wild-type" gastrointestinal stromal tumors. J Transl Med 14(1):339, 2016. e-Pub 2016. PMID: 27974047.
268. George GC, Iwuanyanwu EC, Anderson KO, Yusuf A, Zinner RG, Piha-Paul SA, Tsimberidou AM, Naing A, Fu S, Janku F, Subbiah V, Cleeland CS, Mendoza TR, Hong DS. Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. Cancer 122(21):3401-9, 2016. e-Pub 2016. PMID: 27412379.
269. Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget 7(41):67521-31, 2016. e-Pub 2016. PMID: 27589687.
270. Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco DR, Mumm JB, Chan IH, Bendell JC, Bauer TM, Colen RR, Hong DS, Van Vlasselaer P, Tannir NM, Oft M, Infante JR. Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors. J Clin Oncol 34(29):3562-69, 2016. e-Pub 2016. PMID: 27528724.
271. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong D, Kurzrock R. TP53 alterations correlate with response to VEGF/VEGFR inhibitors: implications for targeted therapeutics. Mol Cancer Ther 15(10):2475-85, 2016. e-Pub 2016. PMID: 27466356.
272. Subbiah V, Hess KR, Khawaja MR, Wagner MJ, Tang C, Naing A, Fu S, Janku F, Piha-Paul S, Tsimberidou AM, Herzog CE, Ludwig JA, Patel S, Ravi V, Benjamin RS, Meric-Bernstam F, Hong DS. Evaluation of novel targeted therapies in aggressive biology sarcoma patients after progression from US FDA approved therapies. Sci Rep 6:35448, 2016. e-Pub 2016. PMID: 27748430.
273. Livingston JA, Hess KR, Naing A, Hong DS, Patel S, Benjamin RS, Ludwig JA, Conley A, Herzog CE, Anderson P, Meric-Bernstam F, Kurzrock R, Subbiah V. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget 7(39):64421-30, 2016. e-Pub 2016. PMID: 27486883.
274. Van Der Steen N, Giovannetti E, Pauwels P, Peters GJ, Hong DS, Cappuzzo F, Hirsch FR, Rolfo C. cMET exon 14 skipping: from the structure to the clinic. J Thorac Oncol 11(9):1423-32, 2016. e-Pub 2016. PMID: 27223456.
275. Jardim DL, Schwaederle M, Hong DS, Kurzrock R. An appraisal of drug development timelines in the era of precision oncology. Oncotarget 7(33):53037-46, 2016. e-Pub 2016. PMID: 27419632.
276. Raghav K, Morris V, Tang C, Morelli P, Amin HM, Chen K, Manyam GC, Broom B, Overman MJ, Shaw K, Meric-Bernstam F, Maru D, Menter D, Ellis LM, Eng C, Hong D, Kopetz S. MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget 7(34):54627-31, 2016. e-Pub 2016. PMID: 27421137.
277. Falchook GS, Rady P, Konopinski JC, Busaidy N, Hess K, Hymes S, Nguyen HP, Prieto VG, Bustinza-Linares E, Lin Q, Parkhurst KL, Hong DS, Sherman S, Tyring SK, Kurzrock R. Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitors. Arch Dermatol Res 308(5):357-65, 2016. e-Pub 2016. PMID: 27098388.
278. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong DS, Kurzrock R. Cancer therapy directed by comprehensive genomic profiling: a single center study. Cancer Res 76(13):3690-701, 2016. e-Pub 2016. PMID: 27197177.
279. Bilen MA, Patel A, Hess KR, Munoz J, Busaidy NL, Wheler JJ, Janku F, Falchook GS, Hong DS, Meric-Bernstam F, Habra MA, Naing A. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in Phase I clinical trials. Cancer Chemother Pharmacol 78(1):167-71, 2016. e-Pub 2016. PMID: 27286994.
280. Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F. BRAF mutation testing in cell-free DNA from the plasma of patients with advanced cancers using a rapid, automated molecular diagnostics system. Mol Cancer Ther 15(6):1397-404, 2016. e-Pub 2016. PMID: 27207774.
281. Hou MM, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D, Westin S, Coleman RL, Sood AK, Tsimberidou AM, Subbiah V, Wheler J, Zinner R, Lu K, Meric-Bernstam F, Fu S. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: Phase I trial experience. Oncotarget 7(23):35132-43, 2016. e-Pub 2016. PMID: 27147567.
282. Rolfo C, Caglevic C, Bretel D, Hong D, Raez LE, Cardona AF, Oton AB, Gomez H, Dafni U, Vallejos C, Zielinski C. Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015. ESMO Open 1(4):e000055, 2016. e-Pub 2016. PMID: 27843620.
283. Khawaja MR, Nick AM, Madhusudanannair V, Fu S, Hong D, McQuinn LM, Ng CS, Piha-Paul SA, Janku F, Subbiah V, Tsimberidou A, Karp D, Meric-Bernstam F, Lu KH, Naing A. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemother Pharmacol 77(5):973-7, 2016. e-Pub 2016. PMID: 27014780.
284. Said R, Kakadiaris E, Piha-Paul S, Fu S, Falchook G, Janku F, Wheler JJ, Zinner R, Hong DS, Kurzrock R, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. Cancer Chemother Pharmacol 77(5):1097-102, 2016. e-Pub 2016. PMID: 27085994.
285. Hong D, Infante J, Janku F, Jones S, Nguyen LM, Burris H, Naing A, Bauer TM, Piha-Paul S, Johnson FM, Kurzrock R, Golden L, Hynes S, Lin J, Lin AB, Bendell J. Phase I study of LY2606368, a checkpoint kinase 1 inhibitor, in patients with advanced cancer. J Clin Oncol 34(15):1764-71, 2016. e-Pub 2016. PMID: 27044938.
286. Parsons HA, Baracos VE, Hong DS, Abbruzzese J, Bruera E, Kurzrock R. The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer. Oncotarget 7(15):20293-304, 2016. e-Pub 2016. PMID: 26934122.
287. Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R. First-in-human phase I study of GSK2126458, an oral pan-class I phosphatidylinositol-3-kinase inhibitor, in patients with advanced solid tumor malignancies. Clin Cancer Res 22(8):1932-9, 2016. e-Pub 2016. PMID: 26603258.
288. Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget 7(17):23227-38, 2016. e-Pub 2016. PMID: 26933802.
289. Said R, Ye Y, Hong DS, Naing A, Falchook G, Fu S, Wheler JJ, Piha-Paul S, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 77(3):575-81, 2016. e-Pub 2016. PMID: 26825327.
290. Siqing F, Culotta KS, Falchook GS, Hong DS, Myers AL, Zhang YP, Naing A, Janku F, Hou MM, Kurzrock R. Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemother Pharmacol 77(2):357-64, 2016. e-Pub 2016. PMID: 26698868.
291. Hong DS, Kurzrock R, Falchook GS, Andresen C, Kwak J, Ren M, Xu L, George GC, Kim KB, Nguyen LM, O'Brien JP, Nemunaitis J. Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. Oncotarget 6(40):43127-34, 2015. e-Pub 2015. PMID: 26503473.
292. Vishnoi M, Peddibhotla S, Yin W, T Scamardo A, George GC, Hong DS, Marchetti D. The isolation and characterization of CTC subsets related to breast cancer dormancy. Sci Rep 5:17533, 2015. e-Pub 2015. PMID: 26631983.
293. Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MV, Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3, with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med 7(314):314ra185, 2015. e-Pub 2015. PMID: 26582900.
294. Fontes Jardim DL, Fontes Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Impact of a biomarker-based strategy on oncology drug development: a meta-analysis of clinical trials leading to FDA approval. J Natl Cancer Inst 107(11):djv253, 2015. e-Pub 2015. PMID: 26378224.
295. Fu S, Shi N, Wheler J, Naing A, Janku F, Piha-Paul S, Gong J, Hong D, Tsimberidou A, Zinner R, Subbiah V, Hou MM, Ramirez P, Ramondetta L, Lu K, Meric-Bernstam F. Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience. Gynecol Oncol Res Pract 2:10, 2015. e-Pub 2015. PMID: 27231570.
296. Hong DS, Kurzrock R, Wheler JJ, Naing A, Falchook GS, Fu S, Kim KB, Davies MA, Nguyen LM, George GC, Xu L, Shumaker R, Ren M, Mink J, Bedell C, Andresen C, Sachdev P, O'Brien JP, Nemunaitis J. Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma. Clin Cancer Res 21(21):4801-10, 2015. e-Pub 2015. PMID: 26169970.
297. Jain RK, Hong DS, Naing A, Wheler J, Helgason T, Shi NY, Gad Y, Kurzrock R. Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies. Cell Cycle 14(21):3434-40, 2015. e-Pub 2015. PMID: 26467427.
298. Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett C, Karp D, Kurzrock R, Zinner R, Raghav K, Subbiah V, Hess K, Meric-Bernstam F, Hong DS, Overman MJ. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer 15(1):713, 2015. e-Pub 2015. PMID: 26474549.
299. Henary H, George GC, Wheler J, Naing A, Piha-Paul S, Fu S, Mistry R, Zinner R, Kurzrock R, Hong DS. A Phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors. Cancer Chemother Pharmacol 76(3):597-603, 2015. e-Pub 2015. PMID: 26210681.
300. Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, Patel SP, Kopetz ES, Subbiah V, Wheler JJ, Zinner RG, Karp DD, Luthra R, Roy-Chowdhuri S, Sablon E, Meric-Bernstam F, Maertens G, Kurzrock R. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget 6(29):26886-94, 2015. e-Pub 2015. PMID: 26330075.
301. Naing A, Dalal S, Abdelrahim M, Wheler J, Hess K, Fu S, Hong DS, Janku F, Falchook GS, Ilustre A, Ouyang F, Kurzrock R. Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines. Support Care Cancer 23(9):2649-54, 2015. e-Pub 2015. PMID: 25680763.
302. Subbiah IM, Falchook GS, Kaseb AO, Hess KR, Tsimberidou AM, Fu S, Subbiah V, Hong DS, Naing A, Piha-Paul SA, Akmal O, Janku F, Kurzrock R. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy Phase 1 trials. Oncotarget 6(29):28453-62, 2015. e-Pub 2015. PMID: 26164085.
303. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, Routbort M, Piha-Paul SA, Janku F, Ueno N, Hong D, De Groot J, Ravi V, Li Y, Luthra R, Patel K, Broaddus R, Mendelsohn J, Mills GB. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J Clin Oncol 33(25):2753-62, 2015. e-Pub 2015. PMID: 26014291.
304. Said R, Kurzrock R, Naing A, Hong DS, Fu S, Piha-Paul SA, Wheler JJ, Janku F, Kee BK, Bidyasar S, Lim J, Wallace M, Tsimberidou AM. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Invest New Drugs 33(4):911-20, 2015. e-Pub 2015. PMID: 25990659.
305. Boland GM, Piha-Paul SA, Subbiah V, Routbort M, Herbrich SM, Baggerly K, Patel KP, Brusco L, Horombe C, Naing A, Fu S, Hong DS, Janku F, Johnson A, Broaddus R, Luthra R, Shaw K, Mendelsohn J, Mills GB, Meric-Bernstam F. Clinical next generation sequencing to identify actionable aberrations in a Phase I program. Oncotarget 6(24):20099-110, 2015. e-Pub 2015. PMID: 26015395.
306. Subbiah V, Bupathi M, Kato S, Livingston A, Slopis J, Anderson PM, Hong DS. Clinical next-generation sequencing reveals aggressive cancer biology in adolescent and young adult patients. Oncoscience 2(7):646-58, 2015. e-Pub 2015. PMID: 26328274.
307. Busaidy NL, LoRusso P, Lawhorn K, Hess KR, Habra MA, Fu S, Hong DS, Chen HX, Doyle LA, Kurzrock R, Naing A. The prevalence and impact of hyperglycemia and hyperlipidemia in patients with advanced cancer receiving combination treatment with the mammalian target of rapamycin inhibitor temsirolimus and insulin growth factor-receptor antibody cixutumumab. Oncologist 20(7):737-41, 2015. e-Pub 2015. PMID: 26054632.
308. Hong DS, Rosen P, Lockhart AC, Fu S, Janku F, Kurzrock R, Khan R, Amore B, Caudillo I, Deng H, Hwang YC, Loberg R, Ngarmchamnanrith G, Beaupre DM, Lee P. A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget 6(21):18693-706, 2015. e-Pub 2015. PMID: 26155941.
309. Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, Routbort M, Patel KP, Zeng J, Kopetz S, Davies MA, Piha-Paul SA, Hong DS, Eterovic AK, Tsimberidou AM, Broaddus R, Bernstam EV, Shaw KR, Mendelsohn J, Mills GB. A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst 107(7):djv098, 2015. e-Pub 2015. PMID: 25863335.
310. Rodrigues HV, Ke D, Lim J, Stephen B, Bellido J, Janku F, Zinner R, Tsimberidou A, Hong D, Piha-Paul S, Fu S, Naing A, Subbiah V, Karp D, Falchook G, Kurzrock R, Wheler J. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Invest New Drugs 33(3):700-9, 2015. e-Pub 2015. PMID: 25902899.
311. Hong DS, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Invest New Drugs 33(3):621-31, 2015. e-Pub 2015. PMID: 25822109.
312. Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, Wolff R, Kurzrock R, Meric-Bernstam F. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol 26(5):1012-1018, 2015. e-Pub 2015. PMID: 25669829.
313. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget 6(14):12809-21, 2015. e-Pub 2015. PMID: 25980577.
314. Bilen MA, Fu S, Falchook GS, Ng CS, Wheler JJ, Abdelrahim M, Erguvan-Dogan B, Hong DS, Tsimberidou AM, Kurzrock R, Naing A. Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. Cancer Chemother Pharmacol 75(4):869-74, 2015. e-Pub 2015. PMID: 25666183.
315. Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong D, Hoff P, Tran H, Menter DG, Heymach J, Overman M, Kopetz S. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer 112(6):1088-97, 2015. e-Pub 2015. PMID: 25688736.
316. Falchook GS, Moulder S, Naing A, Wheler JJ, Hong DS, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Janku F, Jiang Y, Huang M, Parkhurst KL, Kurzrock R. A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Invest New Drugs 33(1):177-86, 2015. e-Pub 2015. PMID: 25323060.
317. Jardim DL, de Melo Gagliato D, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. Clin Genitourin Cancer 13(1):e19-26, 2015. e-Pub 2015. PMID: 25087088.
318. Wheler J, Yelensky R, Falchook G, Kim KB, Hwu P, Tsimberidou AM, Stephens PJ, Hong D, Cronin MT, Kurzrock R. Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. BMC Cancer 15(1):61, 2015. e-Pub 2015. PMID: 25886620.
319. Falchook GS, Wheler JJ, Naing A, Piha-Paul SA, Fu S, Tsimberidou AM, Hong D, Janku F, Zinner R, Jiang Y, Huang M, Lin Q, Parkhurst K, Kurzrock R. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Invest New Drugs 33(1):215-24, 2015. e-Pub 2015. PMID: 25363205.
320. Falchook GS, Millward M, Hong DS, Naing A, Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis M, Goodman V, Kurzrock R. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid 25(1):71-7, 2015. e-Pub 2015. PMID: 25285888.
321. de Melo Gagliato D, Fontes Jardim DL, Falchook G, Tang C, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Hess K, Roy-Chowdhuri S, Moulder S, Gonzalez-Angulo AM, Meric-Bernstam F, Hong DS. Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. Clin Breast Cancer 14(6):468-74, 2014. e-Pub 2014. PMID: 25065564.
322. Falchook G, Kurzrock R, Gouw L, Hong D, McGregor KA, Zhou X, Shi H, Fingert H, Sharma S. Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study. Invest New Drugs 32(6):1181-7, 2014. e-Pub 2014. PMID: 24879333.
323. Hong DS, Henary H, Falchook GS, Naing A, Fu S, Moulder S, Wheler JJ, Tsimberidou A, Durand JB, Khan R, Yang P, Johansen M, Newman RA, Kurzrock R. First-in-human study of PBI-05204, an oleander-derived inhibitor of AKT, FGF-2, NF-κB and p70S6K, in patients with advanced solid tumors. Invest New Drugs 32(6):1204-12, 2014. e-Pub 2014. PMID: 24919855.
324. Tang C, Hess KR, Jardim DL, De Melo-Gagliato D, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul SA, Subbiah V, Wheler JJ, Zinner RG, Kurzrock R, Ellis LM, Meric-Bernstam F, Hong D. Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the Phase I clinic. Clin Cancer Res 20(23):5956-63, 2014. e-Pub 2014. PMID: 25316815.
325. Jardim DL, Tang C, De Melo Gagliato D, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, Salgia R, Kurzrock R, Meric-Bernstam F, Hong DS. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I clinic. Clin Cancer Res 20(24):6336-45, 2014. e-Pub 2014. PMID: 25326232.
326. Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ. Triple negative breast cancer patients treated at MD Anderson Cancer Center in Phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther 13(12):3175-84, 2014. e-Pub 2014. PMID: 25253784.
327. Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, Weatherly J, Zuo M, Zinner R, Hong D, Meric-Bernstam F, Janku F, Crane CH, Mishra L, Vauthey JN, Wolff RA, Mills G, Javle M. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 9(12):e115383, 2014. e-Pub 2014. PMID: 25536104.
328. Hou MM, Liu X, Wheler J, Naing A, Hong D, Coleman RL, Tsimberidou A, Janku F, Zinner R, Lu K, Kurzrock R, Fu S. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: a Phase I clinical experience. Oncotarget 5(22):11168-79, 2014. e-Pub 2014. PMID: 25426553.
329. Hong DS, Kurzrock R, Mulay M, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Rosen LS. A Phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours. Oncotarget 5(22):11154-67, 2014. e-Pub 2014. PMID: 25525888.
330. Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, Howard AN, Parkhurst KL, Amin HM, Kurzrock R. Targeting hypoxia-inducible factor-1 (HIF-1) in combination with antiangiogenic therapy: a Phase I trial of bortezomib plus bevacizumab. Oncotarget 5(21):10280-92, 2014. e-Pub 2014. PMID: 25373733.
331. Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Jr BG, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, Tsimberidou AM. Outcomes of patients with advanced cancer and KRAS mutations in Phase I clinical trials. Oncotarget 5(19):8937-46, 2014. e-Pub 2014. PMID: 25313136.
332. Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Aldape K, Ye Y, Kurzrock R, Berry D. Personalized medicine for patients with advanced cancer in the Phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res 20(18):4827-36, 2014. e-Pub 2014. PMID: 24987059.
333. Bilen MA, Durand JB, McQuinn L, Hess KR, Fu S, Falchook GS, Hong DS, Wheler JJ, Said R, Ewer MS, Kurzrock R, Naing A. Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. Invest New Drugs 32(4):717-22, 2014. e-Pub 2014. PMID: 24764123.
334. Tang C, Liao Z, Gomez D, Levy L, Zhuang Y, Gebremichael RA, Hong DS, Komaki R, Welsh JW. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys 89(5):1084-91, 2014. e-Pub 2014. PMID: 25035212.
335. Falchook GS, Naing A, Wheler JJ, Tsimberidou AM, Zinner R, Hong DS, Fu S, Piha-Paul SA, Janku F, Hess KR, Bastida C, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience 1(8):540-9, 2014. e-Pub 2014. PMID: 25594061.
336. Curry JL, Tetzlaff MT, Nicholson K, Duvic M, Kim KB, Tsai KY, Hwu WJ, Hong DS, Prieto VG, Torres-Cabala CA. Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous lesions biopsied during therapy. Am J Dermatopathol 36(7):557-61, 2014. e-Pub 2014. PMID: 24950418.
337. Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R. Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer 120(14):2164-73, 2014. e-Pub 2014. PMID: 24752867.
338. Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Aldaz M, Issa JP, Kurzrock R, Wistuba II. Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples. Clin Epigenetics 6(1):13, 2014. e-Pub 2014. PMID: 25024751.
339. Bendell JC, Hong DS, 3rd BH, Naing A, Jones SF, Falchook G, Bricmont P, Elekes A, Rock EP, Kurzrock R. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother Pharmacol 74(1):125-30, 2014. e-Pub 2014. PMID: 24819685.
340. Corrales-Medina FF, Herzog C, Hess K, Egas-Bejar D, Hong DS, Falchook G, Anderson P, Nunez C, Huh WW, Naing A, Tsimberidou AM, Wheler J, Paul SP, Janku F, Kleinerman ES, Kurzrock R, Subbiah V. Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in Phase I clinical trials designed for adults: the University of Texas MD Anderson Cancer Center experience. Oncoscience 1(7):522-30, 2014. e-Pub 2014. PMID: 25587555.
341. Fu S, Hou MM, Wheler J, Hong D, Naing A, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Falchook G, Kuo MT, Kurzrock R. Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Invest New Drugs 32(3):465-72, 2014. e-Pub 2014. PMID: 24306314.
342. Said R, Ye Y, Hong DS, Janku F, Fu S, Naing A, Wheler JJ, Kurzrock R, Thomas C, Palmer GA, Hess KR, Aldape K, Tsimberidou AM. Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget 5(11):3871-9, 2014. e-Pub 2014. PMID: 25003695.
343. Hong DS, Gordon MS, Samlowski WE, Kurzrock R, Tannir N, Friedland D, Mendelson DS, Vogelzang NJ, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Appleman LJ. A Phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 12(3):167-177.e2, 2014. e-Pub 2014. PMID: 24365125.
344. Hong DS, Kurzrock R, Naing A, Wheler JJ, Falchook GS, Schiffman JS, Faulkner N, Pilat MJ, O'Brien J, LoRusso P. A Phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mrna) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. Invest New Drugs 32(3):436-44, 2014. e-Pub 2014. PMID: 24258465.
345. Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, Phase 1 dose-escalation and expansion study. Lancet Oncol 15(6):656-66, 2014. e-Pub 2014. PMID: 24746841.
346. Hou MM, Liu X, Wheler J, Naing A, Hong D, Bodurka D, Schmeler K, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Hu CY, Lu K, Kurzrock R, Fu S. Outcomes of patients with metastatic cervical cancer in a Phase I clinical trials program. Anticancer Res 34(5):2349-55, 2014. e-Pub 2014. PMID: 24778042.
347. Wheler JJ, Moulder SL, Naing A, Janku F, Piha-Paul SA, Falchook GS, Zinner R, Tsimberidou AM, Fu S, Hong DS, Atkins JT, Yelensky R, Stephens PJ, Kurzrock R. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget 5(10):3029-38, 2014. e-Pub 2014. PMID: 24912489.
348. Piha-Paul SA, Wheler JJ, Fu S, Levenback C, Lu K, Falchook GS, Naing A, Hong DS, Tsimberidou AM, Kurzrock R. Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. Oncotarget 5(7):1846-55, 2014. e-Pub 2014. PMID: 24742900.
349. Liu X, Lorusso P, Mita M, Piha-Paul S, Hong DS, Fu S, McQuinn L, Asatiani E, Doyle LA, Chen HX, Hess KR, Kurzrock R, Naing A. Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. Oncologist 19(4):426-8, 2014. e-Pub 2014. PMID: 24668327.
350. Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Fu S, Hong DS, Kurzrock R, Janku F, Laday S, Bedikian AY, Kies M, Wolff RA, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Invest New Drugs 32(2):279-86, 2014. e-Pub 2014. PMID: 23756764.
351. Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a Phase I unit. Oncotarget 5(7):1837-45, 2014. e-Pub 2014. PMID: 24742823.
352. Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol 73(3):495-501, 2014. e-Pub 2014. PMID: 24435060.
353. Curry JL, Torres-Cabala CA, Kim KB, Tetzlaff MT, Duvic M, Tsai KY, Hong DS, Prieto VG. Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol 53(3):376-84, 2014. e-Pub 2014. PMID: 23879247.
354. Jardim DL, Wheler JJ, Hess K, Tsimberidou AM, Zinner R, Janku F, Subbiah V, Naing A, Piha-Paul SA, Westin SN, Roy-Chowdhuri S, Meric-Bernstam F, Hong DS. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. PLoS One 9(2):e89388, 2014. e-Pub 2014. PMID: 24586741.
355. Tsimberidou AM, Adamopoulos AM, Ye Y, Piha-Paul S, Janku F, Fu S, Hong D, Falchook GS, Naing A, Wheler J, Fortier A, Kurzrock R, Hess KR. Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. J Natl Compr Canc Netw 12(2):194-203, 2014. e-Pub 2014. PMID: 24586081.
356. Naing A, Fu S, Zinner RG, Wheler JJ, Hong DS, Arakawa K, Falchook GS, Kurzrock R. Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors. Invest New Drugs 32(1):154-9, 2014. e-Pub 2014. PMID: 23609829.
357. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep 6(2):377-87, 2014. e-Pub 2014. PMID: 24440717.
358. Said R, Banchs J, Wheler J, Hess KR, Falchook G, Fu S, Naing A, Hong D, Piha-Paul S, Ye Y, Yeh E, Wolff RA, Tsimberidou AM. The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials. Ann Oncol 25(1):276-82, 2014. e-Pub 2014. PMID: 24356639.
359. Jardim DL, Hess KR, Lorusso P, Kurzrock R, Hong DS. Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs. Clin Cancer Res 20(2):281-8, 2014. e-Pub 2014. PMID: 24190980.
360. Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Issa JP, Wistuba II, Kurzrock R. Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. Clin Epigenetics 6(1):2, 2014. e-Pub 2014. PMID: 24401732.
361. Subbiah V, Brown RE, McGuire MF, Buryanek J, Janku F, Younes, Hong DS. A novel immunomodulatory and molecularly targeted strategy for refractory Hodgkin's lymphoma. Oncotarget 5(1):95-102, 2014. e-Pub 2014. PMID: 24395633.
362. Rolfo C, Fanale D, Hong DS, Tsimberidou AM, Piha-Paul SA, Pauwels P, Van Meerbeeck JP, Caruso S, Bazan V, Cicero G, Russo A, Giovannetti E. Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer. Curr Pharm Biotechnol 15(5):475-85, 2014. e-Pub 2014. PMID: 24846062.
363. Tang C, Fontes Jardim DL, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, De Melo Galgiato D, Westin SN, Meric-Bernstam F, Kurzrock R, Hong DS. MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. Oncoscience 1(1):5-13, 2013. e-Pub 2013. PMID: 25593979.
364. Naing A, Agarwal R, Falchook G, Hong DS, Janku F, Wheler J, Fu S, Kurzrock R. Retreatment after secondary resistance or mixed response: a pilot study. Oncology 85(6):350-5, 2013. e-Pub 2013. PMID: 24335388.
365. Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz S, Wolff RA, Kurzrock R. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther 12(12):2857-63, 2013. e-Pub 2013. PMID: 24092809.
366. Garcia SS, Atkins JT, Falchook GS, Tsimberidou AM, Hong DS, Trivedi MV, Kurzrock R. Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases. Cancer Chemother Pharmacol 72(6):1265-71, 2013. e-Pub 2013. PMID: 24101145.
367. Tsimberidou AM, Vaklavas C, Fu S, Wen S, Lim JA, Hong D, Wheler J, Naing A, Uehara C, Wallace M, Kurzrock R. Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson experience. Hepatogastroenterology 60(127):1611-23, 2013. e-Pub 2013. PMID: 24634931.
368. Veasey Rodrigues H, Baracos VE, Wheler JJ, Parsons HA, Hong DS, Naing A, Fu S, Falchoock G, Tsimberidou AM, Piha-Paul S, Chisholm G, Kurzrock R. Body composition and survival in the early clinical trials setting. Eur J Cancer 49(15):3068-75, 2013. e-Pub 2013. PMID: 23867127.
369. Wheler JJ, Tsimberidou AM, Falchook GS, Zinner RG, Hong DS, Fok JY, Fu S, Piha-Paul SA, Naing A, Kurzrock R. Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. Mol Cancer Ther 12(10):2167-75, 2013. e-Pub 2013. PMID: 23963360.
370. Falchook GS, Fu S, Naing A, Hong DS, Hu W, Moulder S, Wheler JJ, Sood AK, Bustinza-Linares E, Parkhurst KL, Kurzrock R. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs 31(5):1192-200, 2013. e-Pub 2013. PMID: 23907406.
371. Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, Chen H, Naing A, Fu S, Wheler J, Moulder S, Helgason T, Li S, Elias I, Desai N, Kurzrock R. Weekly nab-rapamycin in patients with advanced nonhematologic malignancies: final results of a Phase I trial. Clin Cancer Res 19(19):5474-84, 2013. e-Pub 2013. PMID: 24089446.
372. Hong D, Said R, Falchook G, Naing A, Moulder S, Tsimberidou AM, Galluppi G, Dakappagari N, Storgard C, Kurzrock R, Rosen LS. Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clin Cancer Res 19(17):4824-31, 2013. e-Pub 2013. PMID: 23873691.
373. Janku F, Wheler JJ, Hong DS, Kurzrock R. Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. Target Oncol 8(3):183-8, 2013. e-Pub 2013. PMID: 23400451.
374. Kurzrock R, Atkins J, Wheler J, Fu S, Naing A, Busaidy N, Hong D, Sherman S. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Ann Oncol 24(9):2256-61, 2013. e-Pub 2013. PMID: 23676418.
375. Hong DS, Choe JH, Naing A, Wheler JJ, Falchook GS, Piha-Paul S, Moulder SL, George GC, Choe JM, Strauss LC, Gallick GE, Kurzrock R. A Phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Invest New Drugs 31(4):918-26, 2013. e-Pub 2013. PMID: 23179336.
376. Naing A, Cohen R, Dy GK, Hong DS, Dyster L, Hangauer DG, Kwan R, Fetterly G, Kurzrock R, Adjei AA. A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. Invest New Drugs 31(4):967-73, 2013. e-Pub 2013. PMID: 23361621.
377. Henary H, Hong, DS, Falchook GS, Tsimberidou A, George GC, Wen S, Wheler J, Fu S, Naing A, Piha-Paul S, Janku F, Kim KB, Hwu P, Kurzrock R. Melanoma patients in a Phase I clinic: molecular aberrations, targeted therapy and outcomes. Ann Oncol 24(8):2158-65, 2013. e-Pub 2013. PMID: 23576709.
378. Hong DS, George GC, Iwuanyanwu EC, Tavana B, Falchook GS, Piha-Paul SA, Wheler JJ, Mistry RH, Lei X, Kurzrock R. Factors related to biopsy willingness in patients with advanced cancer in a Phase 1 clinic for molecularly targeted therapy. J Cancer Res Clin Oncol 139(6):963-70, 2013. e-Pub 2013. PMID: 23455881.
379. Wheler J, Hong D, Swisher SG, Falchook G, Tsimberidou AM, Helgason T, Naing A, Stephen B, Janku F, Stephens PJ, Yelensky R, Kurzrock R. Thymoma patients treated in a Phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses. Oncotarget 4(6):890-8, 2013. e-Pub 2013. PMID: 23765114.
380. Said R, Hong, DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, Naing A, Falchook GS, Fu S, Piha-Paul S, Tsimberidou AM, Kurzrock R. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget 4(5):705-14, 2013. e-Pub 2013. PMID: 23670029.
381. Wheler J, Falchook G, Tsimberidou AM, Hong D, Naing A, Piha-Paul S, Chen SS, Heymach J, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center Phase I population. Oncotarget 4(5):772-84, 2013. e-Pub 2013. PMID: 23800712.
382. Tsimberidou AM, Ye Y, Wheler J, Naing A, Hong D, Nwosu U, Hess KR, Wolff RA. A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases. Cancer Chemother Pharmacol 71(4):955-63, 2013. e-Pub 2013. PMID: 23377373.
383. Falchook GS, Rady P, Hymes S, Nguyen HP, Tyring SK, Prieto VG, Hong DS, Kurzrock R. Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib. JAMA Dermatol 149(3):322-6, 2013. e-Pub 2013. PMID: 23552670.
384. Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan AT, Habra MA, Kurzrock R. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer 108(4):826-30, 2013. e-Pub 2013. PMID: 23412108.
385. Holsinger FC, Piha-Paul SA, Janku F, Hong DS, Atkins JT, Tsimberidou AM, Kurzrock R. Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway. J Clin Oncol 31(9):e137-40, 2013. e-Pub 2013. PMID: 23358976.
386. Wheler JJ, Falchook GS, Tsimberidou AM, Hong DS, Naing A, Piha-Paul SA, Chen SS, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy. Ann Oncol 24(3):838-42, 2013. e-Pub 2013. PMID: 23139256.
387. Gomez DR, Hong DS, Allen PK, Welsh JS, Mehran RJ, Tsao AS, Liao Z, Bilton SD, Komaki R, Rice DC. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol 8(2):238-45, 2013. e-Pub 2013. PMID: 23247629.
388. Tsimberidou AM, Leick MB, Lim J, Fu S, Wheler J, Piha-Paul SA, Hong D, Falchook GS, Naing A, Subbiah IM, Fortier A, Avritscher R, Kurzrock R. Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. Cancer Chemother Pharmacol 71(2):389-97, 2013. e-Pub 2013. PMID: 23143207.
389. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from Phase 1 trials. Oncotarget 4(1):153-62, 2013. e-Pub 2013. PMID: 23391555.
390. Falchook GS, Naing A, Hong DS, Zinner R, Fu S, Piha-Paul SA, Tsimberidou AM, Morgan-Linnell SK, Jiang Y, Bastida C, Wheler JJ, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment: a Phase I clinical trial in non-small cell lung cancer. Oncotarget 4(1):118-27, 2013. e-Pub 2013. PMID: 23435217.
391. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res 73(1):276-84, 2013. e-Pub 2013. PMID: 23066039.
392. Fu S, McQuinn L, Naing A, Wheler JJ, Janku F, Falchook GS, Piha-Paul SA, Tu D, Howard A, Tsimberidou A, Zinner R, Hong DS, Kurzrock R. Barriers to study enrollment in patients with advanced cancer referred to a Phase I clinical trials unit. Oncologist 18(12):1315-20, 2013. e-Pub 2013. PMID: 24153239.
393. Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz S, Win S, Kurzrock R. Outcomes in 144 Patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. Clin Colorectal Cancer 11(4):297-303, 2012. e-Pub 2012. PMID: 22537607.
394. Kurzrock R, Goel S, Wheler J, Hong D, Fu S, Rezai K, Morgan-Linnell SK, Urien S, Mani S, Chaudhary I, Ghalib MH, Buchbinder A, Lokiec F, Mulcahy M. Safety, pharmacokinetics and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. Cancer 118(24):6144-51, 2012. e-Pub 2012. PMID: 22674635.
395. Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget 3(12):1566-75, 2012. e-Pub 2012. PMID: 23248156.
396. Naing A, Veasey-Rodrigues H, Hong DS, Fu S, Falchook GS, Wheler JJ, Tsimberidou AM, Wen S, Fessahaye SN, Golden EC, Aaron J, Ewer MS, Kurzrock R. Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol 23(11):2960-3, 2012. e-Pub 2012. PMID: 22745218.
397. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 18(22):6373-83, 2012. e-Pub 2012. PMID: 22966018.
398. Moroney J, Fu S, Moulder S, Falchook G, Helgason T, Levenback C, Hong D, Naing A, Wheler J, Kurzrock R. Phase I study of the anti-angiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res 18(20):5796-805, 2012. e-Pub 2012. PMID: 22927482.
399. Lopez Guerra JL, Gomez D, Zhuang Y, Hong DS, Heymach JV, Swisher SG, Lin SH, Komaki R, Cox JD, Liao Z. Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. Int J Radiat Oncol Biol Phys 84(1):e61-7, 2012. e-Pub 2012. PMID: 22503522.
400. Wheler JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Risk of serious toxicity in 1181 patients treated in Phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Ann Oncol 23(8):1963-7, 2012. e-Pub 2012. PMID: 22377564.
401. Fu S, Barber FD, Naing A, Wheler J, Hong D, Falchook G, Piha-Paul S, Tsimberidou A, Howard A, Kurzrock R. Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience. J Clin Oncol 30(23):2891-6, 2012. e-Pub 2012. PMID: 22778314.
402. Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo AC, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R, Jimeno A. A multicenter Phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 18(15):4173-82, 2012. e-Pub 2012. PMID: 22693357.
403. Jain RK, Lee JJ, Ng C, Hong D, Gong J, Naing A, Wheler J, Kurzrock R. Change in tumor size by RECIST correlates linearly with overall survival in Phase I oncology studies. J Clin Oncol 30(21):2684-90, 2012. e-Pub 2012. PMID: 22689801.
404. Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA, Mier J, Konopleva M, Konoplev S, Andreeff M, Kufe D, Lazarus H, Shapiro GI, Dezube BJ. A Phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res 18(12):3396-406, 2012. e-Pub 2012. PMID: 22634319.
405. Tsimberidou AM, Fu S, Subbiah IM, Naing A, Hong DS, Wen S, Fortier AH, Lim J, Kurzrock R. Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. Hepatogastroenterology 59(116):960-4, 2012. e-Pub 2012. PMID: 22580643.
406. Falchook GS, Duvic M, Hong DS, Wheler J, Naing A, Lim J, Kurzrock R. Age-stratified Phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies. Cancer Chemother Pharmacol 69(5):1117-26, 2012. e-Pub 2012. PMID: 22205203.
407. Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA, Kurzrock R. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res 18(9):2625-31, 2012. e-Pub 2012. PMID: 22465830.
408. Wheler J, Tsimberidou AM, Hong D, Naing A, Falchook G, Piha-Paul S, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Survival of 1,181 patients in a Phase I clinic: the MD Anderson Clinical Center for Targeted Therapy experience. Clin Cancer Res 18(10):2922-9, 2012. e-Pub 2012. PMID: 22452943.
409. Galsky M, Camacho L, Chiorean E, Mulkerin D, Hong D, Oh W, Bajorin D. Phase I study of the effects of renal impairment on the pharmacokinetic (PK) and safety of satraplatin in patients (pts) with refractory non-hematologic cancer. Ann Oncol , 2012. e-Pub 2012. PMID: 21828377.
410. Hong DS, Vence L, Falchook G, Radvanyi LG, Liu C, Goodman V, Legos JJ, Blackman S, Scarmadio A, Kurzrock R, Lizee G, Hwu P. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res 18(8):2326-35, 2012. e-Pub 2012. PMID: 22355009.
411. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 30(8):777-82, 2012. e-Pub 2012. PMID: 22271473.
412. Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I clinical trials program at the MD Anderson Cancer Center. Cancer 118(5):1422-8, 2012. e-Pub 2012. PMID: 21823111.
413. Subbiah V, Slopis J, Hong DS, Ketonen LM, Hamilton J, McCutcheon IE, Kurzrock R. Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. J Clin Oncol 30(5):e64-8, 2012. e-Pub 2012. PMID: 22203760.
414. Munoz J, Hong D, Kurzrock R. Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy. Int J Hematol 95(1):1-2, 2012. e-Pub 2012. PMID: 22170230.
415. Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, Fu S, Wheler JJ, Luthra R, Naing A, Wang X, Kurzrock R. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS One 7(5):e38033, 2012. e-Pub 2012. PMID: 22675430.
416. Parsons HA, Tsimberidou AM, Pontikos M, Fu S, Hong D, Wen S, Baracos VE, Kurzrock R. Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. Nutr Cancer 64(2):206-17, 2012. e-Pub 2012. PMID: 22229660.
417. Parsons HA, Baracos VE, Dhillon N, Hong DS, Kurzrock R. Body composition, symptoms, and survival in advanced cancer patients referred to a Phase I service. PLoS One 7(1):e29330, 2012. e-Pub 2012. PMID: 22235285.
418. Naing A, Stephen SK, Frenkel M, Chandhasin C, Hong DS, Lei X, Falchook G, Wheler JJ, Fu S, Kurzrock R. Prevalence of complementary medicine use in a Phase 1 clinical trials program: the MD Anderson Cancer Center experience. Cancer 117(22):5142-50, 2011. e-Pub 2011. PMID: 21538342.
419. Moroney JW, Schlumbrecht MP, Helgason T, Coleman RL, Moulder S, Naing A, Bodurka DC, Janku F, Hong DS, Kurzrock R. A Phase I trial of liposomal doxorubicin, bevacizumab and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res 17(21):6840-6, 2011. e-Pub 2011. PMID: 21890452.
420. Hong DS, Kurzrock R, Oh Y, Wheler J, Naing A, Brail L, Callies S, André V, Kadam SK, Nasir A, Holzer TR, Meric-Bernstam F, Fishman M, Simon G. A Phase 1 dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res 17(20):6582-91, 2011. e-Pub 2011. PMID: 21831956.
421. Galsky MD, Seng S, Camacho LH, Chiorean EG, Mulkerin D, Hong DS, Oh WK, Bajorin DF. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy. Clin Genitourin Cancer 9(1):27-30, 2011. e-Pub 2011. PMID: 21700509.
422. Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong D, Chen HX, Doyle LA, Heilbrun LK, Rohren E, Ng C, Chandhasin C, Lorusso PM. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res 17(18):6052-60, 2011. e-Pub 2011. PMID: 21750201.
423. Fu S, Hong DS, Naing A, Wheler J, Falchook G, Wen S, Howard A, Barber D, Nates J, Price K, Kurzrock R. Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a Phase I clinical trials program. J Clin Oncol 29(26):3547-52, 2011. e-Pub 2011. PMID: 21844494.
424. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29(19):2660-6, 2011. e-Pub 2011. PMID: 21606412.
425. Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R. Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity. Mol Cancer Ther 10(7):1300-7, 2011. e-Pub 2011. PMID: 21571911.
426. Tsimberidou AM, Letourneau K, Fu S, Hong DS, Naing A, Wheler J, Uehara C, McRae SE, Wen S, Kurzrock R. Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol 68(1):247-53, 2011. e-Pub 2011. PMID: 20941597.
427. Tsimberidou AM, Letourneau K, Wen S, Wheler J, Hong D, Naing A, Iskander NG, Uehara C, Kurzrock R. Phase I clinical trials in 93 patients with brain metastases: the M. D. Anderson Cancer Center experience. Clin Cancer Res 17(12):4110-8, 2011. e-Pub 2011. PMID: 21415223.
428. Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Waguespack SG, Hernandez M, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab 96(4):997-1005, 2011. e-Pub 2011. PMID: 21289252.
429. Piha-Paul SA, Hong DS, Kurzrock R. Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus)-based treatment. J Clin Oncol 29(12):e333-5, 2011. e-Pub 2011. PMID: 21263090.
430. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 10(3):558-65, 2011. e-Pub 2011. PMID: 21216929.
431. Naing A, Reuben JM, Camacho LH, Gao H, Lee BN, Cohen EN, Verschraegen C, Stephen S, Aaron J, Hong D, Wheler J, Kurzrock R. Phase I dose escalation study of sodium stibogluconate (SSG), a protein tyrosine phosphatase inhibitor, combined with interferon alpha for patients with solid tumors. J Cancer 2(1):81-9, 2011. e-Pub 2011. PMID: 21326629.
432. Vaklavas C, Tsimberidou AM, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff RA, Kurzrock R. Phase 1 clinical trials in 83 patients with pancreatic cancer: the M. D. Anderson Cancer Center experience. Cancer 117(1):77-85, 2011. e-Pub 2011. PMID: 20737567.
433. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One 6(7):e22769, 2011. e-Pub 2011. PMID: 21829508.
434. El-Osta H, Falchook G, Tsimberidou A, Hong D, Naing A, Kim K, Wen S, Janku F, Kurzrock R. BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One 6(10):e25806, 2011. e-Pub 2011. PMID: 22039425.
435. Janku F, Tsimberidou AM, Wang X, Hong DS, Naing A, Gong J, Garrido-Laguna I, Parsons HA, Zinner RG, Kurzrock R. Outcomes of patients with advanced non-small cell lung cancer treated in a Phase I clinic. Oncologist 16(3):327-35, 2011. e-Pub 2011. PMID: 21339262.
436. El-Osta H, (co-first author) HD, Wheler J, Fu S, Naing A, Falchook G, Hicks M, Wen S, Tsimberidou AM, Kurzrock R. Outcomes of research biopsies in phase I clinical trials: the MD Anderson Cancer Center experience. Oncologist 16(9):1292-8, 2011. e-Pub 2011. PMID: 21859821.
437. Camacho LH, Garcia S, Panchal AM, Lim J, Hong DS, Ng C, Madoff DC, Fu S, Gayed I, Kurzrock R. Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases. Clin Colorectal Cancer 9(5):311-4, 2010. e-Pub 2010. PMID: 21208846.
438. Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L, Juan G, Hwang YC, Wong S, Hill JS, Friberg G, LoRusso PM. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res 16(23):5883-91, 2010. e-Pub 2010. PMID: 20947515.
439. Tsimberidou AM, Akerley W, Schabel MC, Hong DS, Uehara C, Chhabra A, Warren T, Mather GG, Evans BA, Woodland DP, Swabb EA, Kurzrock R. Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. Mol Cancer Ther 9(12):3410-9, 2010. e-Pub 2010. PMID: 21159616.
440. Moulder S, Dhillon N, Ng C, Hong D, Wheler J, Naing A, Tse S, La Paglia A, Dorr R, Hersh E, Boytim M, Kurzrock R. A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. Invest New Drugs 28(5):634-40, 2010. e-Pub 2010. PMID: 19499186.
441. Tsimberidou AM, Fu S, Ng C, Lim JA, Wen S, Hong D, Wheler J, Bedikian AY, Eng C, Wallace M, Camacho LH, Kurzrock R. A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer 116(17):4086-94, 2010. e-Pub 2010. PMID: 20564148.
442. Garrido-Laguna I, Janku F, Falchook GS, Fu S, Hong DS, Naing A, Aaron J, Wang X, Kies M, Kurzrock R. Patients with advanced head and neck cancers have similar progression-free survival on Phase I trials and their last Food and Drug Administration-approved treatment. Clin Cancer Res 16(15):4031-7, 2010. e-Pub 2010. PMID: 20525754.
443. Moroney J, Wheler J, Hong D, Naing A, Falchook G, Bodurka D, Coleman R, Lu K, Xiao L, Kurzrock R. Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience. Gynecol Oncol 117(3):467-72, 2010. e-Pub 2010. PMID: 20347123.
444. Johnson FM, Agrawal S, Burris H, Rosen L, Dhillon N, Hong D, Blackwood-Chirchir A, Luo FR, Sy O, Kaul S, Chiappori AA. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 116(6):1582-91, 2010. e-Pub 2010. PMID: 20108303.
445. Jain RK, Lee JJ, Hong D, Markman M, Gong J, Naing A, Wheler J, Kurzrock R. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res 16(4):1289-97, 2010. e-Pub 2010. PMID: 20145187.
446. Wheler J, Tsimberidou AM, Moulder S, Cristofanilli M, Hong D, Naing A, Pathak R, Liu S, Feng L, Kurzrock R. Clinical outcomes of patients with breast cancer in a Phase I clinic: the M. D. Anderson Cancer Center experience. Clin Breast Cancer 10(1):46-51, 2010. e-Pub 2010. PMID: 20133258.
447. Tsimberidou AM, Rudek MA, Hong D, Ng CS, Blair J, Goldsweig H, Kurzrock R. Phase 1 first-in-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer Chemother Pharmacol 65(2):235-41, 2010. e-Pub 2010. PMID: 19484470.
448. Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI, Kurzrock R. Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab 94(11):4423-32, 2009. e-Pub 2009. PMID: 19820016.
449. Hong DS, Sebti SM, Newman RA, Blaskovich MA, Ye L, Gagel RF, Moulder S, Wheler JJ, Naing A, Tannir NM, Ng CS, Sherman SI, El Naggar AK, Khan R, Trent J, Wright JJ, Kurzrock R. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res 15(22):7061-8, 2009. e-Pub 2009. PMID: 19903778.
450. Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS. Safety, pharmacokinetics, and anti-tumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 27(21):3557-65, 2009. e-Pub 2009. PMID: 19546406.
451. Tsimberidou AM, Camacho LH, Verstovsek S, Ng C, Hong DS, Uehara CK, Gutierrez C, Daring S, Stevens J, Komarnitsky PB, Schwartz B, Kurzrock R. A Phase I clinical trial of darinaparsin in patients with refractory solid tumors. Clin Cancer Res 15(14):4769-76, 2009. e-Pub 2009. PMID: 19584162.
452. Vemulapalli S, Chintala L, Tsimberidou AM, Dhillon N, Lei X, Hong D, Kurzrock R. Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I clinic: the M. D. Anderson Cancer Center experience. Am J Hematol 84(7):408-13, 2009. e-Pub 2009. PMID: 19437507.
453. Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, Oki Y, Guo Z, Gupta S, Wistuba II. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res 15(11):3881, 2009. e-Pub 2009. PMID: 19470736.
454. Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, Liu S, Feng L, Kurzrock R. Survival of patients in a Phase 1 clinic: the M. D. Anderson Cancer Center experience. Cancer 115(5):1091-9, 2009. e-Pub 2009. PMID: 19165805.
455. Braiteh F, Soriano AO, Garcia-Manero G, Hong D, Johnson MM, Silva DP, Yang H, Alexander S, Wolff J, Kurzrock R. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res 14(19):6296-301, 2008. e-Pub 2008. PMID: 18829512.
456. Hong DS, Reddy SB, Prieto VG, Wright JJ, Tannir NM, Cohen PR, Diwan AH, Evans HL, Kurzrock R. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol 6(144):779-82, 2008. e-Pub 2008. PMID: 18559769.
457. Hong D, Ye L, Gagel R, Chintala L, El-Naggar AK, Wright J, Kurzrock R. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther 7(5):1001-6, 2008. e-Pub 2008. PMID: 18445656.
458. Camacho LH, Marubio L, Purdom MA, Leonard D, Hong DS, Moulder S, Pilat SR, Kurzrock R. Improving the institutional submission and approval process for clinical research protocols in oncology. J Clin Oncol 25(12):1632-3, 2007. e-Pub 2007. PMID: 17443009.
459. Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A, Kuwata K, Hoff PM. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer 107(6):1383-90, 2006. e-Pub 2006. PMID: 16902987.
460. Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY, Donato NJ, Abbruzzese JL, Baker CH, Gallick GE. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol, 2006. e-Pub 2006. PMID: 16507911.
461. Hong D, Lunagomez S, Kim EE, Lee JH, Bresalier RS, Swisher SG, Wu TT, Morris J, Liao Z, Komaki R, Ajani JA. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer 104(8):1620-6, 2005. e-Pub 2005. PMID: 16118804.
462. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Jr PJ, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 101(8):1776-85, 2004. e-Pub 2004. PMID: 15386332.
463. Green NS, Hong DS. Shedding some light on immunoglobin gene mutation. Einstein Quart J Biol Med 15:75-85, 1998. e-Pub 1998.
464. Nakaar V, Dare AO, Hong D, Ullu E, Tschudi C. Upstream tRNA genes are essential for expression of small nuclear and cytoplasmic RNA genes in trypanosomes. Mol Cell Biol 14(10):6736-42, 1994. e-Pub 1994. PMID: 7523857.

Review Articles

1. Lim, JU, Vailati Negrao, M, Hong, DS. Optimizing KRAS Therapeutics for Non–Small Cell Lung Cancer. Annual Review of Medicine 77(1):193-205, 2026. e-Pub 2026. PMID: 40991960.
2. Propst, CL, Sucholeiki, RL, Chandra, J, Livingston, JA, Roth, M, Hong, DS, George, GC. Diet in adolescent and young adult patients with cancer and cancer survivors. Supportive Care in Cancer 33(6), 2025. e-Pub 2025. PMID: 40411574.
3. Ring, K, Mills, AM, Howitt, BE, Grisham, RN, Euscher, ED, Kim, HS, Klopp, AH, Kolin, DL, McCluggage, WG, Mirkovic, J, Park, K, Aoun, E, Awujo, C, Son, J, Mok, S, Ferri-Borgogno, S, Hong, DS, Hoang, L, Jazaeri, AA, How, JA, Lu, KH. Mesonephric-like adenocarcinoma of the female genital tract. Gynecologic oncology 197:57-65, 2025. e-Pub 2025. PMID: 40279981.
4. Gouda MA, Thein KZ, Hong DS. Tissue-Agnostic Targeting of Neurotrophic Tyrosine Receptor Kinase Fusions: Current Approvals and Future Directions. Cancers (Basel) 16(19), 2024. e-Pub 2024. PMID: 39410015.
5. Hong, DS, Drilon, A, Wirth, L. Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancers. Clinical advances in hematology & oncology : H&O 22(6):1-20, 2024. e-Pub 2024. PMID: 38953725.
6. Singh, M, Morris, VK, Bandey, I, Hong, DS, Kopetz, S. Advancements in combining targeted therapy and immunotherapy for colorectal cancer. Trends in Cancer 10(7):598-609, 2024. e-Pub 2024. PMID: 38821852.
7. Li Sucholeiki, R, Propst, CL, Hong, DS, George, GC. Intermittent fasting and its impact on toxicities, symptoms and quality of life in patients on active cancer treatment. Cancer treatment reviews 126, 2024. e-Pub 2024. PMID: 38574507.
8. Aggen, DH, Garcia, A, Saro Suarez, JM, Sauer, A, Cristiani, S, Brophy, F, Streets, S, Norry, E, Nelson, A, Kilari, D, Garmezy, B, Charlson, J, Zugazagoitia, J, Calvo, E, Moreno, I, Moreno, V, Hoimes, C, Hong, DS, Cervantes, A. New phase 1 SURPASS trial cohort. Journal of Clinical Oncology 42:TPS708-TPS708, 2024. e-Pub 2024.
9. Bhamidipati, D, Haro-Silerio, JI, Ileana Dumbrava, EE, Fu, S, Hong, DS, Karp, DD, Naing, A, Pant, S, Piha-Paul, SA, Rodon Ahnert, J, Tsimberidou, AM, Johnson, A, Lee, MS, Dasari, NV, Raghav, KS, Morris, VK, Overman, MJ, Kopetz, S, Meric-Bernstam, F, Yap, TA. Clinical characterization and therapeutic outcomes of patients (pts) with colorectal cancer (CRC) harboring somatic BRCA1/2 mutations. Journal of Clinical Oncology 42:134, 2024. e-Pub 2024.
10. Miyashita, H, Kato, S, Hong, DS. KRAS G12C inhibitor combination therapies. Frontiers in Oncology 14, 2024. e-Pub 2024. PMID: 38756650.
11. Dy, GK, Govindan, R, Velcheti, V, Falchook, GS, Italiano, A, Wolf, J, Sacher, A, Takahashi, T, Ramalingam, SS, Dooms, C, Kim, DW, Addeo, A, Desai, J, Schuler, M, Tomasini, P, Hong, DS, Lito, P, Tran, Q, Jones, S, Anderson, A, Hindoyan, A, Snyder, W, Skoulidis, F, Li, BT. Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer. Future Oncology 20(3):113-120, 2024. e-Pub 2024. PMID: 38010044.
12. Hallick J, Baird AM, Falchook G, Le X, Hong D, Viteri S, Raskin J, Reinmuth N, Vlassak S, Militaru M, Paik PK. Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer called MET exon 14 skipping. Future Oncol 19(10):683-696, 2023. e-Pub 2023. PMID: 36999526.
13. Akhave NS, Biter AB, Hong DS. The Next Generation of KRAS Targeting: Reasons for Excitement and Concern. Mol Cancer Ther 21(11):1645-1651, 2022. e-Pub 2022. PMID: 36282862.
14. Hobbs BP, Pestana RC, Zabor EC, Kaizer AM, Hong DS. Basket Trials: Review of Current Practice and Innovations for Future Trials. J Clin Oncol 40(30):JCO2102285, 2022. e-Pub 2022. PMID: 35537102.
15. Kato S, Fujiwara Y, Hong DS. Targeting KRAS: Crossroads of Signaling and Immune Inhibition. J Immunother Precis Oncol 5(3):68-78, 2022. e-Pub 2022. PMID: 36034582.
16. Kim AJ, Hong DS, George GC. Dietary influences on symptomatic and non-symptomatic toxicities during cancer treatment: A narrative review. Cancer Treat Rev 108:102408, 2022. e-Pub 2022. PMID: 35623220.
17. Coleman, N, Hong, L, Zhang, J, Heymach, JV, Hong, DS, Le, X. Beyond epidermal growth factor receptor. ESMO Open 6(6), 2021. e-Pub 2021. PMID: 34837746.
18. Greenbaum, U, Ileana Dumbrava, EE, Biter, AB, Haymaker, CL, Hong, DS. Engineered T-cell receptor T cells for cancer immunotherapy. Cancer Immunol Res 9(11):1252-1261, 2021. e-Pub 2021. PMID: 34728535.
19. Laetsch TW, Hong DS. Tropomyosin receptor kinase inhibitors for the treatment of TRK fusion cancer. Clin Cancer Res 27(18):4974-4982, 2021. e-Pub 2021. PMID: 33893159.
20. Al-Zubidi N, Gombos DS, Hong DS, Subbiah V, Fu S, Ahnert JR, Piha-Paul SA, Tsimberidou AM, Karp DD, Bernstam FM, Naing A. Overview of ocular side effects of selinexor. Oncologist 26(7):619-623, 2021. e-Pub 2021. PMID: 33728727.
21. Akhave NS, Biter AB, Hong DS. Mechanisms of resistance to KRASG12C-targeted therapy. Cancer Discov 11(6):1345-1352, 2021. e-Pub 2021. PMID: 33820777.
22. Kim, AJ, Hong, DS, George, GC. Diet-related interventions for cancer-associated cachexia. J Cancer Res Clin Oncol 147(5):1443-1450, 2021. e-Pub 2021. PMID: 33718995.
23. Thein KZ, Biter AB, Hong DS. Therapeutics targeting mutant KRAS. Annu Rev Med 72:349-364, 2021. e-Pub 2021. PMID: 33138715.
24. Greenbaum U, Yalniz FF, Srour SA, Rezvani K, Singh H, Olson A, Blumenschein G, Hong DS, Shpall EJ, Kebriaei P. Chimeric antigen receptor therapy: how are we driving in solid tumors?. Biol Blood Marrow Transplant 26(10):1759-1769, 2020. e-Pub 2020. PMID: 32623078.
25. Pestana RC, Sen S, Hobbs BP, Hong DS. Histology-agnostic drug development - considering issues beyond the tissue. Nat Rev Clin Oncol 17(9):555-568, 2020. e-Pub 2020. PMID: 32528101.
26. Kaizer AM, Koopmeiners JS, Kane MJ, Roychoudhury S, Hong DS, Hobbs BP. Basket designs: statistical considerations for oncology trials. JCO Precis Oncol 3:1-9, 2019. e-Pub 2019. PMID: 35100726.
27. Adashek JJ, LoRusso PM, Hong DS, Kurzrock R. Phase I trials as valid therapeutic options for patients with cancer. Nat Rev Clin Oncol 16(12):773-778, 2019. e-Pub 2019. PMID: 31477881.
28. George GC, Barata PC, Campbell A, Chen A, Cortes JE, Hyman DM, Jones L, Karagiannis T, Klaar S, Le-Rademacher JG, LoRusso P, Mandrekar SJ, Merino DM, Minasian LM, Mitchell SA, Montez S, O'Connor DJ, Pettit S, Silk E, Sloan JA, Stewart M, Takimoto CH, Wong GY, Yap TA, Cleeland CS, Hong DS. Improving attribution of adverse events in oncology clinical trials. Cancer Treat Rev 76:33-40, 2019. e-Pub 2019. PMID: 31108240.
29. Kheder ES, Hong DS. Emerging targeted therapy for tumors with NTRK fusion proteins. Clin Cancer Res 24(23):5807-5814, 2018. e-Pub 2018. PMID: 29986850.
30. Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong DS. Untying the gordion knot of targeting MET in cancer. Cancer Treat Rev 66:95-103, 2018. e-Pub 2018. PMID: 29730462.
31. Porta R, Borea R, Coelho A, Khan S, Araújo A, Reclusa P, Franchina T, Van Der Steen N, Van Dam P, Ferri J, Sirera R, Naing A, Hong D, Rolfo C. FGFR a promising druggable target in cancer: molecular biology and new drugs. Crit Rev Oncol Hematol 113:256-267, 2017. e-Pub 2017. PMID: 28427515.
32. Cox VL, Bhosale P, Varadhachary GR, Wagner-Bartak N, Glitza IC, Gold KA, Atkins JT, Soliman PT, Hong DS, Qayyum A. Cancer genomics and important oncologic mutations: a contemporary guide for body imagers. Radiology 283(2):314-340, 2017. e-Pub 2017. PMID: 28418819.
33. Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS. Targeting TRK family proteins in cancer. Pharmacol Ther 173:58-66, 2017. e-Pub 2017. PMID: 28174090.
34. Barata P, Sood AK, Hong DS. RNA-targeted therapeutics in cancer clinical trials: current status and future directions. Cancer Treat Rev 50:35-47, 2016. e-Pub 2016. PMID: 27612280.
35. Seyedin SN, Schoenhals JE, Lee DA, Cortez MA, Wang X, Niknam S, Tang C, Hong DS, Naing A, Sharma P, Allison JP, Chang JY, Gomez DR, Heymach JV, Komaki RU, Cooper LJ, Welsh JW. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy 7(9):967-80, 2015. e-Pub 2015. PMID: 26310908.
36. Rolfo, C, Castiglia, M, Hong, DS, Alessandro, R, Mertens, I, Baggerman, G, Zwaenepoel, K, Gil-Bazo, I, Passiglia, F, Carreca, AP, Taverna, S, Vento, R, Peeters, M, Russo, A, Pauwels, P. Liquid biopsies in lung cancer. Biochim Biophys Acta 1846(2):539-546, 2014. e-Pub 2014. PMID: 25444714.
37. Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A, Gomez D, Ye H, Heymach J, Komaki R, Allison JP, Sharma P, Welsh JW. Combining radiation and immunotherapy: a new systemic therapy for solid tumors?. Cancer Immunol Res 2(9):831-838, 2014. e-Pub 2014. PMID: 25187273.
38. Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez LE, Bronte G, Buffoni L, Reguart N, Santos ES, Germonpre P, Taron M, Passiglia F, Van Meerbeeck JP, Russo A, Peeters M, Gil-Bazo I, Pauwels P, Rosell R. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Cancer Treat Rev 40(8):990-1004, 2014. e-Pub 2014. PMID: 24953979.
39. Munoz J, Dhillon N, Janku F, Watowich SS, Hong DS. STAT3 inhibitors: finding a home in lymphoma and leukemia. Oncologist 19(5):536-44, 2014. e-Pub 2014. PMID: 24705981.
40. Akcakanat A, Hong DS, Meric-Bernstam F. Targeting translation initiation in breast cancer. Translation 2(1):e28968, 2014. e-Pub 2014. PMID: 26779407.
41. Hong DS, Banerji U, Tavana B, George GC, Aaron J, Kurzrock R. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev 39(4):375-87, 2013. e-Pub 2013. PMID: 23199899.
42. Janku F, McConkey DJ, Hong DS, Kurzrock R. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol 8(9):528-39, 2011. e-Pub 2011. PMID: 21587219.
43. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 110(9):1911-28, 2007. e-Pub 2007. PMID: 17849470.
44. Hong DS, Jacobson KL, Raad II, de Lima M, Anderlini P, Fuller GN, Ippoliti C, Cool RM, Leeds NE, Narvios A, Han XY, Padula A, Champlin RE, Hosing C. West Nile encephalitis in 2 hematopoietic stem cell transplant recipients: case series and literature review. Clin Infect Dis 37(8):1044-9, 2003. e-Pub 2003. PMID: 14523768.

Other Articles

1. Thein, KZ, Karp, DD, Tsimberidou, AM, Gong, J, Sulovic, S, Shan, J, Milton, D, Hong, DS, Janku, F, McQuinn, L, Stephen, B, Colen, R, Carter, B, Yap, TA, Piha-Paul, SA, Fu, S, Meric-Bernstam, F, Naing, A Correction to. Investigational New Drugs 43(2):446-447, 2025. PMID: 39976873.
2. Hong, DS, Drilon, A, Wirth, L Q&A: Barriers to testing for NTRK fusions in metastatic lung and thyroid cancer. Clinical advances in hematology & oncology : H&O 22(6):16, 2024. PMID: 38953729.
3. Son JY, Cheng-En Hsieh R, Lin H, Krause KJ, Yuan Y, Biter AB, Welsh J, Curran MA, Hong DS Inhibition of the CD47-SIRPɑ axis for cancer therapy: a meta-analysis of emerging clinical data. Front Immunol, 2022. PMID: 36439116.
4. Thein KZ, Karp DD, Tsimberidou A, Gong J, Sulovic S, Shah J, Milton DR, Hong DS, Janku F, McQuinn L, Stephen BA, Colen R, Carter BW, Yap TA, Piha-Paul SA, Fu S, Meric-Bernstam F, Naing A Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm Phase Ib study. Invest New Drugs 40(2):463, 2022. PMID: 34731355.
5. Saleh MN, Patel MR, Bauer TM, Goel S, Falchook GS, Shapiro GI, Chung KY, Infante JR, Conry RM, Rabinowits G, Hong DS, Wang JS, Steidl U, Walensky LD, Naik G, Guerlavais V, Vukovic V, Annis DA, Aivado M, Meric-Bernstam F Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53. Clin Cancer Res 28(2):429, 2022. PMID: 35045962.
6. Hong DS Targeting the KRAS G12C mutation in patients with advanced solid tumors. Clin Adv Hematol Oncol 17(11):612-614, 2019. PMID: 31851163.
7. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V Corrigendum to: Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer 136:158, 2019. PMID: 31445783.
8. Fu C, Gombos DS, Lee J, George GC, Hess K, Whyte A, Hong DS Erratum: Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. Oncotarget 10(9):1011-1013, 2019. PMID: 30847029.
9. Patnaik A, Gordon M, Tsai F, Papadopoulos KP, Rasco D, Beeram M, Fu S, Janku F, Hynes SM, Gundala SR, Willard MD, Zhang W, Lin AB, Hong D Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. Cancer Chemother Pharmacol 82(3):419, 2018. PMID: 30014222.
10. Fu, S, Hirte, H, Welch, S, Ilenchuk, TT, Lutes, T, Rice, C, Fields, N, Nemet, A, Dugourd, D, Piha-Paul, SA, Subbiah, V, Liu, L, Gong, J, Hong, DS, Stewart, JM Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. Invest New Drugs 35(3):397, 2017. PMID: 28389981.
11. Fu S, Culotta KS, Falchook GS, Hong DS, Myers AL, Zhang YP, Naing A, Janku F, Hou MM, Kurzrock R Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemother Pharmacol 77(4):881, 2016. PMID: 26994910.
12. Jardim, DL, Schwaederle, M, Wei, M, Lee, JJ, Hong, DS, Eggermont, AM, Schilsky, R, Mendelsohn, J, Lazar, V, Kurzrock, R Erratum to: Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-Analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst 108(2), 2016. PMID: 26727926.
13. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget 6(27):24581, 2015. PMID: 26405159.
14. Rolfo, C, Castiglia, M, Hong, DS, Alessandro, R, Mertens, I, Baggerman, G, Zwaenepoel, K, Gil-Bazo, I, Passiglia, F, Carreca, AP, Taverna, S, Vento, R, Santini, D, Peeters, M, Russo, A, Pauwels, P Corrigendum to: Liquid biopsies in lung cancerThe new ambrosia of researchers [Biochem. Biophys. Act. 1846(2014) 539-546]. Biochim Biophys Acta Rev Cancer 1855(1):17, 2015.
15. Hong, DS, Cabanillas, ME, Wheler, JJ, Naing, A, Tsimberidou, AM, Ye, L, Busaidy, NL, Waguespack, SG, Hernandez, M, El-Naggar, AK, Bidyasar, S, Wright, J, Sherman, SI, Kurzrock, R Erratum to: Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, (997-1005)). J Clin Endocrinol Metab 97(4):1399, 2012.
16. Hong, DS, Cabanillas, ME, Wheler, JJ, Naing, A, Tsimberidou, AM, Ye, L, Waguespack, SG, Hernandez, M, El-Naggar, AK, Bidyasar, S, Wright, J, Sherman, SI, Kurzrock, R, Busaidy, NL Erratum to: Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, 997-1005). J Clin Endocrinol Metab 96(7):2286, 2011.
17. Wheler, JJ, Tsimberidou, AM, Hong, DS, Naing, A, Jackson, TL, Liu, S, Feng, L Erratum to: Survival of patients in a Phase 1 clinic: The M. D. anderson cancer center experience (Cancer (2009) 115 (1091-9)). Cancer 115(7):1588, 2009.

Editorials

1. Kurzrock, R, Hong, DS. How to Build a Successful Phase I Clinical Trials Unit. Journal of Immunotherapy and Precision Oncology 7(3):142-149, 2024. PMID: 39220000.
2. Giallombardo M, Taverna S, Alessandro R, Hong D, Rolfo C. Exosome-mediated drug resistance in cancer: the near future is here. Ther Adv Med Oncol 8(5):320-2, 2016. PMID: 27583023.
3. Jardim DLF, Hong DS. Axitinib for the first line therapy of renal cancer: failure of a trial or failure of a strategy?. Transl Cancer Res 3(6):558-561, 2014.
4. Tang C, Jardim DL, Hong DS. MET in ovarian cancer: metastasis and resistance?. Cell Cycle 13(8):1220-1, 2014. PMID: 24621499.
5. Hong DS. The Mutation That Broke the Cell’s Back. Sci Transl Med 4(121):ec25, 2012.
6. Hong, DS. Another window of opportunity. Science Transl Med 4(117), 2012.
7. Hong DS. Putting Out the Fire. Sci Transl Med 3(113):ec203, 2011.
8. Hong, DS. Another reason to exercise. Science Transl Medicine 3(109), 2011.
9. Hong DS. The Great Escape. Sci Transl Med 3(105):ec169, 2011.
10. Hong DS. Good Ideas Come in Small Packages. Sci Transl Med 3(101):ec154, 2011.
11. Hong DS. A Picture Is Worth a Thousand Dollars?. Sci Transl Med 3(97):ec135, 2011.
12. Hong DS. A Death by a Thousand Cuts. Sci Transl Med 3(93):ec119, 2011.
13. Hong, DS. A hair-raising finding in leukemia. Science Transl Med 3(89), 2011.
14. Hong DS. Old Dogs and New Tricks. Sci Transl Med 3(85):ec81, 2011.
15. Hong, DS. A fountain of cancer. Science Transl Med 3(81), 2011.
16. Hong DS. Patient, Heal Thyself. Sci Transl Med 3(77):ec47, 2011.
17. Hong DS. This Changes Everything, Twice!. Sci Transl Med 3(73):ec31, 2011.

Abstracts

1. Murchiano-Goroff YR, Lo Russo P, Garrido-Laguna I, Herzberg B, Patnaik A, Gandhi NJ, Smith K, Cykowski L, Zhi X, Healey DI, Patel VG, Hong DS. Phase 1/2 study of ARV-806, a PROTAC KRAS G12D degrader, in KRAS G12D–mutated advanced solid tumors, including pancreatic cancer. 2026 ASCO Gastrointestinal Cancers Symposium, 2026.
2. Tan HN, Yap TA, Rodon J, Stephen B, Dumbrava EE, Piha-Paul S, Fu S, Champiat S, Akhave N, Gillison M, Heymach JV, Hong D, Meric-Bernstam F, Naing A. Clinical Outcomes and Biomarker Correlates of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Novel Immunotherapies in Phase 1 Trials. 2025 AACR-NCI-EORTC Molecular Targets, 2025. e-Pub 2025.
3. Uzunparmak B, Su F, Johnson AM, Shaw KR, Kong EK, Braganca-Xavier C, Yuan Y, Fowler N, Paradiso F, Kontselidze L, Butusova A, Bagaev A, Dumbrava EE, Rodon-Shnert J, Hong DS, Fu S, Yap TA, Naing A, Piha-Paul SA, Ferrarotto R, Lorgulescu B, Kulkarni S, Patel KP, Meric-Bernstam F. Clinical Utility of Comprehensive Genomic and Transcriptomic Analysis to Guide Therapy for Patients with Metastatic Solid Tumors. 2025 AACR-NCI-EORTC Molecular Targets, 2025. e-Pub 2025.
4. Gouda MA, Kang L, T-Y T, Dumbrava EE, Champiat S, Piha-Paul SA, Pohlmann PR, Naing A, Fu S, Tsimberidou AM, Rodon J, Yap TA, Meric-Bernstam F, Hong DS. Discrepancies Between Calculated and Actual Creatinine Clearance: A Phase 1 Trial Unit Experience. 2025 AACR-NCI-EORTC Molecular Targets, 2025. e-Pub 2025.
5. Aronchik I, Kar S, Zhuang Y, Ahler E, Lai LP, Seshadri V, Chi Yang KY, Bulle A, Menard M, Nayak B, Labrecque MP, Dilly J, Gundlapalli H, Jiang L, Blaj C, Yano J, Wasko-Kornberg U, Helland C, Bredeson S, Garrick B, Gindin Y, Sickler B, Evans J, Seamon K, Jiang J, K-H L, HolderfieldM, Quintana E, Hedge A, Salman Z, Smith JAM, Starodub A, Spira A, Park W, Hong DS, Barve M, Pelster M, Sommerhalder D, Punekar SR, Garrido-Laguna I, Wolpin B, Maitra A, Gustafson C, Lin K, Kelsey S, Aguirre AJ, Singh M. Resistance Mechanisms to Monotherapy RAS(ON) Multi-Selective Inhibitor Daraxonrasib (RMC-6236) in RAS Mutant PDAC Inform Therapeutic Combination Strategies. 2025 AACR-NCI-EORTC Molecular Targets, 2025. e-Pub 2025.
6. Adesoye T, Elders ML, Le H, Hong D, Belay SY, Rodon JA, Dumbrava EE, Naing A, Piha-Paul SA, Fu S, T-Y T, Tsimberidou AM, Tam AL, Murthy R, McNeill LH, Meric-Bernstam F. Research biopsy participation and safety in cancer therapeutic trials. 2025 AACR-NCI-EORTC Molecular Targets, 2025. e-Pub 2025.
7. Hong DS, Sen S, Schweizer C, Sanders A, Grimes C, Pericle F, Gagliardi C, Barlow J, Salameh A, Curran MA. A phase 1a/1b study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of IMGS-001 in patients with relapsed or refractory advanced solid tumors. 2025 ASCO Annual Meeting, 2025. e-Pub 2025.
8. Srour SA, Tannier NM, Jazaeri AA, Campbell MT, Nieto Y, Haymaker CL, Yuan Y, Salih I, Yang Y, Doppler V, Garibal J, Escande M, Yang QM, Kushner J, Koo J, Gurses SA, Hong DS, Fu S, Meric-Bernstam F, Naing A. Safety and efficacy of HLA-G–targeted CAR T cells (IVS-3001) in patients with advanced HLA-G–positive solid tumors: Clinical trial in progress. 2025 ASCO Annual Meeting, 2025. e-Pub 2025.
9. Brose MS, Cabanillas ME, Lin JJ, McDermott RS, Almubarak M, Bauman JR, Casanova M, Kummar S, S-H L, Rieke DT, D-Y O, Qi C, Neu N, D-I B, Mussi CE, Drilon AE, Hong DS, Waguespack SG. Efficacy and safety of larotrectinib in patients with TRK fusion thyroid carcinoma: An updated analysis. 2025 ASCO Annual Meeting, 2025. e-Pub 2025.
10. Venturini J, Baysal MA, Chakraborty A, Yap TA, Fu S, Hong DS, Piha-Paul SA, Naing A, Rodon Ahnert J, Dumbrava EE, Beck J, Andersen C, Kahle M, Vining DJ, Meric-Bernstam F, Tsimberidou AM. Clinical outcomes of patients with or without DNA repair pathway alterations by treatment type: The MD Anderson Cancer Center IMPACT 2 study. 2025 ASCO Annual Meeting, 2025. e-Pub 2025.
11. Su F, Uzunparmak B, Johnson A, Shaw KR, Fowler NH, Kontselidze L, Bagaev A, Butusova A, Dumbrava EE, Rodon Ahnert J, Fu S, Hong DS, Yap TA, Naing A, Piha-Paul SA, Ferrarotto R, Iorgulescu B, Kulkarni S, Patel K, Meric-Bernstam F. Clinical utility of comprehensive transcriptome testing in advanced solid tumors. 2025 ASCO Annual Meeting, 2025. e-Pub 2025.
12. Fox DA, Bhamidipati D, Lin HY, Hinkle LE, Pham CT, Rodon Ahnert J, Champiat S, Dumbrava EE, Fu S, Kang L, Le H, Meric-Bernstam F, Naing A, Piha-Paul SA, Pohlmann PR, T-Y T, Tsimberidou AM, Yap TA, Huey RW, Hong DS. Outcomes of young-onset colorectal cancer vs late-onset colorectal cancer patients on phase 1 matched and non-matched therapies. 2025 ASCO Annual Meeting, 2025. e-Pub 2025.
13. Braganca Xavier C, Lei K, Le Hung Kahle M, Tsimberidou AM, Naing A, Dumbrava EE, Rodon Ahnert J, Pohlmann PR, Piha-Paul SA, Fu S, Champiat S, Yap TA, T-Y T, Kopetz S, Meric-Bernstam F, Hong DS. Colorectal cancer with gene fusions: Navigating the genomic landscape and treatment selection in a phase I unit. 2025 ASCO Annual Meeting, 2025. e-Pub 2025.
14. Uk Lim J, Kang L, Le H, T-Y T, Champiat S, Dumbrava EE, Le X, Naing A, Piha-Paul A, Rodon Ahnert J, Tsimberidou AM, Yap TA, Fu S, Meric-Bernstam F, Hong DS. Therapeutic responses in 555 advanced NSCLC patients enrolled in phase I studies at MD Anderson Cancer Center. 2025 ASCO Annual Meeting, 2025. e-Pub 2025.
15. Arbour KC, Tawee T, Yeager R, Parikh AR, Oberstein P, Papadopoulos KP, Strickler J, Spria A, Powderly J, Barve M, Wang J, Luo J, Hazad NS, Starodub A, LoRusso P, Elgin A, Yang M, Yu W, McCleland M, Lally S, Sohoni S, Hong DS. Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors. AACR Annual Meeting 2025, 2025. e-Pub 2025.
16. Kr S, Zhuang Y, Ahler E, Lai LP, Starodub A, Spria A, Punekar SR, Garrido-Laguna I, Park W, Hong DS, Maitra A, Sommerhalder D, Barve M, Pelster M, Gundlapalli H, Seshadri V, Cai S, Labrecque M, W-Y H, Bredeson S, Eans J, Garrik B, Gindin Y, Blaj C, Menard M, Jiang L, Quintana E, Holderfield M, Hegde A, Jiang J, Salman Z, Gustafson WC, Smith JAM, Wolpin B, Aronchik I, Lin KK, Aguirre AJ, Singh M. Mechanisms of resistance to the RAS(ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC and potential resolution with RAS(ON) combination therapies. AACR Annual Meeting 2025, 2025. e-Pub 2025.
17. George GC, Lee H, Piha-Paul SA, Dumbrava E, Tsimberidou A, Fu S, Appleton G, Noor L, Rodon J, Yap TA, Meric-Bernstam F, Hong DS. Food choices of patients with advanced cancer at start of early-phase combination trials with immune checkpoint blockade. AACR Annual Meeting 2025, 2025. e-Pub 2025.
18. Braganca Xavier C, Andersen C, Lim JT, Slade JH, Bean SA, Kang L, Le H, Tsimberidou A, Naing A, Hong D, Dumbrava E, Rodon J, Pohlmann P, Piha-Paul S, Champiat S, Yap TA, T-Y T, Meric-Bernstam F, Fu S. Modulating treatment outcomes of patients with solid tumors in immunotherapy trials: a drug interaction analysis from a phase I unit. AACR Annual Meeting 2025, 2025. e-Pub 2025.
19. Luo J, Punekar SR, Arbour KC, Johnson M, Spria A, Garrido-Laguna I, Goldman JW, Herzberg B, S-H IO, Kim DW, Wang L, Cheng L, Seshadri V, Kar S, Hiremath M, Hong DS. Early reduction in circulating tumor DNA (ctDNA) is associated with clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC). AACR Annual Meeting 2025, 2025. e-Pub 2025.
20. Srour SA, Tannir N, Jazaeri A, Campbell MT, Nieto Y, Haymaker C, Yuan Y, Salih I, Yang Y, Doppler V, Garibal J, Escande M, Yang M, Kushner J, Koo J, Gurses SA, Hong DS, Fu S, Meric-Bernstam F, Naing A. Safety and efficacy of HLA-G-targeted CAR T cells (IVS-3001) in patients with advanced HLA-G-positive solid tumors: Clinical trial in progress. AACR Annual Meeting 2025, 2025. e-Pub 2025.
21. Torrado C, Tomczak K, Dumbrava EE, Sun B, Ngoi N, Arrechedera C, Para ER, Rodon Anhert J, Piha-Paul SA, Tsimberidou AM, Fu S, Naing A, Pohlmann PR, Hong DS, Meric-Bernstam F, Msaouel P, Haymaker CL, Yap TA. Clinical and translational study of the TGF-β monoclonal antibody SAR439459 in combination with the PD-1 inhibitor cemiplimab for patients (pts) with advanced solid tumors: Results from the phase 1b TACTIC trial. AACR Annual Meeting 2025, 2025. e-Pub 2025.
22. Hong DS. Clinical Trial Design Workshop: Complexities of Current Phase I Clinical Trials. AACR Annual Meeting 2025, 2025. e-Pub 2025.
23. Hong DS. The challenges now and ahead in phase 1. AACR Annual Meeting 2025, 2025. e-Pub 2025.
24. Ngoi NYL, Rodon J, Dumbrava EE, Garmezy B, Hong DS, Piha-Paul S, Tsimberidou AM, Fu S, Naing A, Pohlmann PR, T-Y T, Clemente H, Rhudy J, Valladolid C, Salguero C, Velez NA, Tran HT, Meric-Bernstam F, Yap TAA. TalaCom: Phase Ib investigator-initiated trial combining talazoparib and axitinib in patients with DNA damage response mutated cancers or BRCA1/2 wildtype ovarian cancer incorporating prospective intrapatient dose titration. ESMO Targeted Anticancer Therapies (TAT) Congress 2025, 2025. e-Pub 2025.
25. Casanova M, Drilon A, McDermott R, Italiano A, Tahara M, Brose MS, Krishnamurthy A, Lin JJ, Burcoveanu D, Neu N, Mussi CE, Shen L, Hong DS. Efficacy and safety of larotrectinib (laro) as first-line treatment for adult patients (pts) with TRK fusion cancer. 2025 ESMO Sarcoma and Rare Cancers, 2025. e-Pub 2025. PMID: 12151180.
26. Stephen B, Kwiatkowski E, Anderson MR, Derbala MH, Salih I, Castillo L, Yang Y, Gurses SA, Lim JT, Klekers AR, Le H, Kang L, Xu M, Ahmed J, Tan HN, Champiat S, T-Y T, Dumbrava EE, Fu S, Piha-Paul SA, Rodon Ahnert J, Tsimberidou AM, Yap T, Yuan Y, Hong DS, Meric-Bernstam F, Bhosale P, Naing A. Impact of liver metastases and systemic biomarkers on immunotherapy response and survival outcomes in patients with solid tumors. AACR IO 2025, 2025. e-Pub 2025.
27. Spira A, Papadopoulos K, Kim D, Parikh A, Barve M, Powderly J II, Starodub A, Strickler J, Li B, Oberstein P, Hassan F, Yang M, McCleland M, Lally S, Lin W, Sohoni S, Hong D. Preliminary safety, antitumor activity, and circulating tumor DNA (ctDNA) changes with RMC-9805, an oral, RAS(ON) G12D-selective tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors. 2025 ASCO Gastrointestinal Cancers Symposium, 2025. e-Pub 2025.
28. Garrido-Laguna I, Wolpin B, Park W, Azad N, Spira A, Starodub A, Sommerhalder D, Punekar S, Herzberg B, Barve M, Pelster M, Valerin J, Hecht J, Vora R, Hegde A, Gustafson C, Tao L, Kar S, Lin K, Hong D. Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC). 2025 ASCO Gastrointestinal Cancers Symposium, 2025. e-Pub 2025.
29. Berz D, Alese O, Hong D, Lakhani N, Elez E, Sharma M, O'Neill B, Li Y, Piccione E, Kalabus J, Garcia J, Hartner L, Lieu C. Tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) + FOLFIRI in 2L+ colorectal adenocarcinoma (CRC): Preliminary results from a phase 1 study. 2025 ASCO Gastrointestinal Cancers Symposium, 2025. e-Pub 2025.
30. Hong DS, Lee S, Shin S, LoRusso P, Rolfo C, Jung H, Yoo S, Hong D. A Phase I study of hSTC810 (Nelmastobart), an anti-BTN1A1 antibody, in patients with advanced solid tumors. 2024 SITC Annual Meeting, 2024. e-Pub 2024.
31. Stephen B, Anderson M, Kwiatkowski E, Derbala M, Yang Y, Lim J, Klekers A, Dumbrava E, Fu S, Piha-Paul S, Rodon J, Tsimberidou A, Yap T, Yuan Y, Hong D, Meric-Bernstam F, Bhosale P, Naing A. Impact of liver metastasis on immunotherapy in patients with solid tumors. 2024 SITC Annual Meeting, 2024. e-Pub 2024.
32. Derbala M, McGonagle K, Batra H, Stephen B, Gurses S, Lee S, Hwang W, Hwang S, C-Y O, Gouda M, Castillo L, Zarifa A, Rodriguez E, Hong D, Piha-Paul S, Rodon J, Karp D, Meric-Bernstam F, Raso MG, Naing A. Artificial Intelligence-powered assessment of tumor microenvironment in pre-treatment and on-treatment biopsies informs treatment outcomes to pembrolizumab in patients with rare tumors. 2024 SITC Annual Meeting, 2024. e-Pub 2024.
33. Tao D, Sujit S, Nardo M, Saad M, Leung C, Lin H, Kang L, Le H, Wu J, Hong D. Tumor volumetric analysis to correlate disease burden with outcomes to adoptive cellular therapies in patients with advanced solid tumor. 2024 SITC Annual Meeting, 2024. e-Pub 2024.
34. Coleman N, Ngoi NYL, Nguyen D, Nelson B, Dumbrava E, Fu S, Hong DS, Karp D, Naing A, Piha-Paul SA, Rodon J, Tsimberidou A, Lim B, Pohlman P, Meric-Bernstam F, Litton JK, Arun B, Yap TA. Poly(ADP-Ribose) Polymerase (PARP) inhibition in metastatic breast cancer: comparison of therapeutic outcomes between patients with BRCA1/2 mutations and other alterations. 36th EORTC-NCI-AACR, 2024. e-Pub 2024.
35. Hong, Papadopoulos K, Kim DW, Parikh A, Barve M, Powderly J, Starodub A, Strickler J, Li BT, Oberstein P, Yu W, Bitman B, Lally S, Lin W, Sohoni S, Spira A. Preliminary safety, pharmacokinetics, and antitumor activity of RMC-9805, an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors. 36th EORTC-NCI-AACR, 2024. e-Pub 2024.
36. Tsimberidou, AM, Fu S, Hong DS, Piha-Paul SA, Naing A, Rodon J, Yap TA, Karp DD, Dumbrava EE, Heymach J, Ajani JA, Cartwright C, Beck J, Andersen CR, Kahle M, Vining DJ, Ross JS, Chao CY, Berry DA, Meric-Bernstam F. Final Results of IMPACT 2, a Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer at MD Anderson Cancer Center. 2024 ESMO Congress, 2024. e-Pub 2024.
37. Hong DS, Xu R-H, Shen L, Dierselhuis MP, Orbach D, McDermott RS, Italiano A, Tahara M, Bernard-Gauthier V, Neu N, Mussi CE, De La Cuesta EA, Laetsch T, Drilon AE. Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: an updated analysis. 2024 ESMO Congress 35:S501-S502, 2024. e-Pub 2024.
38. Drilon AE, R-H X, Van Tilburg CM, Doz F, Weng Tan DS, Lin JJ, Geoerger B, Zwaan CM, Lassen UN, Italiano A, Kummar S, McDermott RS, D-I B, Neu N, Brega N, Laetsch T, Hong DS, Shen L. Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer. 2024 ESMO Congress, 2024. e-Pub 2024.
39. Gouda M, Shunyakova J, Naing A, Dumbrava E, Hong D, Yuan Y, Yang P, Myers A, Liang Y, Ping J, Karp D, Tsimberidou A, Rodon Ahnert J, Yap T, Piha-Paul S, Meric-Bernstam F, Fu S. A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors. 2024 ASCO Annual Meeting, 2024. e-Pub 2024.
40. Tao D, Nardo M, Hong Leung C, Lin H, Kang L, Le H, Dumbrava E, Hong D. The role of obesity on outcomes of adoptive cellular therapy in solid tumors. 2024 ASCO Annual Meeting 42(16), 2024. e-Pub 2024.
41. Torrado Martin C, Brink A, Gouda M, Kang L, Osburn J, Patterson C, Charles S, Poullard A, Urschel G, Dumbrava E, Karp D, Naing A, Piha-Paul S, Pohlmann P, Rodon Ahnert J, Tsimberidou A, Yap T, Hong D, Meric-Bernstam F, Fu S. Telehealth consultations and recruitment trends in clinical trials: A retrospective analysis at investigational cancer therapeutics, a dedicated phase I department at The University of Texas MD Anderson Cancer Center. 2024 ASCO Annual Meeting 42(16), 2024. e-Pub 2024.
42. Langer C, Galot R, Prenen H, Hong D, Victoria I, Salgia R, Chenard-Poirier M, Furqan M, Chan E, Nolte-Hippenmeyer J, Xia C, Li B. Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with KRAS G12C mutation: A phase 1b study. 2024 ASCO Annual Meeting, 2024. e-Pub 2024.
43. Spira A, McKean M, Daud A, Thein K, Van Tine B, Wang J, Antal J, Sutton R, Cui Y, Hong D. An open-label study to assess the safety and efficacy of naporafenib (ERAS-254) administered with trametinib in previously treated patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations (SEACRAFT-1). 2024 ASCO Annual Meeting, 2024. e-Pub 2024.
44. Patnaik A, Pelster M, Hong D, Strickler J, Garrido-Laguna I, Aguirre A, Curran D, Woo T, Spira A. A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with solid tumors with KRASG12D mutation. 2024 ASCO Annual Meeting, 2024. e-Pub 2024.
45. Hui D, Subbiah IM, Hong DS, Ellefson J, Becerra J, la Cruz VJD, Urbauer DL, Shete S, Bruera AE. Technology-enhanced palliative care for patients with advanced cancer undergoing phase I therapies: A pilot randomized clinical trial (RCT). 2024 ASCO Annual Meeting, 2024. e-Pub 2024.
46. Cabanillas M, Lin J, Brose M, McDermott R, Almubarak M, Bauman J, Casanova M, Kummar S, Se-Hoon L, Leyvraz S, D-Y O, Shen L, Neu N, Bernard-Gauthier V, Mussi C, Hong D, Drilon A, Waguespack S. Long-term efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion thyroid carcinoma (TC). 2024 ASCO Annual Meeting, 2024. e-Pub 2024.
47. Sun L, Fayette J, Sals S, Hong D, Adkins D, Dunn L, Fortunato C, Cirauqui B, William W, Saba N, Chung C, Birnbaum A, Zandberg D, Wehr A, Viana Nicacio L, Soumaoro I, A-S C, Seiwert T. Tisotumab vedotin in head and neck squamous cell carcinoma: Updated analysis from innovaTV 207 Part C. 2024 ASCO Annual Meeting, 2024. e-Pub 2024.
48. Torrado Martin C, Rai K, Moawad M, Dumbrava E, Fu S, Hong D, Karp D, Meric-Bernstam F, Naing A, Pohlmann P, Rodon Ahnert J, Tsimberidou A, Yap T, Said R, Pelosof L, Piha-Paul S. A phase 1 study of the BET inhibitor ZEN003694 in combination with the MEK1/2 inhibitor binimetinib in solid tumors with RAS pathway alterations and triple-negative breast cancer (NCI number 10449). 2024 ASCO Annual Meeting, 2024. e-Pub 2024.
49. Gounder M, Rosen E, Parikh A, Conley A, Hong D, Sheth S, Mai N, Sgroe E, Mitchell R, Picard R, Brail L, Cote G. Preliminary results from FLAGSHP-1: A phase 1 study of ERAS-601 as a monotherapy or in combination with cetuximab in patients (pts) previously treated for advanced chordoma. 2024 ASCO Annual Meeting, 2024. e-Pub 2024.
50. Gouda M, Lin H, Kang L, Le H, Dumbrava E, Fu S, Karp D, Tsimberidou A, Naing A, Piha-Paul S, Pohlmann P, Rodon Ahnert J, Yap T, Meric-Bernstam F, Hong D. Response to RAF/MEK/ERK inhibitors in patients with RAS altered and wild-type tumors. 2024 ASCO Annual Meeting, 2024. e-Pub 2024.
51. George G, Piha-Paul S, Dumbrava E, Subbiah V, Fu S, Tsimberidou A, Pant S, Appleton G, Noor L, Yap T, Rodon Ahnert J, Meric-Bernstam F, Cleeland C, Mendoza T, Hong D. Patient-reported symptom interference with activity- and mood-related functioning prior to start of an early-phase oncology combination trial including immune checkpoint blockade. 2024 ASCO Annual Meeting, 2024. e-Pub 2024.
52. Mirallas O, Lin R, Alvarez-Ballesteros P, Campbell E, Le H, Dumbrava E, Yap T, Hong D, Meric-Bernstam F, Thall P, Rodon Ahnert J, Martin Cullell B. Total toxicity burden as a practical tool to quantify the overall severity of multiple adverse events in clinical trials. 2024 ASCO Annual Meeting, 2024. e-Pub 2024.
53. Tsimberidou A, Fu S, Hong D, Piha-Paul S, Naing A, Rodon Ahnert J, Yap T, Karp D, Dumbrava E, Heymach J, Ajani J, Cartwright C, Beck J, Andersen C, Kahle M, Vining D, Ross J, Chao C, Berry D, Meric-Bernstam F. Results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center. 2024 ASCO Annual Meeting, 2024. e-Pub 2024.
54. Yap T, Dumbrava E, Rodon Ahnert J, Tsimberidou A, Hong D, Piha-Paul S, Karp D, Fu S, Naing A, Pohlmann P, Rhudy J, Berenji-Jalaei S, Cole A, Valladolid C, Dufner D, Bockorny B, Bullock A, Fein D, Buchbinder E, Choudhury A, Haddox C, Lee E, Wulf G, Ivy P, Said R, Shapiro G, Meric-Bernstam F. NCI10217: Phase Ib biomarker-driven tumor-agnostic combination (Combo) trial of copanlisib (Copa) and olaparib (Ola) in molecularly-selected patients (pts) with advanced cancers with PIK3CA hotspot, PTEN and DNA damage response (DDR) mutations. AACR Annual Meeting 2024, 2024. e-Pub 2024.
55. Chowdhury S, Ahmed J, Haridas V, Hong DS, Koetz S, Shen J. Activating PIK3CA mutations and hedgehog signaling may confer resistance to KRAS inhibition in colorectal cancer. AACR Annual Meeting 2024, 2024. e-Pub 2024.
56. Coker O, Sorokin A, Akhave N, Pan K, Gao F, Liu Z, Kanikarla P, Lee H, Villarreal O, Alshenaifi J, Maddalena G, Mohamed A, Prescod D, Menter D, Chowdury S, Corcoran R, Rai K, Hong D, Kopetz S. YAP-TAZ-TEAD transcriptional program is a prominent driver of acquired resistance to KRASG12C-based therapies in patients with metastatic colorectal cancer. AACR Annual Meeting 2024, 2024. e-Pub 2024.
57. Negrao MV, Molkentine D, Paula AG, Hover L, Nilsson M, Vokes N, Engstrom L, Calinisan A, Waters L, Briere DM, Hallin J, Blumenschein GR, Skoulidis F, Kopetz SE, Hong DS, Gibbons DL, Olson P, Christensen J, Heymach JV. Impact of KEAP1/STK11 co-mutations and NRF2 signaling on resistance to adagrasib in advanced NSCLC. AACR Annual Meeting 2024, 2024. e-Pub 2024.
58. Uzunparmak B, Su F, Johnson AM, Nomie K, Fowler N, Kontselidze L, Bagaev A, Butusova A, Dumbrava EE, Rodon-Ahnert J, Fu S, Hong DS, Yap TA, Naing A, Piha-Paul SA, Karp DD, Pohlmann PR, Tsimberidou AM, Patel KP, Meric-Bernstam F. Comprehensive genomic and transcriptomic analysis to guide therapy for patients with metastatic solid tumors. AACR Annual Meeting 2024, 2024. e-Pub 2024.
59. Garcia A, Saro Suarez JM, Sauer A, Cristiani S, Brophy FE, Streets S, Norry E, Nelson AA, Kilari D, Garmezy B, Charlson JA, Zugazagoitia J, Calvo E, Moreno E, Moreno V, Holmes CJ, Hong DS, Cervantes A. New phase 1 SURPASS trial cohort: Early-line ADP-A2M4CD8 T-cell receptor T-cell therapy plus pembrolizumab in urothelial carcinoma. 2024 ASCO Genitourinary Cancers Symposium, 2024. e-Pub 2024.
60. Shen L, Andre T, Cheol Chung H, Deeken J, Garralda E, Italiano A, Leyvraz S, Liu T, D-I B, Grugel R, Mussi C, R-H X, Hong D, Drilon A, Berlin J. Updated efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion gastrointestinal (GI) cancer. 2024 ASCO Gastrointestinal Cancers Symposium, 2024. e-Pub 2024.
61. Bhamidipati D, Haro-Silerio J, Dumbrava E, Fu S, Hong D, Karp D, Naing A, Pant S, Piha-Paul S, Rodon Ahnert J, Tsimberidou A, Johnson A, Lee M, Raghav K, Morris V, Overman M, Kopetz S, Meric-Bernstam F, Yap T, Dasari A. Clinical characterization and therapeutic outcomes of patients (pts) with colorectal cancer (CRC) harboring somatic BRCA1/2 mutations. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
62. Fountzilas C, Cohen S, Duvivier H, Hong D, Pedersen K, Pisick E, Sommerhalder D, Cacovean A, Follit C, Kowalczyk N, Munneke B, Tong T, Morris S, Butler T, Spira A. COVALENT-102: A Phase 1/1b dose finding study of BMF-219, an oral covalent menin inhibitor, in adults with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC), pancreatic cancer (PDAC) and colorectal cancer (CRC) with activating KRAS mutations. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
63. Yoo S, Lee S, Shin S, LoRusso P, Hur J, Jung H, Hong DS. Update on the phase 1 trial of Nelmastobart in patients with advanced solid tumors. AACR-NCI-EORTC International Conference on Moledular Targets and Cancer Therapeutics, 2023. e-Pub 2023.
64. George GC, Piha-Paul SA, Fu S, Dumbrava E, Subbiah V, Tsimberidou A, Blumenschein G, Pant S, Appleton G, Noor L, Rodon Ahnert J, Yap T, Meric-Bernstam F, Cleeland C, Mendoza T, Hong DS. Patient-reported baseline symptomatic adverse events in early-phase trials of combination treatments with immune checkpoint blockade, and their association with concurrent global health status, health utilities and clinical factors. AACR-NCI-EORTC International Conference on Moledular Targets and Cancer Therapeutics, 2023. e-Pub 2023.
65. Spira AI, Starodub AN, Arbour KC, Sommerhalder D, Wolpin BM, Barve M, Garrido-Laguna I, Punekar S, Pelster M, Kar S, Wong J, Lin T, Raman R, Tao L, Salman Z, Wang X, Gustafson WC, Hong DS. Preliminary safety and pharmacokinetic profiles of RMC-6236, a first-in-class, RAS-selective, tri-complex RASMULTI(ON) inhibitor in patients with KRAS mutant solid tumors on the Phase 1 trial RMC-6236-001. AACR-NCI-EORTC International Conference on Moledular Targets and Cancer Therapeutics, 2023. e-Pub 2023.
66. Hong DS, R-H X, McDermott RS, Shen L, Direselhuis MP, Doz F, Tahara M, Bernard-Gauthier V, Norenberg R, Brega N, Laetsch TW, Drilon A. Efficacy and safety of larotrectinib (laro) as first-line treatment for patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer. ESMO Congress 2023, 2023. e-Pub 2023.
67. Yap TA, Piha-Paul SA, Karp D, Dumbrava EE, Hong DS, Fu S, Subbiah V, Tsimberidou AM, Rodon J, Rhudy J, Valladolid C, Yuan Y, Jana B, Spiliopoulou P, Randall L, Poklepovic A, Sehgal K, Shapiro GI, Said R, Meric-Bernstam F. NCI10221: Phase II Multicenter Biomarker Driven Combination Trial of Copanlisib and Nivolumab in Patients with Molecularly-selected Advanced Solid Tumors (BaCoN). ESMO Congress 2023, 2023. e-Pub 2023.
68. Moreno Garcia V, Calvo E, Asch A, Butler M, Zugazagoitia J, Charlson J, Cervantes A, Van Tine B, Aggen D, Clarke J, Johnson M, Wileman M, Norry A, Hong DS. Clinical and translational data from the Phase 1 SURPASS trial of ADP-A2M4CD8 T-cell receptor (TCR) T-cell therapy alone or combined with nivolumab in solid tumor. ESMO Congress 2023, 2023. e-Pub 2023.
69. Arbour KC, Punekar S, Garrido-Laguna I, Hong DS, Wolpin B, Pelster MS, Barve M, Starodub A, Sommerhalder D, Chang S, Zhang Y, Salman Z, Wang X, Gustafson C, Spira AI. Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). ESMO Congress 2023 34(2):S458, 2023. e-Pub 2023.
70. Coleman N, Zihan W, Hong D, Mitchell E, Zwiebel J, Sharon E, Gray R, Wang V, McShane L, Rubinstein L, Patton D, Williams PM, Tricoli J, Conley B, Arteaga C, Harris L, O'Dwyer P, Chen A, Flaherty K, Hamilton S. Phase II study of crizotinib in patients with MET amplification and MET exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2. 2023 ASCO Annual meeting, 2023. e-Pub 2023.
71. Son J, Zhang Y, Nardo M, Mirallas O, Hillman R, Lin H, Campbell E, Holla V, Johnson A, Clark N, Alvarez-Ballesteros P, Yuan Y, Cobb L, Gershenson D, Jazaeri A, Soliman P, Weston S, Meric-Bernstam, Hong D. Clinical and genomic landscape of RAS pathway mutations in gynecologic cancers. 2023 ASCO Annual meeting, 2023. e-Pub 2023.
72. Hong D, Drilon A, Tan D, Lin J, Kummar S, McDermott R, Berlin J, italiano A, Lassen U, Leyvraz S, Tahara M, Norenberg R, D-I B, Brega N, Shen L. Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer. 2023 ASCO Annual meeting, 2023. e-Pub 2023.
73. Nardo M, Reilley M, Biter A, Lim JA, Bean S, Nguyen L, Bhosale P, Ager C, Couillault C, Piha-Paul S, Fu S, Tsimberidou A, Yap T, Naing A, Rodon Ahnert J, Subbiah V, Karp D, Curran M, Hong D. Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial. 2023 ASCO Annual meeting, 2023. e-Pub 2023.
74. Johnson B, Willis J, Williams C, Wang X, Smith G, You YN, Dumbrava E, Fu S, Karp D, Naing A, Piha-Paul S, Rodon Ahnert J, Tsimberidou A, Yap T, Overman M, Pant S, Hong D, Kopetz S, Meric-Bernstam F, Subbiah V. Molecular landscape and survival outcomes on early phase clinical trials in sporadic young onset colorectal cancer. 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
75. Cabanillas M, Lin J, Brose M, McDermott R, Almubarak M, Bauman J, Casanova M, Kummar S, S-H L, Leyvraz S, D-Y O, Shen L, Norenberg R, Bernard-Gauthier V, Mussi C, Hong D, Drilon A, Waguespack S. Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC). 2023 ASCO Annual meeting, 2023. e-Pub 2023.
76. Lee S, Shin S, LoRusso P, Rolfo C, Jung H, Yoo S, Hong D. A phase I study of nelmastobart (hSTC810), an anti-BTN1A1 antibody, in patients with advanced solid tumors. 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
77. Hong D, Kuboki Y, Strickler J, Fakih M, Houssiau H, Price T, Elez E, Siena S, Chan E, Nolte-Hippenmeyer J, Cardona P, Tran Q, Masuishi T. Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy. 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
78. Nardo M, Gouda M, Ahmed J, Noia Barreto CM, Nelson B, Araujo D, Blumenschein G, Tsimberidou A, Piha-Paul S, Dumbrava E, Hong D. Predictors of survival outcomes in patients (pts) with advanced solid tumors treated with cellular therapies in early clinical trials. 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
79. Gouda M, Ahmed J, Nelson B, Nardo M, Roszik J, Cabanillas M, Hu M, Busaidy N, Sherman S, Dadu R, Naing A, Karp D, Rodon Ahnert J, Hong D, Elamin Y, Blumenschein G, Heymach J, Meric-Bernstam F, Subbiah V. Intrapatient comparative efficacy of selective RET inhibitors using growth modulation index in patients with RET aberrant cancers. 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
80. Hassan R, Butler M, Oh D, O'Cearbhaill R, MacMullen L, Jeter E, Guha U, Muzithras V, Zikaras K, Johnson M, Tanyi J, Ghafoor A, Tighe R, Smalley M, Quintas-Cardama A, Hong D. Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors. 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
81. George GC, Piha-Paul SA, Fu S, Rodon Ahnert J, Yap TA, Subbiah V, Dumbrava E, Tsimberidou A, Pant S, Appleton G, Noor L, Meric-Bernstam F, Cleeland CS, Mendoza TR, Hong DS. Baseline symptom, health status, and health utilities in patients in early-phase clinical trials combining immune checkpoint blockade with other anticancer therapies. 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
82. Davidson T, Le H, Campbell E, Ozenne C, Dumbrava E, Fu S, Hong D, Karp D, Naing A, Piha-Paul S, Rodon Ahnert J, Tsimberidou A, Yap T, Meric-Bernstam F, Subbiah V. Clinical trial deserts: US urban vs rural patient enrollment among patients with advanced cancer in phase 1 clinical trials at a major cancer center. 2023 ASCO Annual meeting, 2023. e-Pub 2023.
83. Hong DS, Kuboki Y, Yaeger R, Strickler JH, Masuishi T, Langer C, Shergill A, Kim E, Hindoyan A, Tran Q, Mukundan L, Chan E, Anderson A, Fakih MG. Biomarkers of acquired resistance to sotorasib (soto) plus panitumumab (pani) in chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC). AACR Annual Meeting 2023, 2023. e-Pub 2023.
84. Uzunparmak B, Haymaker C, Raso G, Zhu C, Masciari S, Wang L, Kirby B, Lin H, Gorur A, A-M C, Kennon A, Ding Q, Palmieri A, Urschel GE, Yuan Y, Feng G, Rizvi Y, Hussain A, Subbiah V, Yap TA, Rodon-Ahnert J, Piha-Paul SA, Hong DS, Meric-Bernstam F, Dumbrava EE. HER2-low expression in patients with advanced or metastatic solid tumors. AACR Annual Meeting 2023, 2023. e-Pub 2023.
85. McKean M, Rosen E, Barve M, Meniawy T, Wang J, Hong DS, Yang J, Li Z, Picard R, Brail L, Vecchio D, John T, Cohen E, Obara G, Parikh A. Preliminary dose escalation results of ERAS-601 in combination with cetuximab in FLAGSHP-1: a phase I study of ERAS-601, a potent and selective SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors. AACR Annual Meeting 2023, 2023. e-Pub 2023.
86. Nelson BE, Janku F, Fu S, Dumbrava EI, Hong DS, Karp D, Naing A, Rodon J, Tsimberidou A, Amaria RN, Conley A, Damodaran S, Raghav KPS, Kreider BL, Tung D, Varterasian M, Khazaie K, Piha-Paul S. Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. AACR Annual Meeting 2023, 2023. e-Pub 2023.
87. Rudzinski ER, Ladanyi M, Ritterhouse LL, Sahm F, Norenberg R, Zheng H, Chen C, Bergard-Gauthier V, Brega N, Van Tilburg CM, Lin JJ, Brose MS, Lasseen UN, McDermott R, Laetsch TW, Hong DS, Drilon A, Roy-Chowdhuri S. Concordance between tissue and circulating tumor DNA (ctDNA) testing for neurotrophic tyrosine receptor kinase (NTRK) gene fusions in larotrectinib (laro) clinical trials. AACR Annual Meeting 2023, 2023. e-Pub 2023.
88. Yoo SS, Lee S, Shin S, Jung H, Hong DS. Pharmacokinetic analyses and immunophenotyping of patients treated with Nelmastobart (hSTC810), a novel immune checkpoint inhibitor. AACR Annual Meeting 2023, 2023. e-Pub 2023.
89. Murciano-Goroff YR, Skoulidis F, Velcheti V, Falchook GS, Dy G, Ramalingam S, Edelman MJ, Wolf J, Italiano A, Reis-Filho JS, Razavi P, Drilon A, Misale S, Yaeger R, Li M, Hindoyan A, Ang A, Anderson AA, Hong D, Lito P, Govindan R, Li BT. Dynamic changes in circulating tumor DNA (ctDNA) in patients treated with sotorasib for KRAS G12C mutant non-small cell lung cancer. AACR Annual Meeting 2023, 2023. e-Pub 2023.
90. Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Ahou T, Akhave N, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott S, Bironzo P, Scheffler M, Christopoulos P, Kim SY, Goldberg S, Ni Y, Resuli B, Landi L, S-C T, Nishino M, Owen D, Blakely C, Mountzios G, Shu CA, Bestvina C, Garassino M, Marrone K, Gray J, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil P, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Molecular determinants of KRAS p.G12C inhibitor efficacy in advanced NSCLC. AACR Annual Meeting 2023, 2023. e-Pub 2023.
91. Ngoi NY, Lin HY, Dumbrava E, Fu S, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Campbell E, Urrutia S, Hong DS, Meric-Bernstam F, Yuan Y, Yap TA. Dynamic changes in monocyte and reticulocyte counts predict mechanism-based anemia development and recovery during ATR inhibitor treatment in phase I/II trials. AACR Annual Meeting 2023, 2023. e-Pub 2023.
92. Aggen D, Hong D, Clarke J, Asch A, Calvo E, Zugazagoitia J, Butler M, Moreno V, Cervantes A, Van Tine B, Lawrence D, Johnson M, Brophy F, Broad R, Isabelle M, Gunn A, J-M N, Saro J, Norry E, Charlson J. Preliminary clinical outcomes of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced urothelial cancer. 2023 ASCO Genitourinary Cancers Symposium, 2023. e-Pub 2023.
93. Blum Murphy MA, Ajani JA, van Tine BA, Melson Clarke J, Butler MO, Lawrence DP, Johnson ML, Cervantes A, Moreno V, Hong DS, Brophy FE, J-M N, Lin Q, Saro J, Norry E. Safety and efficacy from the phase 1 SURPASS trial of ADP-A2M4CD8, a next-generation T-cell receptor T-cell therapy, in patients with advanced esophageal, esophagogastric junction, or gastric cancer. 2023 ASCO Gastrointestinal Cancers Symposium, 2023. e-Pub 2023.
94. Hong DS, Luke JJ, Johnson M, Gadgeel SM, Spira AI, Yang JCH, Johnson JM, Losch-Beridon TR, Snell D, Warmuth S, Cleaver M, vom Baur E, Urech DM, Lichtlen P. First-in-human trial to evaluate safety, PK/PD and initial clinical activity of NM21-1480, an affinity-balanced PD-L1x4-1BBxHSA trispecific antibody: Results of Phase 1 dose escalation. 2022 SITC Annual Meeting, 2022. e-Pub 2022.
95. Lee S, Shin S, Howie L, Jung H, Yoo SS, Hong DS. A first-in-human trial of hSTC810 (anti-BTN1A1 Ab), a novel immune checkpoint with a mutually exclusive expression with PD-1/PD-L1, in patients with relapsed/refractory solid tumors. 2022 SITC Annual Meeting, 2022. e-Pub 2022.
96. Patel SP, Patel MR, Gutierrez M, Anderson M, Szabo P, Valamehr B, Chu YW, Beagle B, Chou J, Hong DS. Results of a Phase I trial of FT500, a first-in-class, off-the-shelf, iPSC‑derived NK cell therapy combined with PD-1/PD-L1 checkpoint blockade therapy and IL-2 in patients with advanced solid tumors. 2022 SITC Annual Meeting, 2022. e-Pub 2022.
97. Gutierrez M, Johnson ML, Sommerhalder D, Messersmith WA, Park H, Furqan M, Chesney JA, Bjordahl R, Zeng L, Szabo P, Y-W C, Beagle B, Valamehr B, Chou J, Hong DS. Interim Phase I clinical data of FT538, an off-the-shelf, multiplexed-engineered, iPSC-derived NK cell therapy, combined with monoclonal antibodies in patients with advanced solid tumors. 2022 SITC Annual Meeting, 2022. e-Pub 2022.
98. Gutierrez M, Patel MR, Liu F, Szabo P, Valamehr B, Y-W C, Beagle B, Chou J, Hong DS. Phase I results of FT516, an off-the-shelf, iPSC-derived NK cell therapy expressing a high-affinity, non-cleavable CD16 (hnCD16) combined with avelumab in patients with advanced solid tumors. 2022 SITC Annual Meeting, 2022. e-Pub 2022.
99. Patel SP, Patel MR, Gutierrez M, Anderson M, Szabo P, Valamehr B, Chu YW, Beagle B, Chou J, Hong DS. 755 Results of a phase I trial of FT500, a first-in-class, off-the-shelf, iPSC–derived NK cell therapy combined with PD-1/PD-L1 checkpoint blockade therapy and IL-2 in patients with advanced solid tumors. 2022 SITC Annual Meeting, 2022. e-Pub 2022.
100. Son JY, Cheng-En Hsieh R, Lin H, Krause KJ, Yuan Y, Biter AB, Welsh J, Curran MA, Hong DS. Inhibition of the CD47-SIRPɑ axis for cancer therapy: a meta-analysis of emerging clinical data. 2022 SITC Annual Meeting, 2022. e-Pub 2022.
101. Italiano A, Drilon AE, Shen L, Hong DS, van Tilburg C, Tan DSW, Lin JJ, Kumar S, Doz F, Geoerger B, Brose MS, Briggs A, Lassen UN, Vassal G, Keating KN, Norenberg R, Dima L, Brega N, Laetsch T, Garcia-Foncillas J. Intra-patient (Pt) comparison from larotrectinib (Laro) clinical trials in tropomyosin receptor kinase (TRK) fusion cancer: An expanded dataset. 2022 ESMO Congress, 2022. e-Pub 2022.
102. Kuboki Y, Yaeger R, Fakih MG, Strickler JH, Masuishi T, Kim EJ, Bestvina CM, Langer CJ, Krauss JC, Puri S, Cardona P, Chan E, Tran Q, Hong DS. Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort. 2022 ESMO Congress, 2022. e-Pub 2022.
103. Hong DS, Tahara M, Baik C, Bauman JR, Gilbert J, Brose MS, Grilley-Olson JE, Patil T, McDermott R, Raez LE, Johnson JM, Shen L, Norenberg R, Dima L, Mussi C, Le X, Drilon AE. Updated efficacy and safety of larotrectinib in patients with TRK fusion salivary gland tumours. 2022 ESMO Congress, 2022. e-Pub 2022.
104. Hong DS, Tahara M, Baik C, Bauman JR, Gilbert J, Brose MS, Grilley-Olson JE, Patil T, McDermott R, Raez LE, Johnson JM, Shen L, Norenberg R, Dima L, Mussi C, Le X, Drilon AE. Updated efficacy and safety of larotrectinib in patients with TRK fusion salivary gland tumours. 2022 ESMO Congress, 2022. e-Pub 2022.
105. Matsuishi T, Kuboki Y, Fakih MG, Strickler JH, Furqan M, Kim EJ, Cardona P, Tran Q, Chan E, Hong DS. A phase Ib study of sotorasib, a selective KRAS G12C inhibitor, in combination with panitumumab and FOLFIRI in treatment naïve and previously treated metastatic colorectal cancer (CodeBreaK 101). 2022 ESMO Congress, 2022. e-Pub 2022.
106. McDermott RS, Tilburg V, Lin JJ, Kummar S, Tan DSW, Albert CM, Berlin JD, Lassen UN, Doz F, Geoerger B, Mascarenhas L, Federman N, Norenber R, Dima L, Mussi C, de la Cuesta EA, Laetsch T, Hong DS, Drilon AE. Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up. 2022 ESMO Congress, 2022. e-Pub 2022.
107. Tolcher A, Hong DS, Vandross A, Amaravadi R, Psoinos C, Brennan D, Sherman ML, Ruiz-Soto R, Viswanathan L, Sprott K, Reu FJ, Weeks C. Initial monotherapy results of a phase 1 first‑in‑human study of ULK1/2 inhibitor DCC‑3116 alone and in combination with MAPK pathway inhibition. 2022 ESMO Congress, 2022. e-Pub 2022.
108. Tolcher A, Hong DS, Vandross A, Amaravadi R, Psoinos C, Brennan D, Sherman ML, Ruiz-Soto R, Viswanathan L, Sprott K, Reu FJ, Weeks C. Initial monotherapy results of a phase 1 first in human study of ULK1/2 inhibitor DCC‑3116 alone and in combination with MAPK pathway inhibition. 2022 ESMO Congress, 2022. e-Pub 2022.
109. Yap TA, Ngoi N, Dumbrava EE, Karp DD, Rodon Ahnert J, Fu S, Hong DS, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Dufner D, Rhudy J, Gore S, Ivy SP, Yuan Y, Westin SN, Mills GB, Meric-Bernstam F. NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly(ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers. 34th EORTC-NCI-AACR Symposium, 2022. e-Pub 2022.
110. McKean, M, Barve, M, Hong, DS, Parikh, AR, Rosen, E, Yang, J, Picard, R, Yi, J, Brail, L, Vecchio, D, Meniawy, T, John, T, Wang, JS. Preliminary results from FLAGSHP-1: A Phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors. 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 174:S34, 2022. e-Pub 2022.
111. Yap, TA, Ngoi, NY, Dumbrava, EE, Karp, DD, Rodon Ahnert, J, Fu, S, Hong, DS, Naing, A, Pant, S, Piha-Paul, SA, Subbiah, V, Tsimberidou, AM, Dufner, D, Rhudy, J, Gore, SD, Ivy, SP, Yuan, Y, Westin, SN, Mills, GB, Meric-Bernstam, F. NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers. 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 174:S7, 2022. e-Pub 2022.
112. Ngoi, NY, Pilie, PG, Piha-Paul, SA, Dumbrava, EE, Fu, S, Hong, DS, Karp, DD, Naing, A, Pant, S, Rodon Ahnert, J, Subbiah, V, Tsimberidou, AM, Salguero, C, Brown, CV, Hoadley, WE, Johnson, A, Yuan, Y, Westin, SN, Meric-Bernstam, F, Yap, TA. DNA Damage Response (DDR) Basket of Baskets (D-BOB) Trial. 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 174:S10, 2022. e-Pub 2022.
113. Hong, DS, Shergill, A, Bazhenova, LA, Cho, BC, Heist, RS, Moreno, V, Falchook, GS, Nagasaka, M, Cassier, PA, Besse, B, Kim, DW, Yoon, S, Le, X, Zhao, T, Atwal, S, Park, E, Lee, J. Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET. 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 174:S72, 2022. e-Pub 2022.
114. Ngoi NY, Lin H, Ileana Dumbrava EE, Fu S, Karp D, Naing A, Pant S, Rodon J, Piha-Paul SA, Subbiah V, Tsimberidou AM, Campbell E, Urrutia S, Hong DS, Meric-Bernstam F, Yuan Y, Yap TA. Correlation of clinical, genomic and hematological parameters with ATR inhibitor (ATRi) outcomes in phase I/II clinical trials. ESMO Congress 2022, 2022. e-Pub 2022.
115. Sommerhalder D, Thevathasan J, Ianopulos X, Volinn W, Hong D. KRYSTAL-16: A phase I/Ib trial of adagrasib (MRTX849) in combination with palbociclib in patients with advanced solid tumors with KRASG12C mutation. AACR Annual Meeting 2022, 2022. e-Pub 2022.
116. Nardo M, Son JY, George GG, Hong DS. Safety and efficacy of CAR T and TCR therapies in solid tumors: A systematic review and meta-analysis, including a comparison with five phase II trials in hematologic malignancies used for the first FDA approvals of these agents. AACR Annual Meeting 2022, 2022. e-Pub 2022.
117. Ladanyi M, Roy-Chowdhuri S, Ritterhouse L, Sahm F, Norenberg R, Shen K, Chen C, Fellous M, Brega N, Van Tilburg CM, Lin JJ, Brose MS, Lassen UN, McDermott R, Laetsch TW, Hong DS, Drilon A, Rudzinski ER. Variability in NTRK gene fusions does not appear to impact response to larotrectinib. AACR Annual Meeting 2022, 2022. e-Pub 2022.
118. Piha-Paul SA, Xu B, Singh Raghav KP, Meric-Bernstam F, Janku F, Dumbrava EE, Fu S, Karp DD, Rodon Ahnert J, Conley AP, Mott F, Ajani JA, Hong DS, Fan Y, Peng P, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. First-in-human, phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors. 2022 ASCO Annual Meeting, 2022. e-Pub 2022.
119. Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul SA, More JA, Yilmaz B, Karp DD, Dumbrava EE, Tsimberidou AM, Hong DS, Rodon Ahnert J, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase Ib study of selinexor and eribulin combination in advanced solid tumors and triple-negative breast cancer. 2022 ASCO Annual Meeting, 2022. e-Pub 2022.
120. Alhalabi O, Tannir NM, Momin HA, Yilmaz B, Stephen B, Ejezie CL, Moyers JT, Gurses SA, How J, Fu S, Rodon Ahnert J, Hong DS, Piha-Paul SA, Subbiah V, Dumbrava EE, Karp DD, Janku F, Meric-Bernstam F, Naing A. Phase Ib trial of selinexor (SEL) in combination with nivolumab (NIVO) alone or nivolumab plus ipilimumab (NIVO+IPI) in patients (pts) with advanced malignancies: The renal cell carcinoma (RCC) experience. 2022 ASCO Annual Meeting, 2022. e-Pub 2022.
121. Benedito XL, Carneiro BA, Hong DS, Birnbaum AE, Taylor MH, Patel SA, William WN, Wang B, Beca F, Jain S, Soumaoro I, Dunn L. innovaTV 207: New combination dosing cohorts in the open label phase 2 study of tisotumab vedotin in solid tumors. 2022 ASCO Annual Meeting, 2022. e-Pub 2022.
122. Kummar S, Shen L, Tilburg V, Tan DSW, Doz F, McDermott RS, Zwaan CM, Keating KN, Chirila C, Norenberg R, Fellous MM, Brega N, R-H X, Wilis Laetsch T, Drilon AE, Hong DS. Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials. 2022 ASCO Annual Meeting, 2022. e-Pub 2022.
123. Ngoi N, Lin HY, Dumbrava EE, Fu S, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon Ahnert J, Subbiah V, Tsimberidou AM, Campbell E, Hong DS, Meric-Bernstam F, Yuan Y, Yap TA. Baseline predictors of hematological toxicity in patients with advanced cancer treated with ATR inhibitors in phase I/II clinical trials. 2022 ASCO Annual Meeting, 2022. e-Pub 2022.
124. Coleman N, DiPeri TP, Nguyen D, Naing A, Piha-Paul SA, Tsimberidou AM, Zheng X, Johnson A, Wang W, Shaw KR, Dumbrava EE, Fu S, Rodon J, Rodon Ahnert J, Hong DS, Subbiah V, Yap TA, Luthra R, Patel KP, Meric-Bernstam F. Repeat large panel genomic sequencing identifies actionable alterations and characterizes the genomic landscape in patients with metastatic solid tumors. 2022 ASCO Annual Meeting, 2022. e-Pub 2022.
125. Nelson BE, Andersen C, Yuan Y, Hong DS, Naing A, Karp DD, Yap TA, Rodon Ahnert J, Campbell E, Tsimberidou AM, Dumbrava EE, Fu S, Piha-Paul SA, Pant S, Blumenschein GR, Altan M, Tawbi HA, Tannir NM, Meric-Bernstam F, Subbiah V. Effect of immunotherapy and time-of-day infusion chronomodulation on survival in advanced cancers. 2022 ASCO Annual Meeting, 2022. e-Pub 2022.
126. Tolcher AW, Hong DS, Vandross AL, Psoinos CM, Brennan DM, Sherman ML, Ruiz-Soto R, Reu FJ, Weekes CD. A phase 1/2 study of DCC‑3116 as a single agent and in combination with trametinib in patients with advanced or metastatic solid tumors with RAS or RAF mutations. 2022 ASCO Annual Meeting, 2022. e-Pub 2022.
127. Alhalabi O, Tannir NM, Momin HA, Yilmaz B, Stephen B, Ejezie CL, Moyers JT, Gurses SA, How J, Fu S, Rodon Ahnert J, Hong DS, Piha-Paul SA, Subbiah V, Dumbrava EE, Karp DD, Janku F, Meric-Bernstam F, Naing A. Phase Ib trial of selinexor (SEL) in combination with nivolumab (NIVO) alone or nivolumab plus ipilimumab (NIVO+IPI) in patients (pts) with advanced malignancies: The renal cell carcinoma (RCC) experience. 2022 ASCO Annual Meeting, 2022. e-Pub 2022.
128. Drilon AE, Hong DS, van Tilburg CM, Doz F, Tan DSW, Kummar S, Lin JJ, McDermott RS, Zwaan CM, Norenberg R, Fellous MM, Brega N, R-H X, Willis Laetsch T, Shen L. Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer. 2022 ASCO Annual Meeting, 2022. e-Pub 2022.
129. Li BT, Velcheti V, Price TJ, Hong DS, Fakih M, D-W K, Falchook GS, J-P D, Dy GK, Ramalingam SS, Strickler JH, Kurata T, Wolf J, Sacher AG, Addeo A, Prenen H, Hindoyan A, Anderson A, Ang A, Skoulidis F. Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non–small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100. 2022 ASCO Annual Meeting, 2022. e-Pub 2022.
130. Lee S, Shin S, Howie L, Jung H, Yoo SS, Hong DS. 740 A first-in-human trial of hSTC810 (anti-BTN1A1 Ab), a novel immune checkpoint with a mutually exclusive expression with PD-1/PD-L1, in patients with relapsed/refractory solid tumors. 2022 ASCO Annual Meeting, 2022. e-Pub 2022.
131. Tolcher AW, Hong DS, Vandross AL, Psoinos CM, Brennan DM, Sherman ML, Ruiz-Soto R, Reu FJ, Weekes CD. A phase 1/2 study of DCC‑3116 as a single agent and in combination with trametinib in patients with advanced or metastatic solid tumors with RAS or RAF mutations. 2022 ASCO Annual Meeting, 2022. e-Pub 2022.
132. Sommerhalder D, Thevathasan J, Ianopulos X, Volinn W, Hong D. KRYSTAL-16: A phase I/Ib trial of adagrasib (MRTX849) in combination with palbociclib in patients with advanced solid tumors with KRASG12C mutation. AACR Annual Meeting 2022, 2022. e-Pub 2022.
133. Wang T, J-M N, Rafail S, Carroll M, Wang R, McAlpine C, Biswas S, Brophy F, ElefantE, Bayer P, McGuigan S, Williams D, Blumenschein Jr G, Butler M, Clarke JM, Gainor JF, Govindan R, Moreno V, Tu J, Hong DS. Identifying MAGE-A4-positive tumors for SPEAR T-cell therapies in HLA-A*02-eligible patients. AACR Annual Meeting 2022, 2022. e-Pub 2022.
134. Dy GK, Govindan R, Velcheti V, Falchook GS, Italiano A, Wolf J, Sacher AG, Takahashi T, Ramalingam SS, Dooms C, D-W K, Addeo A, Desai J, Schuler M, Tomasini P, Tran Q, Jones S, Ang A, Anderson A, Hindoyan AA, Hong DS, Li BT. Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100. AACR Annual Meeting 2022, 2022. e-Pub 2022.
135. Nelson BE, Roszik J, Janku F, Hong D, Kato S, Naing A, Piha-Paul SA, Fu S, Tsimberidou A, Cabanillas M, Busaidy N, Javle M, Byers L, Heymach J, Meric-Bernstam F. B-Raf V600E harboring non-melanoma cancers treated with Vemurafenib monotherapy and in combination with Everolimus/Sorafenib/Crizotinib/Paclitaxel+ Carboplatin: A pooled analysis of five phase 1/2 studies. AACR Annual Meeting 2022, 2022. e-Pub 2022.
136. Hong DS, Yaeger R, Kuboki Y, Masuishi T, Barve MA, Falchook GS, Govindan R, Sohal D, Kasi PM, Burns TF, Langer CJ, Puri S, Chan E, Jafarinasabian P, Ngarmchamnanrith G, Rehn M, Tran Q, Gandara DR, Strickler JH, Fakih M. A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101). ASCO Gastrointestinal Cancers Symposium, 2022. e-Pub 2022.
137. Surana R, Rogers JE, Nogueras-Gonzalez GM, Hong DS, Yap TA, Rodon Ahnert J, Naing A, Wolff RA, Smalgo BG, Meric-Bernstam F, Subbiah V, Pant S. Prognostic factors associated with survival in patients with pancreatic cancer treated on early phase immune-checkpoint inhibitor clinical trials. ASCO Gastrointestinal Cancers Symposium, 2022. e-Pub 2022.
138. Hong DS, Jalal SI, Elimova E, Ajani JA, Blum Murphy MA, Cervantes A, Evans TRJ, Park H, Lin Q, Noto P, Shnaidman M, Campbell D, Rosenberg M, Brophy FE, Danesi H, Ilson DH. SURPASS-2 trial design: A phase 2, open-label study of ADP-A2M4CD8 SPEAR T cells in advanced esophageal or esophagogastric junction cancers. ASCO Gastrointestinal Cancers Symposium, 2022. e-Pub 2022.
139. Welsh J, Ke D, Puebla Osorio N, Barsoumian H, Jackson B, Bai J, Rosenberg M, McAlpine C, Broad R, Liddle A, Navenot JM, Rafail S, Wang R, Sauer A, Lin Q, Danesi H, Hong D. Radiation Sub-Study to Characterize Safety and Tolerability of Low-Dose Radiation in Combination with Afami-Cel in patients with advanced cancers (NCT03132922). 2021 SITC Annual Meeting, 2021. e-Pub 2021.
140. Johnson M, Siu L, Hong D, Schoffski P, Galvao V, Rangwala F, Hernandez R, Gonzalez L, Ma B, Pandite L, Brana I. Phase 1 Dose Escalation and Dose Expansion Study Of An Agonist Redirected Checkpoint (ARC) FUSION Protein, SL-279252 (PD1-FC-OX40L), in subjects with advanced solid tumors or Lymphomas. 2021 SITC Annual Meeting, 2021. e-Pub 2021.
141. Hong DS, Catenacci D, Bazhenova L, Cho BC, Ponz-Sarvise M, Heist R, Moreno V, Falchook GS, Zhu VW, Swalduz A, Besse B, D-W K, Yoon S, Le X, Zhao T, Kadva A, Zimmerman Z, Lee J. Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial. AACR-NCI-EORTC Virtual International Conference On Molecular Targets And Cancer Therapeutics, 2021. e-Pub 2021.
142. George GC, Kim AJ, Gebremeskel M, Manandhar M, Pradeep HM, Piha-Paul SA, Rodon Ahnert J, Subbiah V, Karp DD, Cleeland CS, Hong DS. Compliance with Dietary Guidelines and Its Relationship with Symptoms and Clinical Outcomes in Patients with Advanced Cancer in Early-Phase Oncology Clinical Trials. ASCO Quality Care Symposium, 2021. e-Pub 2021.
143. Moyers, Nguyen D, Hong DS, Dumbrava EI, Fu S, Karp D, Naing A, Pant S, Janku F, Piha-Paul S, Rodon J, Subbiah V, Tsimberidou AM, Meric-Bernstam F, Yap T. Adherence to the Food and Drug Administration (FDA) guidance for the co-development of two or more investigational new drugs in Phase 1/2 cancer trials. 2021 ESMO Virtual Congress, 2021. e-Pub 2021.
144. Hong DS. Gavocabtagene autoleucel (gavo-cel, TC-210) dose escalation in refractory mesothelin-expressing solid tumors. 2021 ESMO Virtual Congress, 2021. e-Pub 2021.
145. Burton E, Dumbrava EEI, Peng W, Milton D, Amaria R, Mcquade J, Glitza IC, Hong D, Patel S, Rodon J, Yap TA, Naing A, Piha-Paul SA, Balmes G, Lazar A, Meric-Bernstam F, Hwu P, Davies MA, Tawbi HA. Ph I/II study of PI3K-β inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumors. 2021 ESMO Virtual Congress, 2021. e-Pub 2021.
146. Burton E, Dumbrava EEI, Peng W, Milton D, Amaria R, Mcquade J, Glitza IC, Hong D, Patel S, Rodon J, Yap TA, Naing A, Piha-Paul SA, Balmes G, Lazar A, Meric-Bernstam F, Hwu P, Davies MA, Tawbi HA. Ph I/II study of PI3Kβ inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumors. 2021 ESMO Virtual Congress, 2021. e-Pub 2021.
147. Hong D, Fayette J, Birnbaum A, Steuer C, Taylor MH, George TJ, Lacy J, Beca F, Nicacio LV, Soumaoro I, Cho M. innovaTV 207: new dosing cohort in the open label Phase II study of tisotumab vedotin in solid tumors. 2021 ESMO Virtual Congress, 2021. e-Pub 2021.
148. Hong DS, Clarke JM, Asch A, Charlson J, Johanns TM, Calvo E, Boni V, de Miguel MJ, Moreno Garcia V, Lawrence DP, Butler MO, Zugazagoitia J, Blum Murphy MA, Kebriaei P, Jr BG, Lin Q, Danesi H, Norry E. Safety and efficacy from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating a CD8α co-receptor and an affinity optimized TCR targeting MAGE-A4. 2021 ESMO Virtual Congress, 2021. e-Pub 2021.
149. Drilon A, Kummar S, Albert CM, Nagasubramanian R, Hechtman JF, Reeves JA, Beckmann G, Rudolph M, Wierzbińska JA, Dima L, Brega N, Laetsch TW, Hong DS. Long-term outcomes of patients with TRK fusion cancer treated with larotrectinib. AACR Annual Meeting 2021, 2021. e-Pub 2021.
150. Hong DS, Johnson M, Tanyi JL, MacMullen L, Tighe R, Jalbert L, Muzithras VP, Zikaras K, Quintas Cardama A, Hassan R. Preliminary safety and efficacy of gavocabtagene autoleucel (gavo-cel, TC-210), a T cell receptor fusion construct (TRuC™), in patients with treatment refractory mesothelin overexpressing solid tumors. AACR Annual Meeting 2021, 2021. e-Pub 2021.
151. Coleman N, Naing A, Zhang S, Anne Piha-Paul SA, Tsimberidou AM, Janku F, Rodon J, Pant S, Dumbrava EE, Fu S, Hong DS, Meric-Bernstam F, Subbiah V. Phase I study of mTORC1/2 inhibitor sapanisertib (TAK-228) in combination with metformin in patients (pts) with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies. ASCO Annual Meeting 2021, 2021. e-Pub 2021.
152. Hong DS, Shen L, van Tilburg CM, Tan DS, Kummar S, Lin JJ, Doz FP, McDermott RS, Albert CM, Berlin J, Bielack SS, Lassen UN, Tahara M, Norenberg R, Shurshalina A, Fellous MM, Nogai H, Xu R, Laetsch TW, Drilon AE. Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer. ASCO Annual Meeting 2021, 2021. e-Pub 2021.
153. Anne Piha-Paul SA, Xu B, Janku F, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Ahnert JR, Tsimberidou AM, Javle MM, Fan Y, Peng P, Levin WJ, Ngo B, Wang H, Sun C, Ru QC, Wu F. Phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors. ASCO Annual Meeting 2021, 2021. e-Pub 2021.
154. Waters N, Patel MR, Schram AM, Rodon Ahnert J, Jauhari S, Sachdev JC, Weijia Zhu V, LoRusso P, Nguyen D, Hong DS, Tarilonte L, Humphrey RW, Janne PA, Hamilton EP, Witt K. Clinical pharmacokinetics of bdtx-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies in MasterKey-01 study. ASCO Annual Meeting 2021, 2021. e-Pub 2021.
155. Hong DS, Strickler JH, Fakih M, Falchook GS, Li BT, Durm GA, Burns TF, Ramalingam SS, Goldberg SB, Lo T, Marrone K, Shu CA, Gandara DR, Soman N, Henary HA, Govindan R. Trial in progress: A Phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101). ASCO Annual Meeting 2021, 2021. e-Pub 2021.
156. Vo HH, Fu S, Hong DS, Karp DD, Anne Piha-Paul SA, Subbiah V, Janku F, Naing A, Yap TA, Ahnert JR, Ajani JA, Cartwright C, Naqvi MF, Nogueras-Gonzalez GM, Miller VA, Palmer GA, Vining DJ, Berry DA, Meric-Bernstam F, Tsimberidou AM. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT2): Challenges and Opportunities in Conducting an MD Anderson Randomized Study in Precision Oncology. ASCO Annual Meeting 2021, 2021. e-Pub 2021.
157. Subbiah IM, Amaram-Davila JS, Wong A, Shih KK, Anderson AE, Mendoza TR, Williams LA, Reddy AS, Joy MP, Harnden KM, Gaffney ML, Shelal Z, Maddi R, Nelson C LD, De la Cruz VJ, Elder SL, Ray DQ, Subbiah V, Hong DS, Bruera E. Technology-enhanced palliative care for patients with cancer on phase 1 clinical trials. ASCO Annual Meeting 2021, 2021. e-Pub 2021.
158. Westin SN, Fu S, Tsimberidou AM, Anne Piha-Paul SA, Akhmedzhanov F, Yilmaz B, McQuinn L, Brink AL, Gong J, Leung CH, Lin HY, Hong DS, Pant S, Jazaeri AA, Gershenson DM, Sood AK, Coleman RL, Shah JJ, Meric-Bernstam F, Naing A. Selinexor in combination with weekly paclitaxel in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multiarm phase 1b study. ASCO Annual Meeting 2021, 2021. e-Pub 2021.
159. Yap TA, Dumbrava EE, Rodon Ahnert J, Hong DS, Pant S, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Fu S, Janku F, Montez S, Ahmad-Taha MT, Guerrero D, Nazarenko NN, Moore Y, Soth M, Kovacs J, Heffernan TP, Jones P. First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients (pts) with molecularly selected advanced solid tumors. ASCO Annual Meeting 2021, 2021. e-Pub 2021.
160. Chung V, Wang L, Fletcher MS, Massarelli E, Cristea MC, Kamaraju S, Alistar AT, Feng C, Li Y, Whiting RL, Giaccone G, Hong DS, Wu J. First-time in-human study of VMD-928, an oral allosteric TrkA selective inhibitor targeting TrkA protein overexpression, in patients with solid tumors or lymphoma. ASCO Annual Meeting 2021, 2021. e-Pub 2021.
161. Hobbs B, Ton T, Li X, Hong DS, Hubbard RA, Mangat PK, Capra W, Kong S, Pang H, Samant M, Segal BD, Garrett-Mayer L. Comparing phase 3 “go” decisions (Ph3-GO) between single arm trials with real-world external control (SAT+rwEC) versus randomized phase 2 trials (rPh2). ASCO Annual Meeting 2021, 2021. e-Pub 2021.
162. Hong DS, Italiano A, Briggs A, Garcia-Foncillas J, Niels Lassen U, Vassal G, Kummar S, Martinus van Tilburg C, Keating KN, Reeves JA, Mardoche Fellous M, Nogai H, Willis Laetsch T, Drilon AE. Intra-patient comparison from larotrectinib clinical trials in TRK fusion cancer: an expanded dataset. ASCO Annual Meeting 2021, 2021. e-Pub 2021.
163. Gordon M, Roszik J, Cabanillas ME, I-Nan Hu M, Busaidy NL, Sherman SI, Dadu R, Gardner Grubbs E, Elamin YY, Cascone T, Byers LA, Blumenschein GR, Fossella FV, Naing A, Hong DS, Heymach J, Meric-Bernstam F, Subbiah V. Prognostic factors in RET-dependent cancers treated with RET inhibitors in early phase clinical trials. ASCO Annual Meeting 2021, 2021. e-Pub 2021.
164. Morris VK, Singh Raghav KP, Dasari A, Overman MJ, Kee BK, Johnson B, Parseghian CM, YC Shen JP, Huey R, Raymond VM, Duose DY, Luthra R, Hong DS, Janku F, Kopetz S. Utility of circulating tumor DNA in the clinical management of patients with BRAFV600E metastatic colorectal cancer. 2021 Gastrointestinal Cancers Symposium, 2021. e-Pub 2021.

Book Chapters

1. Hong DS, Marcelo-Lewis KL, LoRusso P. Practicalities of Setting Up a Phase I Clinical Trial Unit Within an Academic Center. In: Phase I Oncology Drug Development. Springer, 71-83, 2020.
2. Barata PC, Hong DS. Considerations for the Attribution and Management of Toxicities in Phase I Clinical Trials. In: Phase I Oncology Drug Development. Springer, 109-118, 2020.
3. Hong, DS, Barata, P. The challenges of implementing multiarmed early phase oncology clinical trials. In: Novel Designs of Early Phase Trials for Cancer Therapeutics. Academic Press, 47-55, 2018.
4. Tang C, Cortez MA, Hong D, Welsh JW. Targeting the c-Met Kinase. In: Targeted Therapy in Translational Cancer Research. Wiley, 341-346, 2015.
5. Hong, DS, Kopetz, S, George, GC. Targets by organ site: Colorectal cancer (adenocarcinoma). In: Handbook of Targeted Cancer Therapy. First. Wolters Kluwer, 18-21, 2014.
6. Hong, DS, Javle, M, George, GC. Targets by organ site: Pancreatic cancer (Ductal Carcinoma). In: Handbook of Targeted Cancer Therapy. First. Wolters Kluwer, 54, 2014.
7. Hong, DS, Kaseb, A, George, GC. Targets by organ site: Biliary tract adenocarcinoma (gallbladder, bile duct). In: Handbook of Targeted Cancer Therapy. Wolters Kluwer, 2014.
8. Blum Murphy, M, Hong, DS, George, GC. Targets by organ site: Esophageal cancer (squamous cell). In: Handbook of Targeted Cancer Therapy. First. Wolters Kluwer, 22, 2014.
9. Falchook, GS, Hong, DS. Targets by organ site. In: Handbook of Targeted Cancer Therapy. Wolters Kluwer, 1-82, 2014.
10. Blum Murphy, M, Hong, DS, George, GC. Targets by organ site: Gastric cancer/gastroesophageal junction (Adenocarcinoma). In: Handbook of Targeted Cancer Therapy. First. Wolters Kluwer, 23-24, 2014.
11. Hong DS, Chintala L. Combining Targeted Therapies. In: Targeted Cancer Therapy. XII. Humana Press, 361-381, 2008.

Books (edited and written)

1. Ed(s) Yap TA, Rodon J, Hong DS. Phase I Oncology Drug Development. Springer, 2020.

Letters to the Editor

1. Hong, DS, LoRusso, P, Sznol, M. A crisis in clinical research. Journal for immunotherapy of cancer 12, 2024.
2. Brose MS, Hong DS, Drilon A. Important Considerations for Real-World Analysis of Neurotrophic Tyrosine Receptor Kinase Fusion Cancer and Tropomyosin Receptor Kinase Inhibitors. JCO Precis Oncol 7: e2300217, 2023.
3. Osarogiagbon, RU, Vega, DM, Fashoyin-Aje, L, Wedam, S, Ison, G, Atienza, S, De Porre, P, Biswas, T, Holloway, JN, Hong, DS, Wempe, MM, Schilsky, R, Kim, ES, Wade, J. Modernizing clinical trial eligibility criteria. Clin Cancer Res 27: 2408-2415, 2021.
4. McKean M, Oba J, Ma J, Roth KG, Wang WL, Macedo MP, Carapeto FCL, Haydu LE, Siroy AE, Vo P, Hong DS, Eterovic AK, Patel KP, Jr BR, Grimm EA, Lazar AJ, Woodman SE. Tyrosine kinase inhibitor and immune checkpoint inhibitor responses in KIT-mutant metastatic melanoma. J Invest Dermatol 139: 728-731, 2019.
5. Tang C, Welsh JW, Hong D. Phase I trial: SABR and ipilimumab--response. Clin Cancer Res 23: 321, 2017.
6. Subbiah V, Hong DS, Meric-Bernstam F. Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: bench to bedside report. Proc Natl Acad Sci U S A 113: E1419-20, 2016.
7. Jain RK, Lee JJ, Hong D, Kurzrock R. RE: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. J Natl Cancer Inst 105: 833, 2013.
8. Jain, RK, Lee, JJ, Hong, DS, Kurzrock, R. Reply to A. Levy et al. J Clin Oncol 31: 396, 2013.